PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
4355374-1	1973	A low-molecular-weight component of complement, similar to or identical with human C5a, interacts with human polymorphonuclear leukocytes treated with cytochalasin B and provokes extracellular release of lysosomal enzymes from these cells.	Cytochalasin B	151-165	complement C5a receptor 1	Homo sapiens	83-86
4352609-1	1973	Colchicine, vinblastine, podophyllotoxin, and cytochalasin B inhibit the action of vasopressin and cyclic adenosine monophosphate on osmotic water movement across the toad bladder.	Cytochalasin B	46-60	arginine vasopressin	Homo sapiens	83-94
4349222-3	1973	Melanocyte-stimulating hormone (MSH), theophylline, and dibutyryl cyclic AMP (DiBcAMP) induced melanosome dispersion (darkening) which was promptly arrested by cytochalasin B in concentrations of 5-20 microg/ml.	Cytochalasin B	160-174	proopiomelanocortin	Homo sapiens	0-30
4349222-3	1973	Melanocyte-stimulating hormone (MSH), theophylline, and dibutyryl cyclic AMP (DiBcAMP) induced melanosome dispersion (darkening) which was promptly arrested by cytochalasin B in concentrations of 5-20 microg/ml.	Cytochalasin B	160-174	proopiomelanocortin	Homo sapiens	32-35
4573352-3	1973	In order to assess the participation of the microfilamentous cell web in the multiphasic response of the pancreatic beta cell, the effect of cytochalasin B upon both glucose- and sulfonylurea-induced insulin release was investigated in the perfused isolated pancreas.	Cytochalasin B	141-155	insulin	Homo sapiens	200-207
4573352-5	1973	In addition, cytochalasin B lowered the threshold concentration for the stimulant action of glucose upon insulin release.	Cytochalasin B	13-27	insulin	Homo sapiens	105-112
4347169-0	1973	Synthesis of infective poliovirus in BSC-1 monkey cells enucleated with cytochalasin B.	Cytochalasin B	72-86	solute carrier family 12 member 1	Homo sapiens	37-42
4347169-1	1973	BSC-1 monkey kidney cells were enucleated by two cycles of centrifugation in the presence of cytochalasin B.	Cytochalasin B	93-107	solute carrier family 12 member 1	Homo sapiens	0-5
4344086-0	1972	Effect of cytochalasin B on the response of the chromatophores of isolated frog skin to MSH, theophylline, and dibutyryl cyclic AMP.	Cytochalasin B	10-24	msh homeobox 2	Homo sapiens	88-91
4341701-7	1972	Giant, polynucleated, transformed lymphocytes cultured in the presence of cytochalasin B bind about 10 times more insulin than transformed lymphocytes, which is in harmony with a 10-fold increase in cell-surface area in these cells.	Cytochalasin B	74-88	insulin	Homo sapiens	114-121
4342210-16	1972	The stimulation of release of growth hormone by prostaglandin was decreased by preincubation of tissue for 2h in colchicine (100mum) or cytochalasin B (10mug/ml).	Cytochalasin B	136-150	somatotropin	Oryctolagus cuniculus	30-44
32755998-4	2020	This effect was prevented by the use of either Cytochalasin B (5 microM) or Indinavir (100 microM), both antagonists of GLUT4 activity.	Cytochalasin B	47-61	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	120-125
29913554-6	2018	Glucose/fructose/cytochalasin B reduced cellular 6-[18F]FDF uptake by 50%, indicating functional involvement of GLUT2.	Cytochalasin B	17-31	solute carrier family 2 member 2	Homo sapiens	112-117
32546751-0	2020	Refractive index gas sensor based on the Tamm state in a one-dimensional photonic crystal: Theoretical optimisation.	Cytochalasin B	41-45	gastrin	Homo sapiens	17-20
31433692-6	2019	Inhibition of facilitative glucose transport (GLUT) with Cytochalasin B reduced intracellular glucose concentration.	Cytochalasin B	57-71	solute carrier family 2 member 1	Homo sapiens	46-50
32232899-6	2020	Moreover, cytochalasin B and ZCL278 were used to explore the changes of SKA1-induced signalling and cell morphology, with further confirmation by immunoblotting and immunofluorescence assays.	Cytochalasin B	10-24	spindle and kinetochore associated complex subunit 1	Homo sapiens	72-76
28933599-6	2017	Treatment with cytochalasin B in oocytes confirmed that SKAP2 was co-localized with actin.	Cytochalasin B	15-29	src family associated phosphoprotein 2	Mus musculus	56-61
29301091-3	2018	Similarly, the rate of Tyr15 phosphorylation of the complex of cyclin and p34cdc2 (CDK1) was significantly elevated in the JNJ-7706621-treated embryos compared with embryos exposed to cytochalasin B or non-treated controls (P<0.05).	Cytochalasin B	184-198	cyclin dependent kinase 1	Sus scrofa	83-87
29301091-4	2018	In contrast, Thr161 phosphorylation of CDK1 was significantly lower in the JNJ-7706621-treated group compared with the cytochalasin B-treated as well as the non-treated group (P<0.05).	Cytochalasin B	119-133	cyclin dependent kinase 1	Sus scrofa	39-43
28961211-4	2017	The anti-inflammatory activities of compounds 1-12 were assessed by measuring their inhibitory effect on N-formyl-methionyl-leucyl-phenyl-alanine/cytochalasin B (fMLP/CB)-induced superoxide anion generation and elastase release in human neutrophils.	Cytochalasin B	146-160	formyl peptide receptor 1	Homo sapiens	162-166
27651179-8	2017	Addition of nocodazole or cytochalasin B into the culture medium at different stages changed the localisation of Dlg1, indicating that the organisation of Dlg1 is a complex multi-step process and is dependent on microtubules and microfilaments.	Cytochalasin B	26-40	discs large MAGUK scaffold protein 1	Mus musculus	113-117
27651179-8	2017	Addition of nocodazole or cytochalasin B into the culture medium at different stages changed the localisation of Dlg1, indicating that the organisation of Dlg1 is a complex multi-step process and is dependent on microtubules and microfilaments.	Cytochalasin B	26-40	discs large MAGUK scaffold protein 1	Mus musculus	155-159
28279980-7	2017	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.	Cytochalasin B	32-46	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	17-21
28213469-5	2017	We found that normal human primary airway epithelial cells expressed glucose transporter 4 and that application of insulin stimulated cytochalasin B-inhibitable glucose uptake, consistent with a requirement for glucose transporter translocation.	Cytochalasin B	134-148	insulin	Homo sapiens	115-122
29400859-3	2018	Defining a "Zak"-like topological phase in 1D quasi-crystals, we propose a recipe to ascertain the existence of Tamm-like photonic surface modes in a metal-terminated quasi-crystal lattice.	Cytochalasin B	112-116	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	12-15
28824614-11	2017	Cytochalasin B partially inhibited the induction of Tnfa by P25/LPS, but not by free LPS, and suppressed the induction of IRF3-dependent genes by either P25/LPS or free LPS.	Cytochalasin B	0-14	tumor necrosis factor	Mus musculus	52-56
28824614-11	2017	Cytochalasin B partially inhibited the induction of Tnfa by P25/LPS, but not by free LPS, and suppressed the induction of IRF3-dependent genes by either P25/LPS or free LPS.	Cytochalasin B	0-14	lipocalin 2	Mus musculus	60-63
28824614-11	2017	Cytochalasin B partially inhibited the induction of Tnfa by P25/LPS, but not by free LPS, and suppressed the induction of IRF3-dependent genes by either P25/LPS or free LPS.	Cytochalasin B	0-14	toll-like receptor 4	Mus musculus	64-67
28824614-11	2017	Cytochalasin B partially inhibited the induction of Tnfa by P25/LPS, but not by free LPS, and suppressed the induction of IRF3-dependent genes by either P25/LPS or free LPS.	Cytochalasin B	0-14	interferon regulatory factor 3	Mus musculus	122-126
28824614-11	2017	Cytochalasin B partially inhibited the induction of Tnfa by P25/LPS, but not by free LPS, and suppressed the induction of IRF3-dependent genes by either P25/LPS or free LPS.	Cytochalasin B	0-14	lipocalin 2	Mus musculus	153-156
28648460-4	2017	The anti-inflammatory activities of compounds 1-6 were evaluated by measuring their ability to suppress N-formyl-methionyl-leucyl-phenyl-alanine/cytochalasin B (fMLP/CB)-induced superoxide anion generation and elastase release in human neutrophils.	Cytochalasin B	145-159	formyl peptide receptor 1	Homo sapiens	161-165
28457943-5	2017	Results showed that the actin microfilament-disrupting agent, cytochalasin B (CB), reduced BMP2-induced activation, translocation of Smad1/5/8 and Runx2 expression.	Cytochalasin B	62-76	bone morphogenetic protein 2	Homo sapiens	91-95
28457943-5	2017	Results showed that the actin microfilament-disrupting agent, cytochalasin B (CB), reduced BMP2-induced activation, translocation of Smad1/5/8 and Runx2 expression.	Cytochalasin B	62-76	SMAD family member 1	Homo sapiens	133-142
28457943-5	2017	Results showed that the actin microfilament-disrupting agent, cytochalasin B (CB), reduced BMP2-induced activation, translocation of Smad1/5/8 and Runx2 expression.	Cytochalasin B	62-76	RUNX family transcription factor 2	Homo sapiens	147-152
28652743-6	2017	Pretreatment of A549 cells on the apical side of the coculture system with the phagocytosis inhibitor cytochalasin B (CB) blocked ZnO-NP-induced HO-1 and PECAM-1 expression in HCAEC, indicating that endocytosis of ZnO-NPs by alveolar epithelial cells was involved in ZnO-NP-induced HO-1 or PECAM-1 expression in endothelial cells.	Cytochalasin B	102-116	heme oxygenase 1	Homo sapiens	145-149
28652743-6	2017	Pretreatment of A549 cells on the apical side of the coculture system with the phagocytosis inhibitor cytochalasin B (CB) blocked ZnO-NP-induced HO-1 and PECAM-1 expression in HCAEC, indicating that endocytosis of ZnO-NPs by alveolar epithelial cells was involved in ZnO-NP-induced HO-1 or PECAM-1 expression in endothelial cells.	Cytochalasin B	102-116	platelet and endothelial cell adhesion molecule 1	Homo sapiens	154-161
28652743-6	2017	Pretreatment of A549 cells on the apical side of the coculture system with the phagocytosis inhibitor cytochalasin B (CB) blocked ZnO-NP-induced HO-1 and PECAM-1 expression in HCAEC, indicating that endocytosis of ZnO-NPs by alveolar epithelial cells was involved in ZnO-NP-induced HO-1 or PECAM-1 expression in endothelial cells.	Cytochalasin B	102-116	heme oxygenase 1	Homo sapiens	282-286
28652743-6	2017	Pretreatment of A549 cells on the apical side of the coculture system with the phagocytosis inhibitor cytochalasin B (CB) blocked ZnO-NP-induced HO-1 and PECAM-1 expression in HCAEC, indicating that endocytosis of ZnO-NPs by alveolar epithelial cells was involved in ZnO-NP-induced HO-1 or PECAM-1 expression in endothelial cells.	Cytochalasin B	102-116	platelet and endothelial cell adhesion molecule 1	Homo sapiens	290-297
25715702-8	2015	Caffeine, but not ATP, inhibits cytochalasin B binding to GLUT1.	Cytochalasin B	32-46	solute carrier family 2 member 1	Homo sapiens	58-63
28536622-6	2016	METHODS: Immunofluorescent analysis the expression of Exo70, alpha-actin, and tubulin in A7r5 cells showed a co-localization of Exo70 and alpha-actin, we treated the cells with cytochalasin B to depolymerize alpha-actin, in order to further confirm the co-localization of Exo70 and alpha-actin.	Cytochalasin B	177-191	exocyst complex component 7	Rattus norvegicus	54-59
28536622-6	2016	METHODS: Immunofluorescent analysis the expression of Exo70, alpha-actin, and tubulin in A7r5 cells showed a co-localization of Exo70 and alpha-actin, we treated the cells with cytochalasin B to depolymerize alpha-actin, in order to further confirm the co-localization of Exo70 and alpha-actin.	Cytochalasin B	177-191	exocyst complex component 7	Rattus norvegicus	128-133
28536622-6	2016	METHODS: Immunofluorescent analysis the expression of Exo70, alpha-actin, and tubulin in A7r5 cells showed a co-localization of Exo70 and alpha-actin, we treated the cells with cytochalasin B to depolymerize alpha-actin, in order to further confirm the co-localization of Exo70 and alpha-actin.	Cytochalasin B	177-191	exocyst complex component 7	Rattus norvegicus	128-133
27640744-5	2016	In ZR-75-1 cells, cytochalasin B triggered G2/M phase arrest through the modulation of CDK1, cyclin B1, p53, p27 and p21 expressions.	Cytochalasin B	18-32	cyclin dependent kinase 1	Homo sapiens	87-91
27640744-5	2016	In ZR-75-1 cells, cytochalasin B triggered G2/M phase arrest through the modulation of CDK1, cyclin B1, p53, p27 and p21 expressions.	Cytochalasin B	18-32	cyclin B1	Homo sapiens	93-102
27640744-5	2016	In ZR-75-1 cells, cytochalasin B triggered G2/M phase arrest through the modulation of CDK1, cyclin B1, p53, p27 and p21 expressions.	Cytochalasin B	18-32	tumor protein p53	Homo sapiens	104-107
27640744-5	2016	In ZR-75-1 cells, cytochalasin B triggered G2/M phase arrest through the modulation of CDK1, cyclin B1, p53, p27 and p21 expressions.	Cytochalasin B	18-32	interferon alpha inducible protein 27	Homo sapiens	109-112
27640744-5	2016	In ZR-75-1 cells, cytochalasin B triggered G2/M phase arrest through the modulation of CDK1, cyclin B1, p53, p27 and p21 expressions.	Cytochalasin B	18-32	H3 histone pseudogene 16	Homo sapiens	117-120
27640744-9	2016	The apoptotic effects evoked by cytochalasin B were partially inhibited by prechelating cytosolic Ca2+ with BAPTA-AM and the antioxidant NAC.	Cytochalasin B	32-46	X-linked Kx blood group	Homo sapiens	137-140
27119825-3	2016	This report focuses on short- and long-term effects of cytochalasin B (CB) on actin-complexes in fibroblasts and myoblasts.	Cytochalasin B	55-69	actin, beta	Gallus gallus	78-83
27078104-0	2016	Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides.	Cytochalasin B	80-94	solute carrier family 2 member 1	Homo sapiens	53-58
27078104-3	2016	Here, we present three inhibitor-bound, inward-open structures of WT-hGLUT1 crystallized with three different inhibitors: cytochalasin B, a nine-membered bicyclic ring fused to a 14-membered macrocycle, which has been described extensively in the literature of hGLUTs, and two previously undescribed Phe amide-derived inhibitors.	Cytochalasin B	122-136	solute carrier family 2 member 1	Homo sapiens	69-75
26553070-5	2016	The 2-NBDLG uptake was persistently observed in the presence of a GLUT inhibitor cytochalasin B.	Cytochalasin B	81-95	solute carrier family 2 member 1	Homo sapiens	66-70
26690689-8	2015	The transient increase of Orai1 protein abundance was abrogated by Rac1 inhibitor NSC23766 (50 muM) and by prevention of actin reorganization with cytochalasin B (1 muM).	Cytochalasin B	147-161	ORAI calcium release-activated calcium modulator 1	Homo sapiens	26-31
26690689-8	2015	The transient increase of Orai1 protein abundance was abrogated by Rac1 inhibitor NSC23766 (50 muM) and by prevention of actin reorganization with cytochalasin B (1 muM).	Cytochalasin B	147-161	latexin	Homo sapiens	165-168
26497038-8	2016	Thus, DHA promotes the death of stressed neuronal cells, which is reversed by incubating the cells with cytochalasin B, an inhibitor of DHA uptake by GLUT1 and GLUT3.	Cytochalasin B	104-118	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	150-155
26497038-8	2016	Thus, DHA promotes the death of stressed neuronal cells, which is reversed by incubating the cells with cytochalasin B, an inhibitor of DHA uptake by GLUT1 and GLUT3.	Cytochalasin B	104-118	solute carrier family 2 (facilitated glucose transporter), member 3	Mus musculus	160-165
27039889-11	2016	Taken together, the data suggest that curcumin binds directly to GLUT1 at a site that overlaps with the cytochalasin B binding site and thereby inhibits glucose transport.	Cytochalasin B	104-118	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	65-70
25987541-10	2015	IL-1beta-increased IL-6 release was reduced with cytochalasin B, epalrestat, L-NAME or MitoTEMPO treatment (-45%, -62%, -38% and -40%, respectively).	Cytochalasin B	49-63	interleukin 1 beta	Homo sapiens	0-8
25987541-10	2015	IL-1beta-increased IL-6 release was reduced with cytochalasin B, epalrestat, L-NAME or MitoTEMPO treatment (-45%, -62%, -38% and -40%, respectively).	Cytochalasin B	49-63	interleukin 6	Homo sapiens	19-23
25715702-10	2015	These results suggest that the caffeine-binding site bridges two nonoverlapping GLUT1 endofacial sites-the regulatory, nucleotide-binding site and the cytochalasin B-binding site.	Cytochalasin B	151-165	solute carrier family 2 member 1	Homo sapiens	80-85
25437917-3	2014	Anti-inflammatory activity of new metabolites to inhibit the superoxide anion generation and elastase release in N-formyl-methionyl-leucyl phenylalanine/cytochalasin B (FMLP/CB)-induced human neutrophil cells and cytotoxicity of both new compounds toward five cancer cell lines were reported.	Cytochalasin B	153-167	formyl peptide receptor 1	Homo sapiens	169-173
24912776-8	2014	These predictions were experimentally evaluated: the glycolytic flux of hypoglycemic cells was more sensitive to cytochalasin B (a GLUT inhibitor) than that of hyperglycemic cells.	Cytochalasin B	113-127	solute carrier family 2 member 1	Homo sapiens	131-135
24661186-5	2014	In most cases, cytochalasin B also prevented the integration of the male chromosomes into the embryonic genome as determined by the absence of the SRY gene in the embryonic blastomeres or by the frequency of embryos showing green fluorescence after sperm from a GFP-transgenic boar was used for fertilization.	Cytochalasin B	15-29	SRY	Sus scrofa	147-150
24315204-9	2014	Inhibition of IL-1beta secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD.	Cytochalasin B	62-76	interleukin 1 beta	Homo sapiens	14-22
24635700-9	2014	In addition, the accumulation of reactive oxygen species (ROS) and the hypersensitive response (HR) were greatly weakened, whereas cytochalasin B partially rescued the HR in TaADF7 knock-down plants.	Cytochalasin B	131-145	actin-depolymerizing factor 7	Triticum aestivum	174-180
24714077-6	2014	In western blot and RT-PCR analysis the expression of NBCe2 but not NBCe1 or NBCn1 was detected in neutrophils Acidified neutrophils increased the EIPA-insensitive pHi recovery rate when its activity was stimulated with fMLF/ cytochalasin B.	Cytochalasin B	226-240	solute carrier family 4 member 5	Homo sapiens	54-59
23564379-6	2013	Preincubation of the cells with cytochalasin B (a GLUT inhibitor) or N-acetylcysteine (an antioxidant) blocked the stimulatory effect of high glucose concentrations on these profibrotic molecules.	Cytochalasin B	32-46	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	50-54
23664836-2	2013	In both MCF7 and MDA-MB-231 cells (3)H-DG uptake was (a) time-dependent, (b) saturable with similar capacity (Vmax) and affinity (Km), (c) potently inhibited by cytochalasin B, an inhibitor of the facilitative glucose transporters (GLUT), (d) sodium-independent and (e) slightly insulin-stimulated.	Cytochalasin B	161-175	solute carrier family 2 member 4	Homo sapiens	232-236
23664836-2	2013	In both MCF7 and MDA-MB-231 cells (3)H-DG uptake was (a) time-dependent, (b) saturable with similar capacity (Vmax) and affinity (Km), (c) potently inhibited by cytochalasin B, an inhibitor of the facilitative glucose transporters (GLUT), (d) sodium-independent and (e) slightly insulin-stimulated.	Cytochalasin B	161-175	insulin	Homo sapiens	279-286
23615963-7	2013	Resveratrol inhibits glucose exit in human red cells, and the displacement of previously bound cytochalasin B revealed the direct interaction of resveratrol with GLUT1.	Cytochalasin B	95-109	solute carrier family 2 member 1	Homo sapiens	162-167
23321641-9	2013	Cells with overactive Cdk2 fail to arrest after mitotic slippage in the presence of paclitaxel or cytokinesis failure during treatment with cytochalasin-B, generating 8N populations.	Cytochalasin B	140-154	cyclin dependent kinase 2	Homo sapiens	22-26
23411345-7	2013	EGF-induced relocalization of T-cad to cell-cell contacts could be abrogated by specific inhibitors of EGFR tyrosine kinase activity (gefitinib or lapatinib), lipid raft integrity (filipin), actin microfilament polymerization (cytochalasin D or cytochalasin B), p38MAPK (SB203580) or Rac1 (compound4).	Cytochalasin B	245-259	cadherin 13	Homo sapiens	30-35
23411345-7	2013	EGF-induced relocalization of T-cad to cell-cell contacts could be abrogated by specific inhibitors of EGFR tyrosine kinase activity (gefitinib or lapatinib), lipid raft integrity (filipin), actin microfilament polymerization (cytochalasin D or cytochalasin B), p38MAPK (SB203580) or Rac1 (compound4).	Cytochalasin B	245-259	epidermal growth factor receptor	Homo sapiens	103-107
23015548-8	2013	Moreover, degranulation was impaired by actin-stabilizing (phallacidin) and enhanced by actin-disrupting (cytochalasin B) agents to a similar extent in sgk1(+/+) MCs and sgk1(-/-) MCs, implying a regulatory role of actin reorganization in this event.	Cytochalasin B	106-120	serum/glucocorticoid regulated kinase 1	Homo sapiens	152-156
22495587-6	2012	The response was completely abolished in the presence of the GLUT2 inhibitors phloretin or cytochalasin B.	Cytochalasin B	91-105	solute carrier family 2 member 2	Rattus norvegicus	61-66
23383331-5	2013	FK633, an alpha(IIb)beta3 antagonist, and cytochalasin B impaired platelet binding to the fibrin scaffold and significantly reduced PS exposure evoked by thrombin.	Cytochalasin B	42-56	coagulation factor II, thrombin	Homo sapiens	154-162
21948715-6	2012	Furthermore, blocking contraction of collagen I gels by cytochalasin B inhibited Mmp13 and -14 expression and the release of hydroxyproline.	Cytochalasin B	56-70	collagenase 3	Capra hircus	81-86
22673619-4	2012	The displacement of previously bound cytochalasin B revealed a direct interaction between the methylxanthines and GLUT1.	Cytochalasin B	37-51	solute carrier family 2 member 1	Homo sapiens	114-119
22809514-10	2012	The increase of SGK1 protein abundance is blunted by inhibition of PI3K with wortmannin (100 nM) or LY294002 (25 muM), and by disruption of the cytoskeleton with cytochalasin B (1 muM).	Cytochalasin B	162-176	serum/glucocorticoid regulated kinase 1	Homo sapiens	16-20
21569124-4	2011	Our data show that cytochalasin B, LY294002, wortmannin, nocodazole, MG132 and XVA143 inhibitors reduced LVS uptake by >50% in these assays without having significant cytotoxic effects.	Cytochalasin B	19-33	lacking vigorous sperm	Mus musculus	105-108
22113212-4	2012	The osmotic water transport by GLUT3 was completely inhibited by treatment with a selective GLUT inhibitor, cytochalasin B.	Cytochalasin B	108-122	solute carrier family 2 member 3 L homeolog	Xenopus laevis	31-36
22466560-5	2012	We induced macrophage-mediated phagocytosis by using cytochalasin B to artificially cap CD43 on healthy (non-apoptotic) Jurkat cells.	Cytochalasin B	53-67	sialophorin	Homo sapiens	88-92
22293492-4	2012	2,5,6,7-Tetramethoxyflavan (1) showed a potent inhibitory effect on superoxide anion production in formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)/cytochalasin B (CB)-activated human neutrophils.	Cytochalasin B	150-164	formyl peptide receptor 1	Homo sapiens	144-148
22142692-8	2012	Molecular docking of BPA, 17-beta-estradiol, cytochalasin B and glucose with GLUT-2 and GLUT-8 revealed the higher binding affinity of BPA with GLUT-2 and GLUT-8.	Cytochalasin B	45-59	solute carrier family 2 member 2	Rattus norvegicus	77-83
22142692-8	2012	Molecular docking of BPA, 17-beta-estradiol, cytochalasin B and glucose with GLUT-2 and GLUT-8 revealed the higher binding affinity of BPA with GLUT-2 and GLUT-8.	Cytochalasin B	45-59	solute carrier family 2 member 8	Rattus norvegicus	88-94
22142692-8	2012	Molecular docking of BPA, 17-beta-estradiol, cytochalasin B and glucose with GLUT-2 and GLUT-8 revealed the higher binding affinity of BPA with GLUT-2 and GLUT-8.	Cytochalasin B	45-59	solute carrier family 2 member 2	Rattus norvegicus	144-150
22142692-8	2012	Molecular docking of BPA, 17-beta-estradiol, cytochalasin B and glucose with GLUT-2 and GLUT-8 revealed the higher binding affinity of BPA with GLUT-2 and GLUT-8.	Cytochalasin B	45-59	solute carrier family 2 member 8	Rattus norvegicus	155-161
21443604-7	2011	Cytochalasin B treatment abolished elongation, bundling and branching activities of actin filaments in guard cells, and these changes of actin filaments, and as a result, more chloroplasts were localized at the centre of guard cells.	Cytochalasin B	0-14	actin	Nicotiana tabacum	84-89
21443604-7	2011	Cytochalasin B treatment abolished elongation, bundling and branching activities of actin filaments in guard cells, and these changes of actin filaments, and as a result, more chloroplasts were localized at the centre of guard cells.	Cytochalasin B	0-14	actin	Nicotiana tabacum	137-142
21359128-6	2011	When we weaken Cell-Cell junctions (i.e., through a low dose of cytochalasin B or treatment with a VE-cadherin antibody), we observe that cell-substrate adhesion increases, as measured by focal adhesion size and density, and the stiffness of cells within the monolayer approaches that of single cells.	Cytochalasin B	64-78	cadherin 5	Homo sapiens	99-110
21510766-10	2011	In these cells, Na(+)-independent uptake of 2-NBDG was blocked with the GLUT inhibitor, cytochalasin B.	Cytochalasin B	88-102	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	72-76
21384913-1	2011	Cytochalasin B (CB) and forskolin (FSK) inhibit GLUT1-mediated sugar transport in red cells by binding at or close to the GLUT1 endofacial sugar binding site.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	48-53
21384913-1	2011	Cytochalasin B (CB) and forskolin (FSK) inhibit GLUT1-mediated sugar transport in red cells by binding at or close to the GLUT1 endofacial sugar binding site.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	122-127
21426580-9	2011	Functional assessment of the trans-endothelial electrical resistance of the cell monolayers and permeability of dye tracers in animal model validated the pharmacokinetics and molecular findings that inhibition of glucose uptake by GLUT1 inhibitor cytochalasin B (CB) aggravated the METH-induced disruption of the BBB integrity.	Cytochalasin B	247-261	solute carrier family 2 member 1	Homo sapiens	231-236
21081069-6	2010	Depolymerization of vimentin intermediate filaments using a dominant-negative vimentin mutant or actin with cytochalasin B reduced correlation of behavior of individual particles.	Cytochalasin B	108-122	vimentin L homeolog	Xenopus laevis	20-28
20596527-11	2010	In addition, we could show that cytochalasin B decreased the immobile fraction of clustered ICAM-1-GFP, but had no effect on non-clustered ICAM-1.	Cytochalasin B	32-46	intercellular adhesion molecule 1	Homo sapiens	92-98
20533392-9	2010	In contrast, cytochalasin B and latrunculin B did not affect CD203c responses but decreased CD63-based BAT.	Cytochalasin B	13-27	CD63 molecule	Homo sapiens	92-96
19681047-6	2009	GLUT activity was partially inhibited by cytochalasin B (IC(50) = 0.44 +/- 0.1; K(i) = 0.3 +/- 0.1 microM) and phloretin (IC(50) = 8.7 microM) in AS-30D hepatocarcinoma.	Cytochalasin B	41-55	solute carrier family 2 member 1	Homo sapiens	0-4
19769947-4	2010	Actin cytoskeleton disruption by cytochalasin B down-regulated a series of signaling cascades including PI3K, Akt, and IKK, but not MAPKs, necessary for NF-kappaB activation without down-regulating total forms of the proteins as assessed by measuring their phosphorylation levels.	Cytochalasin B	33-47	thymoma viral proto-oncogene 1	Mus musculus	110-113
19769947-5	2010	In particular, cytochalasin B significantly inhibited LPS-induced both phosphorylation and kinase activity of Src without altering total level, implying that Src may be a potential pharmacological target of actin cytoskeleton rearrangement.	Cytochalasin B	15-29	Rous sarcoma oncogene	Mus musculus	110-113
19769947-5	2010	In particular, cytochalasin B significantly inhibited LPS-induced both phosphorylation and kinase activity of Src without altering total level, implying that Src may be a potential pharmacological target of actin cytoskeleton rearrangement.	Cytochalasin B	15-29	Rous sarcoma oncogene	Mus musculus	158-161
20086016-6	2010	Conversely, cytochalasin B-induced disruption of microfilaments caused a severe loss of cell surface Panx1-GFP, a reduction in the recoverable fraction of Panx1-GFP that remained at the cell surface, and a decrease in Panx1-GFP vesicular transport.	Cytochalasin B	12-26	pannexin 1	Homo sapiens	101-106
20086016-6	2010	Conversely, cytochalasin B-induced disruption of microfilaments caused a severe loss of cell surface Panx1-GFP, a reduction in the recoverable fraction of Panx1-GFP that remained at the cell surface, and a decrease in Panx1-GFP vesicular transport.	Cytochalasin B	12-26	pannexin 1	Homo sapiens	155-160
20086016-6	2010	Conversely, cytochalasin B-induced disruption of microfilaments caused a severe loss of cell surface Panx1-GFP, a reduction in the recoverable fraction of Panx1-GFP that remained at the cell surface, and a decrease in Panx1-GFP vesicular transport.	Cytochalasin B	12-26	pannexin 1	Homo sapiens	155-160
21069159-7	2010	GLUT1 inhibitors Hg(II), cytochalasin B and forskolin reduced uptake of glucose but not CH3As(OH)2.	Cytochalasin B	25-39	solute carrier family 2 member 1	Homo sapiens	0-5
19948074-6	2009	The actin cytoskeleton drug cytochalasin B effectively inhibited the pro-apoptotic responses and caspase-3 activation.	Cytochalasin B	28-42	caspase 3	Mus musculus	97-106
19554259-3	2009	We demonstrate here that insulin-like peptides derived from the IR bind glucose at low millimolar, and cytochalasin B at low micromolar, concentrations; several insulin-like IR peptides bind insulin at nanomolar Kd; and this binding is antagonized by increasing glucose concentrations.	Cytochalasin B	103-117	insulin receptor	Rattus norvegicus	64-66
19667069-5	2009	Remarkably, the cytoskeleton inhibitors cytochalasin B and blebbistatin blocked not only PMA-induced apoptosis but also the activation of JNK, a mediator of the cell death effect by the phorbol ester.	Cytochalasin B	40-54	mitogen-activated protein kinase 8	Homo sapiens	138-141
19554259-4	2009	In addition, glucose and cytochalasin B bind to IR isolated from rat liver and increasing glucose decreases insulin binding to this IR preparation.	Cytochalasin B	25-39	insulin receptor	Rattus norvegicus	48-50
19554259-4	2009	In addition, glucose and cytochalasin B bind to IR isolated from rat liver and increasing glucose decreases insulin binding to this IR preparation.	Cytochalasin B	25-39	insulin receptor	Rattus norvegicus	132-134
19285977-7	2009	Cytochalasin B-induced actin filament depolymerization, however, affected both the pattern and the distribution of Cx30 gap junctions.	Cytochalasin B	0-14	gap junction protein beta 6	Homo sapiens	115-119
18768589-9	2008	Visfatin treatment increased glucose transporter-1 (GLUT-1) protein expression in isolated cellular membranes, and pretreatment with cytochalasin B completely inhibited visfatin-induced glucose uptake.	Cytochalasin B	133-147	nicotinamide phosphoribosyltransferase	Homo sapiens	169-177
18776917-8	2008	trans-Resveratrol (<100 microM) significantly inhibited eosinophil peroxidase release after activation with IL-5 (IC(50)=2.9+/-0.9 microM) or C5a (IC(50)=3.9+/-0.5 microM) after 5 min priming with cytochalasin B (CB).	Cytochalasin B	200-214	interleukin 5	Homo sapiens	111-115
19046767-4	2009	Cell migration depends on filamentous actin (F-actin) rearrangement, since pretreatment with cytochalasin B, an inhibitor of F-actin formation, prevented both DNP-HSA- and SCF-induced migration in wild-type BMMC.	Cytochalasin B	93-107	kit ligand	Mus musculus	159-175
19166280-2	2009	Cytochalasin B, a GLUT1 transport inhibitor, abolished the membrane capacitance changes in glucose-exposed red cells.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	18-23
19148495-9	2009	In addition, up-regulated p21WAF/CIP1 was accompanied by reduction of phosphorylation on retinoblastoma (Rb) protein in p53-null cells, implying that p21WAF/CIP1 might in part account for the molecular regulation of cytochalasin B induced G1 phase arrest.	Cytochalasin B	216-230	cyclin dependent kinase inhibitor 1A	Homo sapiens	33-37
19148495-9	2009	In addition, up-regulated p21WAF/CIP1 was accompanied by reduction of phosphorylation on retinoblastoma (Rb) protein in p53-null cells, implying that p21WAF/CIP1 might in part account for the molecular regulation of cytochalasin B induced G1 phase arrest.	Cytochalasin B	216-230	tumor protein p53	Homo sapiens	120-123
19148495-9	2009	In addition, up-regulated p21WAF/CIP1 was accompanied by reduction of phosphorylation on retinoblastoma (Rb) protein in p53-null cells, implying that p21WAF/CIP1 might in part account for the molecular regulation of cytochalasin B induced G1 phase arrest.	Cytochalasin B	216-230	cyclin dependent kinase inhibitor 1A	Homo sapiens	157-161
19108584-6	2009	Docking and electrostatic potential data analysis of GLUT4 model has mapped an ATP binding region close to the binding site of cytochalasin B and genistein, two GLUT4 inhibitors, and this may explain the mechanism by which these inhibitors could potentially affect the GLUT4 function.	Cytochalasin B	127-141	solute carrier family 2 member 4	Homo sapiens	53-58
19108584-6	2009	Docking and electrostatic potential data analysis of GLUT4 model has mapped an ATP binding region close to the binding site of cytochalasin B and genistein, two GLUT4 inhibitors, and this may explain the mechanism by which these inhibitors could potentially affect the GLUT4 function.	Cytochalasin B	127-141	solute carrier family 2 member 4	Homo sapiens	161-166
19108584-6	2009	Docking and electrostatic potential data analysis of GLUT4 model has mapped an ATP binding region close to the binding site of cytochalasin B and genistein, two GLUT4 inhibitors, and this may explain the mechanism by which these inhibitors could potentially affect the GLUT4 function.	Cytochalasin B	127-141	solute carrier family 2 member 4	Homo sapiens	161-166
19055752-7	2008	The actin cytoskeleton drug cytochalasin B and the ROCK inhibitor Y-27632 inhibited FasL induction and caspase-3 activation, indicating that the newly identified Rho/Rock/actin signaling may regulate the downstream pro-apoptotic effectors in DU145 cells.	Cytochalasin B	28-42	Fas ligand	Homo sapiens	84-88
19055752-7	2008	The actin cytoskeleton drug cytochalasin B and the ROCK inhibitor Y-27632 inhibited FasL induction and caspase-3 activation, indicating that the newly identified Rho/Rock/actin signaling may regulate the downstream pro-apoptotic effectors in DU145 cells.	Cytochalasin B	28-42	caspase 3	Homo sapiens	103-112
18768589-12	2008	Furthermore, visfatin treatment dramatically increased the synthesis of profibrotic molecules including transforming growth factor-beta1, plasminogen activator inhibitor-1, and type I collagen, and pretreatment with cytochalasin B completely inhibited visfatin-induced upregulation of profibrotic molecules.	Cytochalasin B	216-230	nicotinamide phosphoribosyltransferase	Homo sapiens	13-21
18768589-12	2008	Furthermore, visfatin treatment dramatically increased the synthesis of profibrotic molecules including transforming growth factor-beta1, plasminogen activator inhibitor-1, and type I collagen, and pretreatment with cytochalasin B completely inhibited visfatin-induced upregulation of profibrotic molecules.	Cytochalasin B	216-230	serpin family E member 1	Homo sapiens	138-171
18768589-12	2008	Furthermore, visfatin treatment dramatically increased the synthesis of profibrotic molecules including transforming growth factor-beta1, plasminogen activator inhibitor-1, and type I collagen, and pretreatment with cytochalasin B completely inhibited visfatin-induced upregulation of profibrotic molecules.	Cytochalasin B	216-230	nicotinamide phosphoribosyltransferase	Homo sapiens	252-260
18057092-6	2008	Similarly, in hyperinsulinemic-euglycemic clamp experiments in sensitive mice, insulin abolished GLUT2 (i.e., the cytochalasin B-sensitive component of fructose absorption), decreased BBM GLUT2, and concomitantly increased intracellular GLUT2.	Cytochalasin B	114-128	solute carrier family 2 (facilitated glucose transporter), member 2	Mus musculus	97-102
18504046-5	2008	NP57 and 265-3K1 gave 10-fold higher fluorescence when detecting intracellular HNE than 39A and 203, and intracellular fluorescence decreased by 10-28% following maximal stimulation of purified neutrophils with fMLP and cytochalasin B (compared to 40% release determined by functional assay).	Cytochalasin B	220-234	formyl peptide receptor 1	Homo sapiens	211-215
18046311-6	2008	Inhibition of glucose transport by cytochalasin B, phloretin, or phlorizin also interfered with beta(3)-AR-mediated memory enhancement 20 min posttraining, whereas inhibition of glycogenolysis interfered with beta(2)-AR agonist enhancement of memory.	Cytochalasin B	35-49	adrenoceptor beta 3	Homo sapiens	96-106
18425424-8	2008	In contrast, the cytoskeleton disrupting reagents, nocodazole and cytochalasin B barely affected NEP2 activity.	Cytochalasin B	66-80	membrane metallo-endopeptidase-like 1	Mus musculus	97-101
16953252-7	2007	Suppression of glucose metabolism with cytochalasin B was accompanied by suppression of leptin secretion.	Cytochalasin B	39-53	leptin	Rattus norvegicus	88-94
17604950-5	2007	END and ENK release triggered by a CXCR1/2 ligand in vitro was dependent on the presence of cytochalasin B (CyB) and on p38 MAPK, but not on p42/44 MAPK.	Cytochalasin B	92-106	proenkephalin	Rattus norvegicus	8-11
17604950-5	2007	END and ENK release triggered by a CXCR1/2 ligand in vitro was dependent on the presence of cytochalasin B (CyB) and on p38 MAPK, but not on p42/44 MAPK.	Cytochalasin B	92-106	C-X-C motif chemokine receptor 1	Rattus norvegicus	35-42
17604950-5	2007	END and ENK release triggered by a CXCR1/2 ligand in vitro was dependent on the presence of cytochalasin B (CyB) and on p38 MAPK, but not on p42/44 MAPK.	Cytochalasin B	108-111	proenkephalin	Rattus norvegicus	8-11
17604950-5	2007	END and ENK release triggered by a CXCR1/2 ligand in vitro was dependent on the presence of cytochalasin B (CyB) and on p38 MAPK, but not on p42/44 MAPK.	Cytochalasin B	108-111	C-X-C motif chemokine receptor 1	Rattus norvegicus	35-42
17763154-6	2007	The latter was partially inhibited by cytochalasin B thus indicating that a subpopulation of GPIIb-IIIa required cytoskeletal remodelling for translocation.	Cytochalasin B	38-52	integrin subunit alpha 2b	Homo sapiens	93-98
17626897-7	2007	The glucose transporter inhibitor cytochalasin B, the aldose reductase inhibitor alrestatin, and the advanced glycation end product formation inhibitor aminoguanidine attenuated HG-induced Ang II generation.	Cytochalasin B	34-48	angiotensinogen	Rattus norvegicus	189-195
17655889-3	2008	Compound 10 showed a significant inhibitory effect on the release of beta-glucuronidase from rat neutrophils stimulated with formyl-Met-Leu-Phe (fMLP)/cytochalasin B (CB) whereas compound 9 significantly inhibited superoxide anion formation in fMLP/CB-stimulated rat neutrophils.	Cytochalasin B	151-165	glucuronidase, beta	Rattus norvegicus	69-87
18042368-6	2007	In addition, binding of cytochalasin B indicated that the maximum binding to GLUT1 (Bmax) was reduced in deficient rats.	Cytochalasin B	24-38	solute carrier family 2 member 1	Rattus norvegicus	77-82
17400609-8	2007	Surface association of hCAP-18 on fMLF-stimulated neutrophils was confirmed by immunofluorescence microscopy and flow cytometry analysis, which also suggested a significant up-regulation of surface hCAP-18 on cytochalasin B-pretreated, fully degranulated neutrophils.	Cytochalasin B	209-223	cathelicidin antimicrobial peptide	Homo sapiens	23-30
17400609-8	2007	Surface association of hCAP-18 on fMLF-stimulated neutrophils was confirmed by immunofluorescence microscopy and flow cytometry analysis, which also suggested a significant up-regulation of surface hCAP-18 on cytochalasin B-pretreated, fully degranulated neutrophils.	Cytochalasin B	209-223	cathelicidin antimicrobial peptide	Homo sapiens	198-205
16843534-6	2006	In contrast, secretion of the proinflammatory cytokine Il-1beta by U937 cells was decreased after phagocytosis of apoptotic trophoblasts and the changes in both IL-10 and IL-1beta secretion were blocked by co-incubation with the phagocytosis inhibitor cytochalasin B.	Cytochalasin B	252-266	interleukin 1 beta	Homo sapiens	55-63
17030506-5	2006	Furthermore, superoxide production was remarkably reactivated by cytochalasin B addition after fMLP-stimulated production had disappeared, and this was correlated with highly activated p38 MAP kinase.	Cytochalasin B	65-79	formyl peptide receptor 1	Homo sapiens	95-99
17030506-5	2006	Furthermore, superoxide production was remarkably reactivated by cytochalasin B addition after fMLP-stimulated production had disappeared, and this was correlated with highly activated p38 MAP kinase.	Cytochalasin B	65-79	mitogen-activated protein kinase 14	Homo sapiens	185-199
16840500-8	2006	The association between L-selectin and c-Abl was reduced by cytochalasin B.	Cytochalasin B	60-74	selectin L	Homo sapiens	24-34
17040968-8	2007	Internalization accounted for at least 50% of macrophage-associated PAPP-A, as assessed in studies with cytochalasin B.	Cytochalasin B	104-118	pappalysin 1	Homo sapiens	68-74
16840500-8	2006	The association between L-selectin and c-Abl was reduced by cytochalasin B.	Cytochalasin B	60-74	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	39-44
16785555-7	2006	In other studies, eosinophils cocultured with epithelial cells were stimulated with FMLP/cytochalasin B (FMLP/B) and/or endothelin-1 (ET-1) before LTC(4) assay.	Cytochalasin B	89-103	formyl peptide receptor 1	Homo sapiens	105-109
16731301-8	2006	This ability could be inhibited by cytochalasin B (GLUT 1 inhibitor).	Cytochalasin B	35-49	solute carrier family 2 member 1	Homo sapiens	51-57
16626518-9	2006	Moreover, the inhibitor cytochalasin B largely blocked the increase of CD18 expression as well as the adhesion of PSGL-1-engaged neutrophils to ICAM-1.	Cytochalasin B	24-38	integrin subunit beta 2	Homo sapiens	71-75
16337244-5	2006	Inhibition of FFA release by these vanadyl compounds was found to be reversed by the addition of inhibitors, typically by cytochalasin B (glucose transporter 4 (GLUT4) inhibitor), cilostamide (phosphodiesterase inhibitor), HNMPA-(AM)3 (tyrosine kinase inhibitor), and wortmannin (PI3-k inhibitor), indicating that these compounds affect primarily GLUT4 and phosphodiesterase, as named "ensemble mechanism".	Cytochalasin B	122-136	solute carrier family 2 member 4	Homo sapiens	138-159
16337244-5	2006	Inhibition of FFA release by these vanadyl compounds was found to be reversed by the addition of inhibitors, typically by cytochalasin B (glucose transporter 4 (GLUT4) inhibitor), cilostamide (phosphodiesterase inhibitor), HNMPA-(AM)3 (tyrosine kinase inhibitor), and wortmannin (PI3-k inhibitor), indicating that these compounds affect primarily GLUT4 and phosphodiesterase, as named "ensemble mechanism".	Cytochalasin B	122-136	solute carrier family 2 member 4	Homo sapiens	161-166
16337244-5	2006	Inhibition of FFA release by these vanadyl compounds was found to be reversed by the addition of inhibitors, typically by cytochalasin B (glucose transporter 4 (GLUT4) inhibitor), cilostamide (phosphodiesterase inhibitor), HNMPA-(AM)3 (tyrosine kinase inhibitor), and wortmannin (PI3-k inhibitor), indicating that these compounds affect primarily GLUT4 and phosphodiesterase, as named "ensemble mechanism".	Cytochalasin B	122-136	solute carrier family 2 member 4	Homo sapiens	347-374
16626518-9	2006	Moreover, the inhibitor cytochalasin B largely blocked the increase of CD18 expression as well as the adhesion of PSGL-1-engaged neutrophils to ICAM-1.	Cytochalasin B	24-38	selectin P ligand	Homo sapiens	114-120
16626518-9	2006	Moreover, the inhibitor cytochalasin B largely blocked the increase of CD18 expression as well as the adhesion of PSGL-1-engaged neutrophils to ICAM-1.	Cytochalasin B	24-38	intercellular adhesion molecule 1	Homo sapiens	144-150
16640563-6	2006	The p130-angiomotin protein remained associated with actin after destabilization of actin fibers with cytochalasin B.	Cytochalasin B	102-116	nucleolar and coiled-body phosphoprotein 1	Homo sapiens	4-8
16640563-6	2006	The p130-angiomotin protein remained associated with actin after destabilization of actin fibers with cytochalasin B.	Cytochalasin B	102-116	angiomotin	Homo sapiens	9-19
16047190-5	2005	However, cellular ATP-level showed a transient increase at 2 h; also ROS levels increased up to 6 h. In cells treated with cytochalasin B (2 muM), which inhibits glucose uptake, the rate of O(2)-consumption increased and the acidification activity dropped, even upon glutamine depletion.	Cytochalasin B	123-137	latexin	Homo sapiens	141-144
16287074-6	2006	Treatment of SW480-LPL cells with cytochalasin B, an inhibitor of endocytosis, attenuated the loss of E-cadherin expression in these cells.	Cytochalasin B	34-48	cadherin 1	Homo sapiens	102-112
16380442-6	2006	Treatment with phalloidin or cytochalasin B attenuated the magnitude of the pHi-induced decrease in TRC volume.	Cytochalasin B	29-43	glucose-6-phosphate isomerase	Rattus norvegicus	76-79
16219911-0	2006	The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells.	Cytochalasin B	62-76	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	29-36
16219911-2	2006	In this study, we investigated the roles of survivin and securin on cytochalasin B, a cytokinesis blocker mediating the cytotoxicity and cell growth inhibition in human cancer cells.	Cytochalasin B	68-82	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	57-64
16219911-4	2006	Cytochalasin B significantly decreased cell survival, inhibited cell growth, increased the levels of G(2)/M fractions, and induced binuclei formation in lung carcinoma cells; however, the survivin proteins were concentration-dependently increased by 1 to 5 mug/ml cytochalasin B for 24 h. It is noteworthy that the expression of securin proteins was decreased in cytochalasin B-treated lung carcinoma cells.	Cytochalasin B	0-14	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	329-336
16219911-7	2006	In addition, the securin-null colorectal carcinoma cells were more susceptible to the cytotoxicity after cytochalasin B and survivin siRNA treatments than the securin-wild-type cells.	Cytochalasin B	105-119	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	17-24
16219911-8	2006	As a whole, our results indicate that the inhibition of survivin and securin protein expression may increase the cell death and growth inhibition after cytochalasin B treatment in human cancer cells.	Cytochalasin B	152-166	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	69-76
16466666-6	2006	The increase in intracellular SOD activity was significantly inhibited in the presence of cytochalasin B, an endocytosis inhibitor.	Cytochalasin B	90-104	superoxide dismutase 1	Homo sapiens	30-33
16466666-8	2006	In addition, the protective effect of Cat-SOD against paraquat-induced cell injury was completely abolished by the presence of cytochalasin B.	Cytochalasin B	127-141	superoxide dismutase 1	Homo sapiens	42-45
16489404-3	2006	In present study, we discussed the effects of cell microfilament on the activity of collagen type I alpha 1 chain gene (COL1A1) promoter under microgravity simulated by clinostat and/or cytochalasin B as microfilament depolymerizer in the established EGFP-ROS cell line using the method of fluorescence semi-quantitative analysis and the fluorescent stain of microfilament.	Cytochalasin B	186-200	collagen type I alpha 1 chain	Rattus norvegicus	84-107
16489404-3	2006	In present study, we discussed the effects of cell microfilament on the activity of collagen type I alpha 1 chain gene (COL1A1) promoter under microgravity simulated by clinostat and/or cytochalasin B as microfilament depolymerizer in the established EGFP-ROS cell line using the method of fluorescence semi-quantitative analysis and the fluorescent stain of microfilament.	Cytochalasin B	186-200	collagen type I alpha 1 chain	Rattus norvegicus	120-126
16489404-5	2006	Treatment with suitable concentration of cytochalasin B in normal gravity induced disruption of microfilament, increased the activity of COL1A1 promoter and resulted in a dose-dependent increase of EGFP fluorescence.	Cytochalasin B	41-55	collagen type I alpha 1 chain	Rattus norvegicus	137-143
15759055-10	2005	Cytochalasin B pretreatment attenuated p38MAP kinase and JNK effects (p < 0.05) without altering ERK1/2 phosphorylation.	Cytochalasin B	0-14	mitogen-activated protein kinase 1	Homo sapiens	39-42
15820500-7	2005	After pre-incubation of PG50 with cytochalasin B, the exocytosis of elastase was initiated using PAF and fMLP.	Cytochalasin B	34-48	elastase, neutrophil expressed	Homo sapiens	68-76
15820500-7	2005	After pre-incubation of PG50 with cytochalasin B, the exocytosis of elastase was initiated using PAF and fMLP.	Cytochalasin B	34-48	formyl peptide receptor 1	Homo sapiens	105-109
15823019-6	2005	GLUT1-HA-H6 confers GLUT1-specific sugar transport characteristics to transfected RE700A, including inhibition by cytochalasin B and high-affinity transport of the nonmetabolized sugar 3-O-methylglucose.	Cytochalasin B	114-128	solute carrier family 2 member 1	Homo sapiens	0-5
15823019-6	2005	GLUT1-HA-H6 confers GLUT1-specific sugar transport characteristics to transfected RE700A, including inhibition by cytochalasin B and high-affinity transport of the nonmetabolized sugar 3-O-methylglucose.	Cytochalasin B	114-128	solute carrier family 2 member 1	Homo sapiens	20-25
15661859-7	2005	This pattern of inhibition of GLUT4 was also observed with cytochalasin B.	Cytochalasin B	59-73	solute carrier family 2 member 4	Rattus norvegicus	30-35
15800051-2	2005	Cytochalasin B inhibited hKv1.5 currents rapidly and reversibly at +60 mV in a concentration-dependent manner with an IC(50) of 4.2 microM.	Cytochalasin B	0-14	potassium voltage-gated channel subfamily A member 5	Homo sapiens	25-31
15800051-3	2005	Cytochalasin A, which has a structure very similar to cytochalasin B, inhibited hKv1.5 (IC(50) of 1.4 microM at +60 mV).	Cytochalasin B	54-68	potassium voltage-gated channel subfamily A member 5	Homo sapiens	80-86
15800051-6	2005	Cytochalasin B-induced inhibition of the hKv1.5 channels was voltage dependent with a steep increase over the voltage range of the channel"s opening.	Cytochalasin B	0-14	potassium voltage-gated channel subfamily A member 5	Homo sapiens	41-47
15800051-10	2005	Cytochalasin B produced a use-dependent inhibition of hKv1.5 current that was consistent with the slow recovery from inactivation in the presence of the drug.	Cytochalasin B	0-14	potassium voltage-gated channel subfamily A member 5	Homo sapiens	54-60
15800051-12	2005	These results indicate that cytochalasin B primarily blocks activated hKv1.5 channels and endogenous I(K,ur) in a cytoskeleton-independent manner as an open-channel blocker.	Cytochalasin B	28-42	potassium voltage-gated channel subfamily A member 5	Homo sapiens	70-76
15856411-3	2005	Compounds 1, 4, and 5 showed significant concentration-dependent inhibitory effects on the release of beta-glucuronidase from rat neutrophils in response to formyl-Met-Leu-Phe/cytochalasin B (fMLP/CB) with IC50 values of 5.5 +/- 1.8, 8.4 +/- 2.9 and 19.2 +/- 3.3 microM, respectively.	Cytochalasin B	176-190	glucuronidase, beta	Rattus norvegicus	102-120
15759055-10	2005	Cytochalasin B pretreatment attenuated p38MAP kinase and JNK effects (p < 0.05) without altering ERK1/2 phosphorylation.	Cytochalasin B	0-14	mitogen-activated protein kinase 8	Homo sapiens	57-60
15759055-11	2005	ROS formation, which was increased in Ang II stimulated cells, was significantly reduced by cytochalasin B (p < 0.01).	Cytochalasin B	92-106	angiogenin	Homo sapiens	38-41
15642415-4	2005	2"-Hydroxychalcones 1-3, and 2",5"-dihydroxychalcone 7 exhibited potent inhibitory effects on the release of beta-glucuronidase or lysozyme from rat neutrophils stimulated with formyl-Met-Leu-Phe (fMLP)/cytochalasin B (CB).	Cytochalasin B	203-217	lysozyme	Homo sapiens	131-139
14674705-2	2003	In this study, the effects of cytochalasin B on the apoptosis-related proteins, protein kinase B and survivin were investigated.	Cytochalasin B	30-44	protein tyrosine kinase 2 beta	Homo sapiens	80-96
15058574-0	2004	Ethanol weakens cytochalasin B binding to the GLUT1 glucose transporter and drug partitioning into lipid bilayers.	Cytochalasin B	16-30	solute carrier family 2 member 1	Homo sapiens	46-51
15058574-1	2004	Ethanol weakens the specific interaction between the human red blood cell (RBC) glucose transporter GLUT1 and the inhibitor cytochalasin B (CB).	Cytochalasin B	124-138	solute carrier family 2 member 1	Homo sapiens	100-105
15496451-3	2005	The endocytosis inhibitor, cytochalasin B, reduced tumor necrosis factor alpha (TNF-alpha) production by a plasmid DNA (pDNA)/cationic liposome complex.	Cytochalasin B	27-41	tumor necrosis factor	Mus musculus	51-78
15496451-3	2005	The endocytosis inhibitor, cytochalasin B, reduced tumor necrosis factor alpha (TNF-alpha) production by a plasmid DNA (pDNA)/cationic liposome complex.	Cytochalasin B	27-41	tumor necrosis factor	Mus musculus	80-89
16399354-9	2005	Supernatants obtained from neutrophils stimulated with cytochalasin B and ionomycin showed higher levels of beta-glucuronidase activity than those of nonstimulated neutrophils.	Cytochalasin B	55-69	glucuronidase beta	Homo sapiens	108-126
15033941-5	2004	The Glut2 transporter inhibitors phloretin and cytochalasin B added following 30-min mannose uptake reduced the previously accumulated D-mannose, whereas these two agents increased the cell to external medium 3-O-methyl-glucose (3-OMG) concentration ratio.	Cytochalasin B	47-61	solute carrier family 2 member 2	Gallus gallus	4-9
15157285-0	2004	Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils.	Cytochalasin B	0-14	tumor necrosis factor	Homo sapiens	69-78
15157285-3	2004	RESULTS: Tumor necrosis factor alpha (TNF-alpha) primes neutrophils for subsequent activation by cytochalasin B.	Cytochalasin B	97-111	tumor necrosis factor	Homo sapiens	9-36
15157285-3	2004	RESULTS: Tumor necrosis factor alpha (TNF-alpha) primes neutrophils for subsequent activation by cytochalasin B.	Cytochalasin B	97-111	tumor necrosis factor	Homo sapiens	38-47
15157285-4	2004	Pretreatment with TNF-alpha induced mobilization of receptor-storing neutrophil organelles, suggesting that receptor up-regulation significantly contributes to the response, but the receptor mobilization was not sufficient for induction of the cytochalasin B sensitive state.	Cytochalasin B	244-258	tumor necrosis factor	Homo sapiens	18-27
15157285-9	2004	CONCLUSIONS: The TNF-alpha-induced priming signals could possibly trigger a release of an endogenous GPCR-agonist, amplifying the response to the receptor-uncoupling effect of cytochalasin B.	Cytochalasin B	176-190	tumor necrosis factor	Homo sapiens	17-26
14623873-8	2004	In addition, the continuous exchange of flavocytochrome b(558)-bound p67GFP and GFP-Rac2 for cytosolic p67GFP and GFP-Rac2 was still intact in cytochalasin B-treated cells, indicating that the translocation of these proteins does not depend on a rearrangement of the actin cytoskeleton.	Cytochalasin B	143-157	Rac family small GTPase 2	Homo sapiens	84-88
14668487-7	2004	The actin depolymerizing agent cytochalasin B inhibited this KLEIP recruitment around E-cadherin-coated beads.	Cytochalasin B	31-45	kelch like family member 20	Homo sapiens	61-66
14668487-7	2004	The actin depolymerizing agent cytochalasin B inhibited this KLEIP recruitment around E-cadherin-coated beads.	Cytochalasin B	31-45	cadherin 1	Canis lupus familiaris	86-96
12522806-9	2003	Increasing concentrations of cytochalasin B (0-50 microM) inhibited macrophage spreading and reduced BMP-2 mRNA expression, suggesting a relationship between cell shape and BMP-2 expression.	Cytochalasin B	29-43	bone morphogenetic protein 2	Mus musculus	101-106
14627128-11	2003	Both secretion of IL-12 p70 and IFN-gamma and activation of NF-kappaB induced by OK-432 were suppressed when imMo-DCs were pretreated with cytochalasin B.	Cytochalasin B	139-153	ubiquitin associated and SH3 domain containing B	Homo sapiens	24-27
14627128-11	2003	Both secretion of IL-12 p70 and IFN-gamma and activation of NF-kappaB induced by OK-432 were suppressed when imMo-DCs were pretreated with cytochalasin B.	Cytochalasin B	139-153	interferon gamma	Homo sapiens	32-41
14627128-11	2003	Both secretion of IL-12 p70 and IFN-gamma and activation of NF-kappaB induced by OK-432 were suppressed when imMo-DCs were pretreated with cytochalasin B.	Cytochalasin B	139-153	nuclear factor kappa B subunit 1	Homo sapiens	60-69
12937300-9	2003	The glucose transport inhibitors cytochalasin B (0.5 to 50 micro M) and phloretin (0.05 to 0.25 mM) mimicked the effect of acidosis and reduced leptin secretion in a dose-dependent fashion (P < 0.02).	Cytochalasin B	33-47	leptin	Rattus norvegicus	144-150
12873613-7	2003	Cytochalasin B, a specific inhibitor of the glucose transporter (GLUT) protein, produced significant hyperglycemia in the mice.	Cytochalasin B	0-14	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	44-63
12873613-7	2003	Cytochalasin B, a specific inhibitor of the glucose transporter (GLUT) protein, produced significant hyperglycemia in the mice.	Cytochalasin B	0-14	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	65-69
12642506-11	2003	Treatment with a beta1-integrin-blocking antibody or integrin signaling inhibitor cytochalasin B but not growth factor receptor inhibitor suramin abrogated both stretch-induced phosphorylation of p38 MAPK and p53 expression.	Cytochalasin B	82-96	tumor protein p53	Homo sapiens	209-212
12642506-12	2003	Akin to the inhibition of p38 MAPK-p53 signaling, pretreatment with a beta1-integrin-blocking antibody or cytochalasin B but not suramin inhibited stretch-induced apoptosis on collagen plates.	Cytochalasin B	106-120	tumor protein p53	Homo sapiens	35-38
12628696-7	2003	The GLUT1 inhibitor cytochalasin B and the GLUT1 substrate 2-deoxy-D-glucose did not inhibit Tyr transport into the cells.	Cytochalasin B	20-34	solute carrier family 2 member 1	Homo sapiens	4-9
12628696-8	2003	Upon immobilized biomembrane affinity chromatography, Trp decreased the cytochalasin B retardation by GLUT1 only at levels far above the physiological Trp concentration.	Cytochalasin B	72-86	solute carrier family 2 member 1	Homo sapiens	102-107
14615410-6	2003	Moreover, the actin-binding protein ezrin was expressed on phagocytic vacuoles of melanoma cells and of cells deriving from a human adenocarcinoma; both treatment with cytochalasin B and specific inhibition of ezrin synthesis strongly affected the phagocytic activity of melanoma cells.	Cytochalasin B	168-182	ezrin	Homo sapiens	36-41
12796497-6	2003	hVPLA2 also augmented the release of AA and LTC4 from eosinophils activated with formyl-Met-Leu-Phe + cytochalasin B.	Cytochalasin B	102-116	phospholipase A2 group V	Homo sapiens	0-6
12522806-9	2003	Increasing concentrations of cytochalasin B (0-50 microM) inhibited macrophage spreading and reduced BMP-2 mRNA expression, suggesting a relationship between cell shape and BMP-2 expression.	Cytochalasin B	29-43	bone morphogenetic protein 2	Mus musculus	173-178
12701204-2	2003	In membrane transportation studies, the uptake of 14C-FDG into erythrocytes decreased with an increase in glucose concentration, and Cytochalasin B, inhibitor of glucose transporter (GLUT), blocked the uptake about 75%.	Cytochalasin B	133-147	solute carrier family 2 member 1	Homo sapiens	183-187
12417182-7	2003	Expression of PCNA was suppressed in the presence of Cytochalasin B, Cytochalasin D, Aphidicolin, and AraC.	Cytochalasin B	53-67	proliferating cell nuclear antigen	Ovis aries	14-18
12504199-3	2003	This allowed improved frontal affinity chromatographic analyses of cytochalasin B (CB)-binding to the glucose transporter GLUT1 which established a ratio of one CB-binding site per GLUT1 dimer for both plain RBCs or those treated with different poly amino acids.	Cytochalasin B	67-81	solute carrier family 2 member 1	Homo sapiens	122-127
12504199-3	2003	This allowed improved frontal affinity chromatographic analyses of cytochalasin B (CB)-binding to the glucose transporter GLUT1 which established a ratio of one CB-binding site per GLUT1 dimer for both plain RBCs or those treated with different poly amino acids.	Cytochalasin B	67-81	solute carrier family 2 member 1	Homo sapiens	181-186
12391262-7	2002	Cytochalasin B, an actin disruptor, alone stimulated actin-mediated nuclear translocation of Nrf2 and induced rGSTA2.	Cytochalasin B	0-14	NFE2 like bZIP transcription factor 2	Rattus norvegicus	93-97
12558136-4	2003	By brief exposure (10-120 min) to LPS, CD14 was transferred to the surface in a cytochalasin B-sensitive manner, as were CD16 and CD64.	Cytochalasin B	80-94	CD14 molecule	Homo sapiens	39-43
12558136-4	2003	By brief exposure (10-120 min) to LPS, CD14 was transferred to the surface in a cytochalasin B-sensitive manner, as were CD16 and CD64.	Cytochalasin B	80-94	Fc gamma receptor IIIa	Homo sapiens	121-125
12391262-7	2002	Cytochalasin B, an actin disruptor, alone stimulated actin-mediated nuclear translocation of Nrf2 and induced rGSTA2.	Cytochalasin B	0-14	glutathione S-transferase alpha 2	Rattus norvegicus	110-116
12590949-5	2002	In contrast, thrombin-induced shape change was inhibited by cytochalasin B but not by taxol.	Cytochalasin B	60-74	prothrombin	Oryctolagus cuniculus	13-21
12370398-7	2002	The expression of PAR-2 on the cell surface was promoted by PR3, and inhibited by cytochalasin B, but not by cycloheximide.	Cytochalasin B	82-96	F2R like trypsin receptor 1	Homo sapiens	18-23
12381828-2	2002	Phloretin or cytochalasin B was used to inhibit GLUT2 and phloridzin to inhibit SGLT1.	Cytochalasin B	13-27	solute carrier family 2 member 2	Rattus norvegicus	48-53
12381828-2	2002	Phloretin or cytochalasin B was used to inhibit GLUT2 and phloridzin to inhibit SGLT1.	Cytochalasin B	13-27	solute carrier family 5 member 1	Rattus norvegicus	80-85
12381828-7	2002	Simultaneous inhibition of SGLT1 and GLUT2 in high stress perfusions with phloridzin and cytochalasin B inhibited absorption by 92 +/- 7 %; non-carrier-mediated transport is therefore minimal.	Cytochalasin B	89-103	solute carrier family 2 member 2	Rattus norvegicus	37-42
12166630-6	2002	The elevations in TBARS concentrations were blocked by cytochalasin B, a GLUT inhibitor.	Cytochalasin B	55-69	solute carrier family 2 member 1	Homo sapiens	73-77
12237255-12	2002	They also suggest that cytochalasin B, genistein, and SB203580 inhibit GPI-80 release by suppressing signals for cell adherence, rather than by a direct effect on its secretion.	Cytochalasin B	23-37	vanin 2	Homo sapiens	71-77
12032668-3	2002	Here we show that although disruption of the actin cytoskeleton by cytochalasin B (CyB) itself induces moderate apoptosis, it enhances apoptosis in HeLa cells induced either by UV radiation or an agonistic anti-CD95 antibody.	Cytochalasin B	67-81	Fas cell surface death receptor	Homo sapiens	211-215
11786928-0	2002	Effects of cytochalasin B and D upon insulin release and pancreatic islet cell metabolism.	Cytochalasin B	11-25	insulin	Homo sapiens	37-44
11939556-7	2002	Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competitive substrate D-glucose (non-labeled) showed that GLUT1 interconverted between two states, exhibiting one or two cytochalasin B-binding sites per two GLUTI monomers, dependent on the membrane composition and environment.	Cytochalasin B	85-99	solute carrier family 2 member 1	Homo sapiens	55-60
11939556-7	2002	Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competitive substrate D-glucose (non-labeled) showed that GLUT1 interconverted between two states, exhibiting one or two cytochalasin B-binding sites per two GLUTI monomers, dependent on the membrane composition and environment.	Cytochalasin B	85-99	solute carrier family 2 member 1	Homo sapiens	190-195
11939556-7	2002	Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competitive substrate D-glucose (non-labeled) showed that GLUT1 interconverted between two states, exhibiting one or two cytochalasin B-binding sites per two GLUTI monomers, dependent on the membrane composition and environment.	Cytochalasin B	253-267	solute carrier family 2 member 1	Homo sapiens	55-60
11939556-7	2002	Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competitive substrate D-glucose (non-labeled) showed that GLUT1 interconverted between two states, exhibiting one or two cytochalasin B-binding sites per two GLUTI monomers, dependent on the membrane composition and environment.	Cytochalasin B	253-267	solute carrier family 2 member 1	Homo sapiens	190-195
11830497-6	2002	PLD activity increased by 3-fold in G-CSF-primed PMNs stimulated by FMLP and by 30-fold in cytochalasin B-treated PMNs stimulated by FMLP.	Cytochalasin B	91-105	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-3
11830497-6	2002	PLD activity increased by 3-fold in G-CSF-primed PMNs stimulated by FMLP and by 30-fold in cytochalasin B-treated PMNs stimulated by FMLP.	Cytochalasin B	91-105	formyl peptide receptor 1	Homo sapiens	133-137
11830497-8	2002	In conclusion, superoxide, gelatinase, and lactoferrin release require activation of the PLD pathway in primed PMNs and cytochalasin B-treated PMNs.	Cytochalasin B	120-134	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	89-92
11786928-1	2002	Cytochalasin B is known to enhance insulin release evoked by nutrient and non-nutrient secretagogues, including D-glucose, despite inhibiting D-glucose uptake and metabolism in pancreatic islets.	Cytochalasin B	0-14	insulin	Homo sapiens	35-42
11786928-5	2002	Nevertheless, even in the presence of forskolin, cytochalasin B was more efficient than cytochalasin D in augmenting glucose-stimulated insulin secretion.	Cytochalasin B	49-63	insulin	Homo sapiens	136-143
11786928-6	2002	Thus, although these data document that non-B islet cells are more sensitive than purified islet B cells to cytochalasin B, at least in terms of inhibition of D-glucose catabolism, such a difference and its possible consequence upon the release of glucagon and other non-insulinic hormones by non-B islet cells do not appear sufficient to account for the greater enhancing action of cytochalasin B, as distinct from cytochalasin D, upon glucose-stimulated insulin output.	Cytochalasin B	108-122	insulin	Homo sapiens	271-278
11150242-7	2001	Conversely, disturbance of the aggregation of cyclin B mRNA with a low concentration (1 microg/ml) of cytochalasin B inhibited 17alpha,20beta-DP-induced GVBD.	Cytochalasin B	102-116	cyclin B1	Danio rerio	46-54
11794696-1	2001	Cytochalasin B, despite its potent enhancing effect on superoxide (O2-) release triggered by N-formyl-methionyl-leucyl-phenylalanine (FMLP) and many other agonists, significantly inhibited O2- release triggered by interleukin 8 (IL-8) and platelet-activating factor in human neutrophils.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	134-138
11794696-1	2001	Cytochalasin B, despite its potent enhancing effect on superoxide (O2-) release triggered by N-formyl-methionyl-leucyl-phenylalanine (FMLP) and many other agonists, significantly inhibited O2- release triggered by interleukin 8 (IL-8) and platelet-activating factor in human neutrophils.	Cytochalasin B	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	214-227
11794696-1	2001	Cytochalasin B, despite its potent enhancing effect on superoxide (O2-) release triggered by N-formyl-methionyl-leucyl-phenylalanine (FMLP) and many other agonists, significantly inhibited O2- release triggered by interleukin 8 (IL-8) and platelet-activating factor in human neutrophils.	Cytochalasin B	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	229-233
11557588-2	2001	Activation with formyl-Met-Leu-Phe + cytochalasin B (fMLP/B) caused a time-dependent release of eosinophil peroxidase (EPO) and LTC(4), which was inhibited by pertussis toxin.	Cytochalasin B	37-51	formyl peptide receptor 1	Homo sapiens	53-57
11557588-2	2001	Activation with formyl-Met-Leu-Phe + cytochalasin B (fMLP/B) caused a time-dependent release of eosinophil peroxidase (EPO) and LTC(4), which was inhibited by pertussis toxin.	Cytochalasin B	37-51	eosinophil peroxidase	Homo sapiens	96-117
11557588-2	2001	Activation with formyl-Met-Leu-Phe + cytochalasin B (fMLP/B) caused a time-dependent release of eosinophil peroxidase (EPO) and LTC(4), which was inhibited by pertussis toxin.	Cytochalasin B	37-51	eosinophil peroxidase	Homo sapiens	119-122
11590193-10	2001	The CD1c exocytosis pathway was sensitive to Brefeldin A, cytochalasin B, and chloroquine.	Cytochalasin B	58-72	CD1c molecule	Homo sapiens	4-8
11472441-3	2001	We have now investigated the effect of metalloproteinase inhibitors and a serine proteinase inhibitor on the shedding of Fc gamma RIIIb induced by phorbol 12-myristate 13-acetate (PMA) or cytochalasin B (cyto B) + N-formyl-methionyl-leucyl-phenylalanine (fMLP).	Cytochalasin B	188-202	Fc gamma receptor IIIb	Homo sapiens	121-135
11435497-5	2001	Cycloheximide, monodansylcadaverine, and cytochalasin B all blocked TNF-alpha release from macrophages stimulated with LTA or poly I:C, whereas monensin only nominally reduced TNF-alpha production.	Cytochalasin B	41-55	tumor necrosis factor	Mus musculus	68-77
11402500-7	2001	Effect of actin filament polymerization blocking agent, cytochalasin B, was also studied and it was found that cytochalasin B completely inhibited CD147 mAb-induced cell aggregation.	Cytochalasin B	111-125	basigin (Ok blood group)	Homo sapiens	147-152
11747430-4	2001	Phloretin-inhibitable cytochalasin B binding to human red blood cells, to human red blood cell integral membrane proteins, and to purified human red blood cell glucose transport protein (GluT1) displays positive cooperativity at very low cytochalasin B levels.	Cytochalasin B	22-36	solute carrier family 2 member 1	Homo sapiens	187-192
11747430-10	2001	ATP (but not AMP) enhances [3H]cytochalasin B photoincorporation into GluT1 while cytochalasin B (but not cytochalasin D) enhances [gamma-32P]azidoATP photoincorporation into GluT1.	Cytochalasin B	31-45	solute carrier family 2 member 1	Homo sapiens	70-75
11794696-2	2001	Cytochalasin B also enhanced changes in membrane potential stimulated by FMLP but inhibited those stimulated by IL-8.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	73-77
11794696-2	2001	Cytochalasin B also enhanced changes in membrane potential stimulated by FMLP but inhibited those stimulated by IL-8.	Cytochalasin B	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	112-116
11594756-6	2001	MRASAL proteins were localized at the plasma membrane in NIH3T3 cells, and this plasma membrane association was unchanged even after cytochalasin B or wortmannin treatment.	Cytochalasin B	133-147	RAS protein activator like 1 (GAP1 like)	Mus musculus	0-6
11498455-7	2001	Selective inhibition of Rho-kinase by Y-27632 (10 micromol/L) and selective disruption of the actin filament network by cytochalasin B (10 micromol/L) both decreased the Ang II-induced contraction by 78+/-1.2% and 87+/-1.9%, respectively, and significantly diminished ERK1/2 activity.	Cytochalasin B	120-134	angiotensinogen	Rattus norvegicus	170-176
11498455-10	2001	Pressure-induced ERK1/2 activation was markedly attenuated by cytochalasin B but not by Y-27632.	Cytochalasin B	62-76	mitogen activated protein kinase 3	Rattus norvegicus	17-23
11448159-7	2001	Activation of JNK1 by Tat was also inhibited by cytochalasin B, suggesting that Tat signaling was dependent upon intact cytoskeletal function.	Cytochalasin B	48-62	mitogen-activated protein kinase 8	Homo sapiens	14-18
11448159-7	2001	Activation of JNK1 by Tat was also inhibited by cytochalasin B, suggesting that Tat signaling was dependent upon intact cytoskeletal function.	Cytochalasin B	48-62	tyrosine aminotransferase	Homo sapiens	22-25
11448159-7	2001	Activation of JNK1 by Tat was also inhibited by cytochalasin B, suggesting that Tat signaling was dependent upon intact cytoskeletal function.	Cytochalasin B	48-62	tyrosine aminotransferase	Homo sapiens	80-83
11309203-5	2001	Treatment of oocytes with cytochalasin B caused clumping of Vg1 and Xwnt-11 as revealed by in situ hybridization of the IVC, but did not cause their release, as confirmed by RT-PCR analysis.	Cytochalasin B	26-40	growth differentiation factor 1 S homeolog	Xenopus laevis	60-63
11309203-5	2001	Treatment of oocytes with cytochalasin B caused clumping of Vg1 and Xwnt-11 as revealed by in situ hybridization of the IVC, but did not cause their release, as confirmed by RT-PCR analysis.	Cytochalasin B	26-40	wingless-type MMTV integration site family, member 11B L homeolog	Xenopus laevis	68-75
11248211-3	2001	In an effort to identify this putative GLUT1 inhibitor molecule, we studied here the effects of adenosine and adenosine triphosphate (ATP) on the binding of D-glucose to GLUT1 by assessing their abilities to displace cytochalasin B (CB), using purified GLUT1 in vesicles.	Cytochalasin B	217-231	solute carrier family 2 member 1	Homo sapiens	39-44
11248211-3	2001	In an effort to identify this putative GLUT1 inhibitor molecule, we studied here the effects of adenosine and adenosine triphosphate (ATP) on the binding of D-glucose to GLUT1 by assessing their abilities to displace cytochalasin B (CB), using purified GLUT1 in vesicles.	Cytochalasin B	217-231	solute carrier family 2 member 1	Homo sapiens	170-175
11248211-3	2001	In an effort to identify this putative GLUT1 inhibitor molecule, we studied here the effects of adenosine and adenosine triphosphate (ATP) on the binding of D-glucose to GLUT1 by assessing their abilities to displace cytochalasin B (CB), using purified GLUT1 in vesicles.	Cytochalasin B	217-231	solute carrier family 2 member 1	Homo sapiens	170-175
11327057-9	2001	The thrombin-induced collagen lattice contraction was inhibited by PPACK (20 microg/ml) and an actin filament polymerization inhibitor, cytochalasin B (1 microg/ml).	Cytochalasin B	136-150	coagulation factor II, thrombin	Homo sapiens	4-12
11175497-8	2001	iNOS expression was increased by IFN-gamma treatment, while calcium ionophore and cytochalasin B had a negative influence on both myosin and iNOS expression, which was decreased.	Cytochalasin B	82-96	nitric oxide synthase 2, inducible	Mus musculus	141-145
11169502-3	2001	This portion of beta-glucuronidase was resistant to extractions in the presence of 1 M KCl, chaotropic agents, colchicine, or cytochalasin B, being only partially solubilized by 3 M KCl or DNAse I treatment.	Cytochalasin B	126-140	LOW QUALITY PROTEIN: beta-glucuronidase	Capra hircus	16-34
11244575-5	2001	Disruption of cytoskeletal organization with colchicine or cytochalasin B stimulated IL-1beta gene transcription and enhanced the cells" response to Col.	Cytochalasin B	59-73	interleukin 1 beta	Homo sapiens	85-93
11242283-11	2001	Cytoskeletal disruption (cytochalasin B) prevented HTS attenuation of receptor-mediated p38 MAPK activation.	Cytochalasin B	25-39	mitogen-activated protein kinase 14	Homo sapiens	88-91
10970799-7	2000	When the endocytosis of oxLDL was blocked by cytochalasin B, NF-kappaB transactivation by oxLDL was synergistically increased, while PPAR transactivation was blocked.	Cytochalasin B	45-59	peroxisome proliferator activated receptor alpha	Mus musculus	133-137
12064594-4	2001	However, disruption of microfilaments with cytochalasin B inhibited the recruitment and assembly of both Cx26-YFP and Cx43-GFP into gap junctions within photobleached areas.	Cytochalasin B	43-57	gap junction protein beta 2	Homo sapiens	105-109
12064594-4	2001	However, disruption of microfilaments with cytochalasin B inhibited the recruitment and assembly of both Cx26-YFP and Cx43-GFP into gap junctions within photobleached areas.	Cytochalasin B	43-57	gap junction protein alpha 1	Homo sapiens	118-126
11329620-6	2001	Translocation of Btk to the cytoskeleton but not aggregation was prevented by cytochalasin B, which inhibits actin polymerization.	Cytochalasin B	78-92	Bruton tyrosine kinase	Homo sapiens	17-20
11517664-5	2001	Under stress-less conditions cytochalasin B would result in an increased water transport through the cytoplasmic channel of plasmodesmata due apparently to a destruction of their actin-myosin sphincters.	Cytochalasin B	29-43	actin-7	Triticum aestivum	179-184
11082199-0	2000	Conversion between two cytochalasin B-binding states of the human GLUT1 glucose transporter.	Cytochalasin B	23-37	solute carrier family 2 member 1	Homo sapiens	66-71
11082199-1	2000	Two cytochalasin B-binding states of the human red blood cell facilitative glucose transporter GLUT1 were studied, one exhibiting one cytochalasin B-binding site on every second GLUT1 monomer (state 1) and the other showing one site per monomer (state 2).	Cytochalasin B	4-18	solute carrier family 2 member 1	Homo sapiens	95-100
11082199-10	2000	In summary, the cytochalasin B-binding state of GLUT1 seemed to be affected by (a) biotinylation of the cell surface, (b) removal of the cytoskeleton at high pH and low ionic strength, (c) interaction between the dextran-grafted agarose gel matrix and the membrane vesicles, and (d) reconstitution to form proteoliposomes.	Cytochalasin B	16-30	solute carrier family 2 member 1	Homo sapiens	48-53
11052983-0	2000	Cytochalasin B modulation of Caco-2 tight junction barrier: role of myosin light chain kinase.	Cytochalasin B	0-14	myosin light chain kinase	Homo sapiens	68-93
11052983-3	2000	Cytochalasin B (Cyto B) (5 microg/ml) produced an increase in Caco-2 MLCK activity, which correlated with the increase in Caco-2 TJ permeability.	Cytochalasin B	0-14	myosin light chain kinase	Homo sapiens	69-73
11052983-3	2000	Cytochalasin B (Cyto B) (5 microg/ml) produced an increase in Caco-2 MLCK activity, which correlated with the increase in Caco-2 TJ permeability.	Cytochalasin B	16-22	myosin light chain kinase	Homo sapiens	69-73
11035728-8	2000	Similar effects of porin on the chemiluminescence response were observed in cytochalasin B-treated neutrophils exposed to the soluble chemotactic peptide N-formylmethionyl-leucyl-phenylalanine.	Cytochalasin B	76-90	voltage dependent anion channel 1	Homo sapiens	19-24
11035061-9	2000	An inhibitor of phagocytosis, cytochalasin B, abrogated the induction of TNF-alpha in CD14-deficient macrophages by E. coli.	Cytochalasin B	30-44	tumor necrosis factor	Mus musculus	73-82
11035061-9	2000	An inhibitor of phagocytosis, cytochalasin B, abrogated the induction of TNF-alpha in CD14-deficient macrophages by E. coli.	Cytochalasin B	30-44	CD14 antigen	Mus musculus	86-90
11150242-5	2001	Cytochalasin B, but not nocodazole or taxol, deformed the aggregation of cyclin B mRNA, indicating the involvement of microfilaments in organizing this form.	Cytochalasin B	0-14	cyclin B1	Danio rerio	73-81
11150242-6	2001	Like 17alpha,20beta-DP, cytochalasin B (10 microg/ml) induced both complete dispersion of the aggregation and translational activation of cyclin B mRNA, forcing the oocytes to undergo GVBD without 17alpha,20beta-DP.	Cytochalasin B	24-38	cyclin B1	Danio rerio	138-146
11202232-2	2000	The CD23 expression on the U937 cells was enhanced at 24 hr after culture with cytochalasin B, D, or E, especially cytochalasin E having the most remarkable effect on it at the low concentration.	Cytochalasin B	79-93	Fc epsilon receptor II	Homo sapiens	4-8
11015298-2	2000	Following pre-treatment with 5 microg ml(-1) cytochalasin B(CB), C5a induced a concentration-dependent release of EPO from eosinophils isolated from healthy donors.	Cytochalasin B	45-59	complement C5a receptor 1	Homo sapiens	65-68
11015298-2	2000	Following pre-treatment with 5 microg ml(-1) cytochalasin B(CB), C5a induced a concentration-dependent release of EPO from eosinophils isolated from healthy donors.	Cytochalasin B	45-59	erythropoietin	Homo sapiens	114-117
10920220-5	2000	Pretreatment of MG-63 cells with cytochalasin B prevented the particle-induced increase of IL-6 expression but did not alter the basal level of IL-6 release from cells cultured in the absence of particles.	Cytochalasin B	33-47	interleukin 6	Homo sapiens	91-95
10903502-5	2000	ERK-1/2 hyperphosphorylation was dependent on intact cytoskeleton, as treatment with cytochalasin B and nocodazole blocked this activity.	Cytochalasin B	85-99	mitogen-activated protein kinase 3	Homo sapiens	0-7
10825458-6	2000	The purified GLUT2 catalyzed mercury chloride-sensitive 3OMG uptake, and cytochalasin B inhibited this 3OMG uptake.	Cytochalasin B	73-87	solute carrier family 2 member 2	Rattus norvegicus	13-18
10814971-9	2000	The release of MPO, estimated by the chemiluminescence of the luminol/H(2)O(2) reaction in the supernatant of PMN incubated in the absence and presence of stimuli and absence and presence of cytochalasin B, was also higher for PMN isolated by a density gradient.	Cytochalasin B	191-205	myeloperoxidase	Homo sapiens	15-18
10821868-4	2000	COS-7 cells transfected with GLUT8 cDNA expressed a 42-kDa protein exhibiting specific, glucose-inhibitable cytochalasin B binding (K(D) = 56.6 +/- 18 nm) and reconstitutable glucose transport activity (8.1 +/- 1.	Cytochalasin B	108-122	solute carrier family 2 member 8	Homo sapiens	29-34
10872813-4	2000	Wortmannin, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor that works as a second messenger for pp60c-src, and cytochalasin B, an inhibitor of actin polymerization, suppressed the secretion of both CAK and CAL without suppressing synthesis.	Cytochalasin B	119-133	cathepsin K	Homo sapiens	206-209
10839628-4	2000	The role of Glut in glucose uptake response to hypoglycemia in the embryonic heart is evaluated using the Glut inhibitor cytochalasin B.	Cytochalasin B	121-135	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	12-16
10807662-8	2000	The calmodulin antagonist W-7 and cytochalasin B which enhances actin depolymerization also prevented the effect of CGS 21680; the calmodulin kinase II inhibitors CaM kinase II(281 - 309) and KN-93 but not the inactive structural analogue KN-92 were also effective.	Cytochalasin B	34-48	calmodulin 1	Rattus norvegicus	131-141
10719055-7	2000	These findings support the view that the entry of D-mannoheptulose into cells may be mediated by a cytochalasin B-sensitive transport system, such as the GLUT2 carrier.	Cytochalasin B	99-113	solute carrier family 2 member 2	Rattus norvegicus	154-159
10714946-8	2000	Almost all of the hydroxychalcones exhibited potent inhibitory effects on the release of beta-glucuronidase and lysozyme from rat neutrophils stimulated with formyl-Met-Leu-Phe/cytochalasin B (fMLP/CB).	Cytochalasin B	177-191	glucuronidase, beta	Rattus norvegicus	89-107
10872813-4	2000	Wortmannin, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor that works as a second messenger for pp60c-src, and cytochalasin B, an inhibitor of actin polymerization, suppressed the secretion of both CAK and CAL without suppressing synthesis.	Cytochalasin B	119-133	cathepsin L	Homo sapiens	214-217
10709783-6	2000	Induction of Jurkat homotypic aggregation by MT99/3 was, however blocked by the protein kinase C inhibitor, sphingosine, the protein tyrosine kinase inhibitor, genistein, and by actin filament polymerization blocking agent, cytochalasin B.	Cytochalasin B	224-238	metallothionein 3	Homo sapiens	45-51
10564725-10	2000	Cytochalasin B, an actin-disrupting agent, severely affected the LPS induced increased percentage of "S" phase cells and IL-6 synthesis in HSILPF.	Cytochalasin B	0-14	interleukin 6	Homo sapiens	121-125
11108059-6	2000	When sialidase-treated neutrophils were stimulated with N-formyl-methionyl-leucyl-phenylalanine (fMLP), an inflammatory mediator peptide, in the presence of cytochalasin B, we observed by immunogold electron microscopy and flow cytometry that sLe(x) again appeared on the plasma membrane.	Cytochalasin B	157-171	formyl peptide receptor 1	Homo sapiens	97-101
10666003-0	2000	The inhibition of GLUT1 glucose transport and cytochalasin B binding activity by tricyclic antidepressants.	Cytochalasin B	46-60	solute carrier family 2 member 1	Homo sapiens	18-23
10666003-7	2000	All four antidepressants also noncompetitively displace cytochalasin B binding to GLUT1.	Cytochalasin B	56-70	solute carrier family 2 member 1	Homo sapiens	82-87
10570313-3	1999	Adhesion of T cells induced by chemokines macrophage inflammatory protein (MIP)-1alpha and MIP-1beta was inhibited by pertussis toxin, wortmannin, and cytochalasin B, suggesting that both G protein-sensitive phosphatidylinositol (PI) 3-kinase activation and cytoskeletal assemblies are involved.	Cytochalasin B	151-165	C-C motif chemokine ligand 3	Homo sapiens	42-86
10570313-3	1999	Adhesion of T cells induced by chemokines macrophage inflammatory protein (MIP)-1alpha and MIP-1beta was inhibited by pertussis toxin, wortmannin, and cytochalasin B, suggesting that both G protein-sensitive phosphatidylinositol (PI) 3-kinase activation and cytoskeletal assemblies are involved.	Cytochalasin B	151-165	C-C motif chemokine ligand 4	Homo sapiens	91-100
10529371-4	1999	Using a range of concentrations (3-20 microM) which inhibit ERK activity, PD 98059 inhibited PLD activity induced by fMLP in cytochalasin B-primed PMN, as assessed by production-tritiated phosphatidylethanol (PEt), phosphatidic acid (PA), and hydrolysis of PC.	Cytochalasin B	125-139	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	93-96
10529371-4	1999	Using a range of concentrations (3-20 microM) which inhibit ERK activity, PD 98059 inhibited PLD activity induced by fMLP in cytochalasin B-primed PMN, as assessed by production-tritiated phosphatidylethanol (PEt), phosphatidic acid (PA), and hydrolysis of PC.	Cytochalasin B	125-139	formyl peptide receptor 1	Homo sapiens	117-121
10514464-9	1999	Functional analyses of NHE1/NHE3 chimeras revealed that the cytoplasmic domain of NHE3 conferred sensitivity to cytochalasin B.	Cytochalasin B	112-126	solute carrier family 9 member A1	Homo sapiens	23-27
10514464-9	1999	Functional analyses of NHE1/NHE3 chimeras revealed that the cytoplasmic domain of NHE3 conferred sensitivity to cytochalasin B.	Cytochalasin B	112-126	solute carrier family 9 member A3	Homo sapiens	28-32
10514464-9	1999	Functional analyses of NHE1/NHE3 chimeras revealed that the cytoplasmic domain of NHE3 conferred sensitivity to cytochalasin B.	Cytochalasin B	112-126	solute carrier family 9 member A3	Homo sapiens	82-86
10393099-8	1999	Treatment with cytochalasin B at a concentration that partially disrupted the cortical actin cytoskeleton inhibited Ca2+ inflow and ER Ca2+ release induced by vasopressin by 73 and 45%, respectively.	Cytochalasin B	15-29	arginine vasopressin	Rattus norvegicus	159-170
11068150-14	2000	In the presence of cytochalasin B, an actin disrupting agent, endothelin-3 and VO(4)(3-) did not phosphorylate focal adhesion kinase and paxillin.	Cytochalasin B	19-33	endothelin 3	Rattus norvegicus	62-74
11068150-15	2000	Application of cytochalasin B after treatment with endothelin-3 and VO(4)(3-) stimulated dephosphorylation of focal adhesion kinase and paxillin.	Cytochalasin B	15-29	endothelin 3	Rattus norvegicus	51-63
10516222-3	1999	Adhesion to HUVECs augmented EPO release caused by formyl-methionyl-leucyl-phenylalanine plus cytochalasin B from 403 +/- 15.3 (BSA control) to 778 +/- 225 ng/10(6) cells for eosinophils exposed to interleukin-1alpha-treated HUVECs (P < 0.05) and also caused a twofold increase in stimulated LTC(4) secretion (P < 0.05).	Cytochalasin B	94-108	eosinophil peroxidase	Homo sapiens	29-32
10455018-3	1999	Cytochalasin B, an inhibitor of GLUT1- and GLUT4-mediated glucose transport, inhibited insulin-stimulated 2-deoxyglucose uptake by >95% in wild-type and GLUT4-null soleus muscle.	Cytochalasin B	0-14	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	32-37
10455018-3	1999	Cytochalasin B, an inhibitor of GLUT1- and GLUT4-mediated glucose transport, inhibited insulin-stimulated 2-deoxyglucose uptake by >95% in wild-type and GLUT4-null soleus muscle.	Cytochalasin B	0-14	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	43-48
10455018-3	1999	Cytochalasin B, an inhibitor of GLUT1- and GLUT4-mediated glucose transport, inhibited insulin-stimulated 2-deoxyglucose uptake by >95% in wild-type and GLUT4-null soleus muscle.	Cytochalasin B	0-14	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	156-161
10455018-10	1999	In conclusion, insulin-stimulated glucose-transport activity in female GLUT4-null soleus muscle is mediated by a facilitative transport process that is glucose- and cytochalasin B-inhibitable, but which is not labelled strongly by ATB-BMPA.	Cytochalasin B	165-179	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	71-76
10415161-7	1999	When the cells were treated with cytochalasin B, MIF secretion in the medium was increased.	Cytochalasin B	33-47	macrophage migration inhibitory factor	Rattus norvegicus	49-52
9792999-5	1998	The expression of platelet membrane glycoproteins Ib, IIb/IIIa, IIIa and thrombospondin and transferrin receptors was augmented after treatment with cytochalasin B.	Cytochalasin B	149-163	transferrin	Homo sapiens	92-103
10189943-6	1999	Superoxide anion generation induced by fMLP in cytochalasin B-treated cells primed with PAF was not inhibited by the aqueous fraction.	Cytochalasin B	47-61	formyl peptide receptor 1	Homo sapiens	39-43
9887052-6	1999	Preincubation of eosinophils with cytochalasin B (10 mg/ml) and depletion of the incubation medium of Ca2+ also significantly attenuated degranulation of eosinophils incubated with purified free neutrophil elastase or CF sputum (P < 0.05).	Cytochalasin B	34-48	elastase, neutrophil expressed	Homo sapiens	195-214
10373607-5	1999	Increased rates of 14C-methylglucose uptake and sensitivity to cytochalasin B indicated the presence of facilitative hexose transport due to hGLUT1 expression.	Cytochalasin B	63-77	solute carrier family 2 member 1	Homo sapiens	141-147
10350483-3	1999	Cytochalasin B binding to the purified, human erythrocyte glucose transport protein (GLUT1) induces quenching of GLUT1 intrinsic tryptophan fluorescence.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	85-90
10350483-3	1999	Cytochalasin B binding to the purified, human erythrocyte glucose transport protein (GLUT1) induces quenching of GLUT1 intrinsic tryptophan fluorescence.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	113-118
10350483-6	1999	Rate constants for cytochalasin B binding to GLUT1 (k1) and dissociation from the GLUT1.cytochalasin B complex (k-1) are obtained from the relationship: kobs = k-1 + k1[cytochalasin B].	Cytochalasin B	19-33	solute carrier family 2 member 1	Homo sapiens	45-50
10350483-6	1999	Rate constants for cytochalasin B binding to GLUT1 (k1) and dissociation from the GLUT1.cytochalasin B complex (k-1) are obtained from the relationship: kobs = k-1 + k1[cytochalasin B].	Cytochalasin B	19-33	solute carrier family 2 member 1	Homo sapiens	82-87
10350483-6	1999	Rate constants for cytochalasin B binding to GLUT1 (k1) and dissociation from the GLUT1.cytochalasin B complex (k-1) are obtained from the relationship: kobs = k-1 + k1[cytochalasin B].	Cytochalasin B	88-102	solute carrier family 2 member 1	Homo sapiens	82-87
10350483-6	1999	Rate constants for cytochalasin B binding to GLUT1 (k1) and dissociation from the GLUT1.cytochalasin B complex (k-1) are obtained from the relationship: kobs = k-1 + k1[cytochalasin B].	Cytochalasin B	88-102	solute carrier family 2 member 1	Homo sapiens	82-87
10369472-2	1999	In the presence of cytochalasin B (CB), C5a induced a dose-dependent release of the granular eosinophil peroxidase (EPO), but not O2-, whereas in the absence of CB O2- , but not EPO, was released.	Cytochalasin B	19-33	complement C5a receptor 1	Homo sapiens	40-43
10369472-2	1999	In the presence of cytochalasin B (CB), C5a induced a dose-dependent release of the granular eosinophil peroxidase (EPO), but not O2-, whereas in the absence of CB O2- , but not EPO, was released.	Cytochalasin B	19-33	eosinophil peroxidase	Homo sapiens	93-114
10369472-2	1999	In the presence of cytochalasin B (CB), C5a induced a dose-dependent release of the granular eosinophil peroxidase (EPO), but not O2-, whereas in the absence of CB O2- , but not EPO, was released.	Cytochalasin B	19-33	eosinophil peroxidase	Homo sapiens	116-119
10218769-3	1999	The exposure of HMCs to cytochalasin B, a disrupter of the cytoskeleton assembly, reduced basal tyrosine phosphorylation of both proteins.	Cytochalasin B	24-38	MKKS centrosomal shuttling protein	Homo sapiens	16-20
9758899-8	1998	Eotaxin-induced EDN release was blocked by cytochalasin B in a dose-dependent manner.	Cytochalasin B	43-57	C-C motif chemokine ligand 11	Homo sapiens	0-7
9758899-8	1998	Eotaxin-induced EDN release was blocked by cytochalasin B in a dose-dependent manner.	Cytochalasin B	43-57	ribonuclease A family member 2	Homo sapiens	16-19
9738664-3	1998	Inhibitors of internalization (cytochalasin B, monodansylcadaverine) prevented LPS-stimulated TNF-alpha release when added simultaneously with LPS but when added 10 min after LPS, no significant inhibition occurred.	Cytochalasin B	31-45	tumor necrosis factor	Rattus norvegicus	94-103
9759655-5	1998	u-PAR activation by u-PA produced de novo synthesis of diacylglycerol (DAG) from glucose by a cytochalasin B-inhibitable mechanism, indicating the involvement of a specific glucose transporter (GLUT).	Cytochalasin B	94-108	urokinase-type plasminogen activator	Oryctolagus cuniculus	0-4
9681995-1	1998	Glut1, the only glucose transporter isoform expressed in the human red blood cell (RBC), binds to and is inhibited by cytochalasin B (CB).	Cytochalasin B	118-132	solute carrier family 2 member 1	Homo sapiens	0-5
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	TIMP metallopeptidase inhibitor 2	Homo sapiens	86-125
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	TIMP metallopeptidase inhibitor 2	Homo sapiens	127-133
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	matrix metallopeptidase 2	Homo sapiens	157-162
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	matrix metallopeptidase 14	Homo sapiens	190-212
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	plasminogen	Homo sapiens	244-251
9639398-4	1998	Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity.	Cytochalasin B	33-47	coagulation factor II, thrombin	Homo sapiens	255-263
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cytochalasin B	33-47	matrix metallopeptidase 14	Homo sapiens	251-259
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cytochalasin B	33-47	matrix metallopeptidase 1	Homo sapiens	254-259
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cytochalasin B	33-47	matrix metallopeptidase 2	Homo sapiens	268-273
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cytochalasin B	33-47	TIMP metallopeptidase inhibitor 1	Homo sapiens	275-281
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cytochalasin B	33-47	TIMP metallopeptidase inhibitor 2	Homo sapiens	285-291
9639398-6	1998	GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2.	Cytochalasin B	11-25	matrix metallopeptidase 1	Homo sapiens	86-91
9639398-6	1998	GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2.	Cytochalasin B	11-25	matrix metallopeptidase 2	Homo sapiens	96-101
9639398-6	1998	GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2.	Cytochalasin B	11-25	matrix metallopeptidase 14	Homo sapiens	179-187
9639398-6	1998	GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2.	Cytochalasin B	11-25	matrix metallopeptidase 2	Homo sapiens	189-194
9639398-6	1998	GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2.	Cytochalasin B	11-25	TIMP metallopeptidase inhibitor 2	Homo sapiens	199-205
9754716-3	1998	Stimulation of PMNs with formyl-methionyl-leucyl-phenylalanine fMLP; 0.1 microM induced a weak elevation of mass choline (+25% of basal level) that was strongly potentiated in PMNs primed with cytochalasin B (+350% relative to the control value of 657+/-53 pmol/10(7) cells).	Cytochalasin B	193-207	formyl peptide receptor 1	Homo sapiens	63-67
9686924-3	1998	This proposition is based on the finding that only 21% of the total fructose uptake was cytochalasin B (CB) sensitive which most likely reflects transport via GLUT1 and/or GLUT4.	Cytochalasin B	88-102	solute carrier family 2 member 1	Rattus norvegicus	159-164
9686924-3	1998	This proposition is based on the finding that only 21% of the total fructose uptake was cytochalasin B (CB) sensitive which most likely reflects transport via GLUT1 and/or GLUT4.	Cytochalasin B	88-102	solute carrier family 2 member 4	Rattus norvegicus	172-177
9681394-11	1998	Upregulation of IL-6 synthesis was significantly inhibited by alphaBCG or Cytochalasin B, indicating that internalization is a prerequisite for BCG-induced upregulation of IL-6 synthesis.	Cytochalasin B	74-88	interleukin 6	Homo sapiens	16-20
9681394-11	1998	Upregulation of IL-6 synthesis was significantly inhibited by alphaBCG or Cytochalasin B, indicating that internalization is a prerequisite for BCG-induced upregulation of IL-6 synthesis.	Cytochalasin B	74-88	interleukin 6	Homo sapiens	172-176
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cytochalasin B	227-241	Fas cell surface death receptor	Homo sapiens	21-25
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cytochalasin B	227-241	Fas ligand	Homo sapiens	26-32
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cytochalasin B	227-241	Fas cell surface death receptor	Homo sapiens	26-30
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cytochalasin B	227-241	Fas cell surface death receptor	Homo sapiens	26-30
9550521-11	1998	Notably, the currents were desensitized, reduced in a glucose concentration-dependent manner, and markedly inhibited by either a second application of glucose or the addition of glucose to the patch electrode filling solution; they were potentiated, however, by treatment with cytochalasin B, a GLUT1 to GLUT5 inhibitor.	Cytochalasin B	277-291	solute carrier family 2 member 1	Bos taurus	295-300
9550521-11	1998	Notably, the currents were desensitized, reduced in a glucose concentration-dependent manner, and markedly inhibited by either a second application of glucose or the addition of glucose to the patch electrode filling solution; they were potentiated, however, by treatment with cytochalasin B, a GLUT1 to GLUT5 inhibitor.	Cytochalasin B	277-291	solute carrier family 2, facilitated glucose transporter member 5	Bos taurus	304-309
9481487-7	1998	Furthermore, cytochalasin B, which is known to prime PA production induced by fMLP, synergised the priming of respiratory burst by staurosporine, which further suggests a functional role of PA.	Cytochalasin B	13-27	formyl peptide receptor 1	Homo sapiens	78-82
9449624-7	1998	Two other inhibitors of glucose transport, phloretin (0.05-0.25 mM) and cytochalasin-B (0.5-50 microM), also inhibited leptin secretion.	Cytochalasin B	72-86	leptin	Rattus norvegicus	119-125
9321896-5	1997	Quantitative immunoblotting indicated that GLUT-1 accounted for 86.8 +/- 1.6% at day 75 and 56.1 +/- 4.1% at day 140 of total cytochalasin B binding sites.	Cytochalasin B	126-140	solute carrier family 2, facilitated glucose transporter member 1	Ovis aries	43-49
9832332-7	1998	Finally, disruption of either microtubules (with colchicine) or microfilaments (with cytochalasin B) resulted in reduced GMCSF mRNA expression in response to IL-1beta.	Cytochalasin B	85-99	colony stimulating factor 2	Homo sapiens	121-126
9832332-7	1998	Finally, disruption of either microtubules (with colchicine) or microfilaments (with cytochalasin B) resulted in reduced GMCSF mRNA expression in response to IL-1beta.	Cytochalasin B	85-99	interleukin 1 beta	Homo sapiens	158-166
9434626-5	1997	The reduced cellular activity of cytochalasins in P-gp-positive cell lines was correlated with decreased intracellular accumulation ([3H]cytochalasin B accumulation) which was also restorable by P-gp modulators.	Cytochalasin B	137-151	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
9434626-5	1997	The reduced cellular activity of cytochalasins in P-gp-positive cell lines was correlated with decreased intracellular accumulation ([3H]cytochalasin B accumulation) which was also restorable by P-gp modulators.	Cytochalasin B	137-151	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
9744301-7	1998	After cytochalasin-B-induced depolymerization of the ER-associated F-actin system, alpha-spectrin remains colocalized with the ER, indicating that alpha-spectrin is bound to the ER membrane.	Cytochalasin B	6-20	alpha Spectrin	Drosophila melanogaster	89-97
9744301-7	1998	After cytochalasin-B-induced depolymerization of the ER-associated F-actin system, alpha-spectrin remains colocalized with the ER, indicating that alpha-spectrin is bound to the ER membrane.	Cytochalasin B	6-20	alpha Spectrin	Drosophila melanogaster	153-161
9536127-8	1998	When human granulocytes were stimulated with cytochalasin B and N-formyl-methionyl-leucyl-phenylalanine (fMLP), cathepsin G was released.	Cytochalasin B	45-59	cathepsin G	Homo sapiens	112-123
9414485-6	1998	Culturing of 3T3-L1 cells without glucose or with cytochalasin B, a blocker of facilitative glucose transporters (GLUT), was effective in reducing LPL activity (P < 0.05).	Cytochalasin B	50-64	lipoprotein lipase	Mus musculus	147-150
9391000-7	1997	4-CIN did not alter the morphology of pyramidal neurons in the presence of 10 mM glucose but produced significant damage during glucose deprivation or CCB administration.	Cytochalasin B	151-154	pyridoxal phosphatase	Homo sapiens	2-5
9366406-9	1997	Cytochalasin B selectively triggered the secretion of TNF-alpha and significantly augmented the frequency of apoptosis of anti-CD16-treated NK cells.	Cytochalasin B	0-14	tumor necrosis factor	Homo sapiens	54-63
9366406-9	1997	Cytochalasin B selectively triggered the secretion of TNF-alpha and significantly augmented the frequency of apoptosis of anti-CD16-treated NK cells.	Cytochalasin B	0-14	Fc gamma receptor IIIa	Homo sapiens	127-131
9298523-3	1997	When cells were primed by preincubation with 5 microns cytochalasin B for 5 min arachidonate release, a measure of phospholipase A2 activation, was observed within 20 s. 2 Priming by cytochalasin B did not involve or require a change in intracellular free calcium concentration.	Cytochalasin B	55-69	phospholipase A2 group IB	Homo sapiens	115-131
9298523-3	1997	When cells were primed by preincubation with 5 microns cytochalasin B for 5 min arachidonate release, a measure of phospholipase A2 activation, was observed within 20 s. 2 Priming by cytochalasin B did not involve or require a change in intracellular free calcium concentration.	Cytochalasin B	183-197	phospholipase A2 group IB	Homo sapiens	115-131
9378774-10	1997	Interaction between NF2 protein and the actin-containing cytoskeleton was indicated by partial colocalization, by cytochalasin B-induced coclustering, and by retention of NF2 protein in the detergent-insoluble fraction.	Cytochalasin B	114-128	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	20-23
9307082-6	1997	Participation of cytoskeletal proteins in the pervanadate-induced T cell adhesion was indicated because cytoskeleton disruption by cytochalasin B inhibited cell adhesion to fibronectin.	Cytochalasin B	131-145	fibronectin 1	Homo sapiens	173-184
9449202-3	1997	Perifusion of adrenal explants with the microfilament-disrupting agent cytochalasin B (5 x 10(-5) M) induced a reversible inhibition of the spontaneous secretion of corticosterone and aldosterone, and markedly reduced the stimulatory effect of frog CGRP (3 x 10(-7) M) on corticosteroid release.	Cytochalasin B	71-85	calcitonin related polypeptide alpha	Homo sapiens	249-253
9141624-9	1997	Cytochalasin B stimulated PTHrP secretion and mRNA expression in A253 cells, but had no effect in NHFK cells.	Cytochalasin B	0-14	parathyroid hormone like hormone	Homo sapiens	26-31
9224764-3	1997	The small proportion of CD43 molecules, which "spontaneously" precipitated in Triton, appeared associated with F-actin, as demonstrated by the fact that this insolubility did not occur when cells were incubated with cytochalasin B or when F-actin was depolymerized with DNase I in the Triton precipitate.	Cytochalasin B	216-230	sialophorin	Homo sapiens	24-28
9224764-5	1997	By immunofluorescence as well as by electron microscopy, we observed a redistribution of CD43 on the neutrophil membrane, initially in patches followed by caps, during anti-CD43 cross-linking at 37 degrees C. This capping did not occur at 4 degrees C and was inhibited by cytochalasin B and by a myosin disrupting drug butanedione monoxime, thus providing evidence that the actomyosin contracile sytem is involved in the capping and further suggesting an association of CD43 with the cytoskeleton.	Cytochalasin B	272-286	sialophorin	Homo sapiens	89-93
9200480-6	1997	This subsequent disappearance of surface CD63 and CD66b was inhibited by cytochalasin B and probably represents internalization of the granular markers into the forming phagosome.	Cytochalasin B	73-87	CD63 molecule	Homo sapiens	41-45
9200480-6	1997	This subsequent disappearance of surface CD63 and CD66b was inhibited by cytochalasin B and probably represents internalization of the granular markers into the forming phagosome.	Cytochalasin B	73-87	CEA cell adhesion molecule 8	Homo sapiens	50-55
9230344-8	1997	The apparent IC50 of cytochalasin B for inhibiting 3-O-methylglucose transport in beta HC9 cells was nine times as high as in beta TC3 cells, indicating that GLUT1 is the critically important glucose transporter in the beta TC3 cell line and GLUT2 in the beta HC9 cell line.	Cytochalasin B	21-35	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	158-163
9230344-8	1997	The apparent IC50 of cytochalasin B for inhibiting 3-O-methylglucose transport in beta HC9 cells was nine times as high as in beta TC3 cells, indicating that GLUT1 is the critically important glucose transporter in the beta TC3 cell line and GLUT2 in the beta HC9 cell line.	Cytochalasin B	21-35	solute carrier family 2 (facilitated glucose transporter), member 2	Mus musculus	242-247
9354367-6	1997	The specific interaction between GLUT-1 on erythrocytes and the PVG polymer carrying reducing glucose was suppressed by the inhibitors, phloretin, phloridzin, and cytochalasin B, and a monoclonal antibody to GLUT-1.	Cytochalasin B	163-177	solute carrier family 2 member 1	Homo sapiens	33-39
9453467-5	1997	In the presence of cytochalasin B, the chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP; 0.5 microM) induced leukotriene C4 production in human eosinophils isolated in discontinuous metrizamide gradients.	Cytochalasin B	19-33	formyl peptide receptor 1	Homo sapiens	106-110
9286080-0	1997	D-Glucose, forskolin and cytochalasin B affinities for the glucose transporter Glut1.	Cytochalasin B	25-39	solute carrier family 2 member 1	Homo sapiens	79-84
9286080-2	1997	The affinities of D-glucose and the transport inhibitors, forskolin and cytochalasin B (CB), for Glut1 were studied by frontal affinity chromatography at pH 5-10 on sterically immobilized proteoliposomes with reconstituted human red cell glucose transporter Glut1.	Cytochalasin B	72-86	solute carrier family 2 member 1	Homo sapiens	97-102
9286081-2	1997	The affinity of D-glucose and the transport inhibitor cytochalasin B (CB) for the glucose transporter Glut1 was studied at 5-42 degrees C by quantitative frontal affinity chromatography on sterically immobilized human red cell membrane vesicles, and on proteoliposomes containing reconstituted red cell membrane proteins.	Cytochalasin B	54-68	solute carrier family 2 member 1	Homo sapiens	102-107
9166863-7	1997	Similarly, cytochalasin B, a potent inhibitor of the functional activity of GLUT1 and GLUT2, did not affect the transport of fructose in human erythrocytes.	Cytochalasin B	11-25	solute carrier family 2 member 1	Homo sapiens	76-81
9166863-7	1997	Similarly, cytochalasin B, a potent inhibitor of the functional activity of GLUT1 and GLUT2, did not affect the transport of fructose in human erythrocytes.	Cytochalasin B	11-25	solute carrier family 2 member 2	Homo sapiens	86-91
9112019-5	1997	Insulin-dependent (maximally stimulated-basal) 2-DG uptake and cytochalasin B binding were decreased three-fold in cells from the diabetic and/or obese subjects (p < 0.01).	Cytochalasin B	63-77	insulin	Homo sapiens	0-7
9142987-7	1997	Treatment of stage VI oocytes with cytochalasin B disrupted the organization of both cortical and cytoplasmic CK filaments, releasing CK filaments from the oocyte cortex and inducing formation of numerous cytoplasmic CK filament aggregates.	Cytochalasin B	35-49	Keratin 12, gene 4 L homeolog	Xenopus laevis	110-112
9142987-7	1997	Treatment of stage VI oocytes with cytochalasin B disrupted the organization of both cortical and cytoplasmic CK filaments, releasing CK filaments from the oocyte cortex and inducing formation of numerous cytoplasmic CK filament aggregates.	Cytochalasin B	35-49	Keratin 12, gene 4 L homeolog	Xenopus laevis	134-136
9142987-7	1997	Treatment of stage VI oocytes with cytochalasin B disrupted the organization of both cortical and cytoplasmic CK filaments, releasing CK filaments from the oocyte cortex and inducing formation of numerous cytoplasmic CK filament aggregates.	Cytochalasin B	35-49	Keratin 12, gene 4 L homeolog	Xenopus laevis	134-136
9130630-4	1997	C5a- and FMLP-induced eosinophil MCP-1 production was absolutely dependent on pretreatment with cytochalasin B.	Cytochalasin B	96-110	complement C5a receptor 1	Homo sapiens	0-3
9130630-4	1997	C5a- and FMLP-induced eosinophil MCP-1 production was absolutely dependent on pretreatment with cytochalasin B.	Cytochalasin B	96-110	formyl peptide receptor 1	Homo sapiens	9-13
9130630-4	1997	C5a- and FMLP-induced eosinophil MCP-1 production was absolutely dependent on pretreatment with cytochalasin B.	Cytochalasin B	96-110	C-C motif chemokine ligand 2	Homo sapiens	33-38
9103534-3	1997	In the in vitro study, upon application of cytochalasin B and fMLP, formation of superoxide anion and release of myeloperoxidase increased with increased neutrophil aggregation.	Cytochalasin B	43-57	myeloperoxidase	Oryctolagus cuniculus	113-128
9087173-5	1997	Using cytochalasin B or vinblastine, two drugs which disrupt the cytoskeleton, we demonstrate that the redistribution of HD1 was probably induced by the reorganization of the basal cytokeratin network.	Cytochalasin B	6-20	plectin	Homo sapiens	121-124
9140523-3	1997	Although IL-5 alone induced little or no IL-8 production from eosinophils, short-term preincubation with IL-5 markedly enhanced the eosinophil IL-8 generation caused by C5a plus cytochalasin B (CB).	Cytochalasin B	178-192	interleukin 5	Homo sapiens	105-109
9140523-3	1997	Although IL-5 alone induced little or no IL-8 production from eosinophils, short-term preincubation with IL-5 markedly enhanced the eosinophil IL-8 generation caused by C5a plus cytochalasin B (CB).	Cytochalasin B	178-192	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
9066006-5	1997	When both fusion and differentiation were blocked by specific inhibitors (DMSO, cytochalasin B) the levels of uPA were strongly downregulated.	Cytochalasin B	80-94	plasminogen activator, urokinase	Mus musculus	110-113
9059504-11	1997	The mutated Glut4 was inhibited by pCMB or pCMBS and the IC50 of HgCl2 decreased to 47 microM, whereas K(m), substrate specificity and the sensitivity to cytochalasin B were not significantly changed, indicating that the existence of exofacial cysteine contributed only to increase SH sensitivity in Glut4.	Cytochalasin B	154-168	solute carrier family 2 member 4	Rattus norvegicus	12-17
9020138-5	1997	Interestingly, pretreatment of tonsillar B cells with cytochalasin B dramatically reduced both integrin- and BCR-induced HEF1 phosphorylation, suggesting that some component of the BCR-mediated signaling pathway is closely linked with a cytoskeletal reorganization.	Cytochalasin B	54-68	BCR activator of RhoGEF and GTPase	Homo sapiens	109-112
9020138-5	1997	Interestingly, pretreatment of tonsillar B cells with cytochalasin B dramatically reduced both integrin- and BCR-induced HEF1 phosphorylation, suggesting that some component of the BCR-mediated signaling pathway is closely linked with a cytoskeletal reorganization.	Cytochalasin B	54-68	neural precursor cell expressed, developmentally down-regulated 9	Homo sapiens	121-125
9020138-5	1997	Interestingly, pretreatment of tonsillar B cells with cytochalasin B dramatically reduced both integrin- and BCR-induced HEF1 phosphorylation, suggesting that some component of the BCR-mediated signaling pathway is closely linked with a cytoskeletal reorganization.	Cytochalasin B	54-68	BCR activator of RhoGEF and GTPase	Homo sapiens	181-184
8995252-6	1997	Phosphorylation of RAFTK following integrin- or B cell antigen receptor-mediated stimulation was decreased by prior treatment of cells with cytochalasin B, indicating that this process was at least partially cytoskeleton-dependent.	Cytochalasin B	140-154	protein tyrosine kinase 2 beta	Homo sapiens	19-24
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	40-45
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	solute carrier family 2 (facilitated glucose transporter), member 3	Mus musculus	47-52
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	57-60
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	112-115
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	205-210
9010020-8	1997	A comparison of protein sequences among GLUT1, GLUT3 and MRP revealed a putative cytochalasin B binding site in MRP, which displayed 44% sequence similarity/12% identity with that previously identified in GLUT1 and GLUT3; these regions also exhibited a similar hydropathy plot pattern.	Cytochalasin B	81-95	solute carrier family 2 (facilitated glucose transporter), member 3	Mus musculus	215-220
8645210-5	1996	Interestingly, stimulation with N-formylmethionyl leucylphenylalanine in the presence of cytochalasin B showed an increase in membrane NDP kinase activity together with the translocation of the enzyme from the cytosol to the membrane, suggesting a possible role of NDP kinase in regulating G-proteins as previously reported.	Cytochalasin B	89-103	cytidine/uridine monophosphate kinase 2	Homo sapiens	135-145
8989906-3	1997	beta 1 integrin stimulation of p120c-CBL phosphorylation was observed in both transformed and normal human B cells, and was inhibited by prior treatment of cells with cytochalasin B, which disrupts the actin network.	Cytochalasin B	167-181	integrin subunit beta 1	Homo sapiens	0-15
9272702-5	1997	The presentation of P12-25 is sensitive to cytochalasin B and D, brefeldin A and gelonin, a ribosome-inactivating protein synthesis inhibitor, but less sensitive or resistant to lactacystin, a highly specific inhibitor of the proteasome.	Cytochalasin B	43-57	CDK2 (cyclin-dependent kinase 2)-associated protein 1	Mus musculus	20-23
16793633-4	1997	The present study has added cytochalasin B after exposure of platelets to thrombin or TRAP in suspension in order to prevent spreading and movement of GP Ib/IX during subsequent exposure to surface activation on formvar grids.	Cytochalasin B	28-42	coagulation factor II, thrombin	Homo sapiens	74-82
16793633-4	1997	The present study has added cytochalasin B after exposure of platelets to thrombin or TRAP in suspension in order to prevent spreading and movement of GP Ib/IX during subsequent exposure to surface activation on formvar grids.	Cytochalasin B	28-42	TRAP	Homo sapiens	86-90
9425641-1	1997	We studied the effect of R-, S- and R,S-albuterol in inhibiting the eosinophil peroxidase (EPO) secretion caused by 10(-10) to 10(-6) M formyl-met-leu-phe + 5 micrograms/ml cytochalasin B (FMLP/CB) in non-allergic and allergic subjects.	Cytochalasin B	173-187	eosinophil peroxidase	Homo sapiens	91-94
8970377-6	1996	Flow-cytometric analysis showed that in the presence of surface stimulation with cytochalasin B followed by formyl-methionyleucylphenylalanine (fMLP), mean intracellular alpha 1-AT was decreased in stimulated neutrophils compared with that in resting cells, suggesting that the stored alpha 1-AT was rapidly released following surface triggering.	Cytochalasin B	81-95	serpin family A member 1	Homo sapiens	170-180
8970377-6	1996	Flow-cytometric analysis showed that in the presence of surface stimulation with cytochalasin B followed by formyl-methionyleucylphenylalanine (fMLP), mean intracellular alpha 1-AT was decreased in stimulated neutrophils compared with that in resting cells, suggesting that the stored alpha 1-AT was rapidly released following surface triggering.	Cytochalasin B	81-95	serpin family A member 1	Homo sapiens	285-295
9088544-3	1996	In this study, we have investigated the ability of soluble immune complexes to: (1) induce oxidant generation; (2) bind to the cell surface; and (3) induce Ca2+ transients in neutrophils primed by incubation with GM-CSF or cytochalasin B.	Cytochalasin B	223-237	colony stimulating factor 2	Homo sapiens	213-219
8980906-4	1996	Addition of cytochalasin B together with LI abolished nitrite and L-citrulline accumulation as well as the amount of iNOS antigen in activated macrophage.	Cytochalasin B	12-26	nitric oxide synthase 2, inducible	Mus musculus	117-121
8980906-5	1996	Moreover, addition of cytochalasin B 6 or 12 h after stimulus, also decreased the nitrite and L-citrulline production by macrophages although iNOS antigen content by Western blot was the same in the presence or in the absence of cytochalasin B added 12 h after activation.	Cytochalasin B	22-36	nitric oxide synthase 2, inducible	Mus musculus	142-146
8944713-4	1996	ICAM-1 was redistributed on the cell surface after the disruption of actin filaments with cytochalasin B, suggesting interaction with the actin cytoskeleton.	Cytochalasin B	90-104	intercellular adhesion molecule 1	Rattus norvegicus	0-6
8810921-3	1996	The specific interactions between the transport inhibitor cytochalasin B (CB), D-glucose, and Glut1 were analyzed by quantitative frontal affinity chromatography.	Cytochalasin B	58-72	solute carrier family 2 member 1	Homo sapiens	94-99
8756575-4	1996	Cytochalasin B, a microfilament-disrupting agent, reduced the GHR level, but GHBP was not affected.	Cytochalasin B	0-14	growth hormone receptor	Oryctolagus cuniculus	62-65
8853123-7	1996	Addition of the phagocytosis inhibitor cytochalasin B inhibited the morphological changes of the monocytes and reduced interleukin-1 beta production.	Cytochalasin B	39-53	interleukin 1 beta	Homo sapiens	119-137
8896790-0	1996	Modulation of the junctional integrity by low or high concentrations of cytochalasin B and dihydrocytochalasin B is associated with distinct changes in F-actin and ZO-1.	Cytochalasin B	72-86	tight junction protein 1	Canis lupus familiaris	164-168
8872506-8	1996	Cytochalasin B-treatment, which blocks actin reorganization, partly reduced COYP-mediated PLD activity, but had no effect on activity caused by anti-CD18-coated particles.	Cytochalasin B	0-14	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	90-93
8942661-8	1996	These findings suggest that cadmium induces a specific conformational change in GLUT1 that interferes with cytochalasin B binding but enhances substrate binding.	Cytochalasin B	107-121	solute carrier family 2 member 1	Homo sapiens	80-85
8944708-3	1996	Cytochalasin B and methylpalmitate, blockers of endocytosis, decreased LPS-stimulated TNF-alpha release by > 92%.	Cytochalasin B	0-14	tumor necrosis factor	Rattus norvegicus	86-95
8944708-5	1996	Cytochalasin B and bafilomycin A decreased TNF-alpha mRNA levels by > 90% after LPS stimulation.	Cytochalasin B	0-14	tumor necrosis factor	Rattus norvegicus	43-52
8871621-4	1996	To test whether the interaction of CD80 with the cytochalasin B-sensitive cytoskeleton was necessary for T cell costimulation through CD28, we constructed a tailless form of CD80 and generated stable transfectants of Chinese hamster ovary epithelial cells and Reh B cells expressing either the tailless or wild-type CD80 molecules.	Cytochalasin B	49-63	T-lymphocyte activation antigen CD80	Cricetulus griseus	35-39
8898915-4	1996	Three isoforms of MRP-14 were markedly phosphorylated in the membrane and in the cytosol upon activation with extracellular calcium-dependent stimuli, such as opsonized zymosan, the calcium ionophore A23187, N-formylmethionylleucylphenylalanine in the presence of cytochalasin B and arachidonic acid, or upon extracellular calcium-independent stimulation (PMA).	Cytochalasin B	264-278	S100 calcium binding protein A9	Homo sapiens	18-24
8928850-6	1996	Pretreatment with cytochalasin B prevented the accumulation of cadherins-catenins and ZO-1 at the sites of apoptosis and resulted in microscopic holes in the TNF-treated cell sheet.	Cytochalasin B	18-32	tumor necrosis factor	Sus scrofa	158-161
8621505-10	1996	Binding studies showed that genistein inhibited glucose-displaceable binding of cytochalasin B to GLUT1 in erythrocyte ghosts in a competitive manner, with a Ki of 7 microM.	Cytochalasin B	80-94	solute carrier family 2 member 1	Homo sapiens	98-103
8721674-7	1996	ET-3 stimulated stress fiber formation in stellate astrocytes induced by 50 microM ML-9, 20 microM W-7, and 5 microM cytochalasin B (CB).	Cytochalasin B	117-131	endothelin 3	Rattus norvegicus	0-4
8634433-7	1996	Beta1 or beta7 mediated tyrosine phosphorylations were markedly decreased when the microfilament assembly was inhibited by cytochalasin B.	Cytochalasin B	123-137	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	0-5
8645210-5	1996	Interestingly, stimulation with N-formylmethionyl leucylphenylalanine in the presence of cytochalasin B showed an increase in membrane NDP kinase activity together with the translocation of the enzyme from the cytosol to the membrane, suggesting a possible role of NDP kinase in regulating G-proteins as previously reported.	Cytochalasin B	89-103	cytidine/uridine monophosphate kinase 2	Homo sapiens	265-275
8608229-7	1996	Fourth, cytochalasin B, an inhibitor of actin polymerization, completely inhibited the cathepsin G-, TRAP-, and ADP/epinephrine-induced decreases in platelet surface GPV.	Cytochalasin B	8-22	cathepsin G	Homo sapiens	87-98
8683296-5	1996	Additionally, the biodistribution of two compounds which bind to Glut, 7-[[(2-(3-(125I-p-hydroxyphenyl)propionyl)aminoethyl)amino]carbonyl]-7-+ ++desacetyl-forskolin([125I]HPP forskolin) and [3H]cytochalasin B, were studied in a tumor model which overexpressed Glut.	Cytochalasin B	195-209	solute carrier family 2 member 1	Homo sapiens	65-69
8608229-7	1996	Fourth, cytochalasin B, an inhibitor of actin polymerization, completely inhibited the cathepsin G-, TRAP-, and ADP/epinephrine-induced decreases in platelet surface GPV.	Cytochalasin B	8-22	TRAP	Homo sapiens	101-105
8604023-1	1996	Interleukin-8 (IL-8), the prototype of the alpha (e.i., C-X-C branch) chemokine family, induced elastase release in a concentration-dependent manner (50-1000 ng/mL) in cytochalasin B-treated human polymorphonuclear leukocytes (PMNs).	Cytochalasin B	168-182	C-X-C motif chemokine ligand 8	Homo sapiens	0-13
8619824-6	1996	This action of HGF was suppressed by actin selective inhibitor, cytochalasin B, indicating that it was mediated by an actin-myosin contractile system.	Cytochalasin B	64-78	hepatocyte growth factor	Oryctolagus cuniculus	15-18
8604023-1	1996	Interleukin-8 (IL-8), the prototype of the alpha (e.i., C-X-C branch) chemokine family, induced elastase release in a concentration-dependent manner (50-1000 ng/mL) in cytochalasin B-treated human polymorphonuclear leukocytes (PMNs).	Cytochalasin B	168-182	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
12232595-1	1996	Cytochalasin B was used to inhibit the glucose transport through the glucose transport protein (GluT-1) in red cell membranes.	Cytochalasin B	0-14	solute carrier family 2 member 1	Homo sapiens	96-102
8683474-11	1996	The inhibitory effect of EHNA on the onset phase of the vasopressin response was attenuated after exposure of the tissue to the microtubule-disruptive drug nocodazole but was fully additive with that of cytochalasin B.	Cytochalasin B	203-217	arginine vasopressin	Homo sapiens	56-67
8655363-4	1996	In addition, N alpha-p-tosyl-L-lysine chloromethylketone (TLCK), a serine esterase inhibitor, as well as cytochalasin B and monensin, antagonists of secretory pathways, inhibited CD4+ CTLs, whereas the absence of extracellular Ca+2 or the presence of Ca+2 channel blockers partially inhibited cytotoxicity.	Cytochalasin B	105-119	CD4 molecule	Homo sapiens	179-182
7493642-9	1995	NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization.	Cytochalasin B	18-32	ornithine decarboxylase 1	Homo sapiens	90-93
8541554-2	1995	MBP did not produce an immediate increase in the cytosolic free calcium concentration ([Ca2+]i), characteristic of phospholipase C activation, but did cause a gradual increase in [Ca2+]i in cytochalasin B-treated cells.	Cytochalasin B	190-204	myelin basic protein	Homo sapiens	0-3
7493642-9	1995	NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization.	Cytochalasin B	18-32	ornithine decarboxylase 1	Homo sapiens	176-179
7493642-9	1995	NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization.	Cytochalasin B	18-32	ornithine decarboxylase 1	Homo sapiens	176-179
7730638-4	1995	In addition, TCA3 treatment induced the production of reactive nitrogen intermediates, whereas stimulation with higher concentrations (100 nM) of TCA3 induced the exocytosis of lysozyme and elastase in the presence of cytochalasin B (7 micrograms/ml).	Cytochalasin B	218-232	chemokine (C-C motif) ligand 1	Mus musculus	13-17
7594500-7	1995	Furthermore, GM-CSF augmentation of FMLP + cytochalasin B-activated NEUT O2- generation was not affected by anti-beta 2 Ab but was blocked by a 5-lipoxygenase-activating protein antagonist, BAY x 1005.	Cytochalasin B	43-57	colony stimulating factor 2	Homo sapiens	13-19
7594500-7	1995	Furthermore, GM-CSF augmentation of FMLP + cytochalasin B-activated NEUT O2- generation was not affected by anti-beta 2 Ab but was blocked by a 5-lipoxygenase-activating protein antagonist, BAY x 1005.	Cytochalasin B	43-57	formyl peptide receptor 1	Homo sapiens	36-40
7594500-7	1995	Furthermore, GM-CSF augmentation of FMLP + cytochalasin B-activated NEUT O2- generation was not affected by anti-beta 2 Ab but was blocked by a 5-lipoxygenase-activating protein antagonist, BAY x 1005.	Cytochalasin B	43-57	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	113-119
7595062-6	1995	Prevention of actin polymerization with cytochalasin B hampered the TNF-induced redistribution of these proteins from a Triton-soluble to an insoluble fraction.	Cytochalasin B	40-54	tumor necrosis factor	Homo sapiens	68-71
8564520-4	1995	To drive the mobilization process further, cytochalasin B was introduced to increase the stimulatory effect of fMLP.	Cytochalasin B	43-57	formyl peptide receptor 1	Homo sapiens	111-115
8564520-7	1995	In addition, the total pool of CR1 in cytochalasin B treated neutrophils was reduced after 15 minutes stimulation with fMLP measured by flow cytometry and immunoblotting, indicating degradation of CR1.	Cytochalasin B	38-52	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	31-34
8564520-7	1995	In addition, the total pool of CR1 in cytochalasin B treated neutrophils was reduced after 15 minutes stimulation with fMLP measured by flow cytometry and immunoblotting, indicating degradation of CR1.	Cytochalasin B	38-52	formyl peptide receptor 1	Homo sapiens	119-123
8564520-7	1995	In addition, the total pool of CR1 in cytochalasin B treated neutrophils was reduced after 15 minutes stimulation with fMLP measured by flow cytometry and immunoblotting, indicating degradation of CR1.	Cytochalasin B	38-52	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	197-200
7584840-5	1995	On the other hand, Na(+)-independent AMG uptake was inhibited by cytochalasin B or 2-deoxy-D-glucose.	Cytochalasin B	65-79	amelogenin X-linked L homeolog	Xenopus laevis	37-40
7654231-2	1995	We reported that the release of major basic protein (MBP) from mature eosinophils stimulated with cytochalasin B and C5a were augmented after preincubation with recombinant ADF/TRX.	Cytochalasin B	98-112	myelin basic protein	Homo sapiens	32-51
7654231-2	1995	We reported that the release of major basic protein (MBP) from mature eosinophils stimulated with cytochalasin B and C5a were augmented after preincubation with recombinant ADF/TRX.	Cytochalasin B	98-112	myelin basic protein	Homo sapiens	53-56
7654231-2	1995	We reported that the release of major basic protein (MBP) from mature eosinophils stimulated with cytochalasin B and C5a were augmented after preincubation with recombinant ADF/TRX.	Cytochalasin B	98-112	thioredoxin	Homo sapiens	173-176
7654231-2	1995	We reported that the release of major basic protein (MBP) from mature eosinophils stimulated with cytochalasin B and C5a were augmented after preincubation with recombinant ADF/TRX.	Cytochalasin B	98-112	thioredoxin	Homo sapiens	177-180
7667244-7	1995	Substances that block glucose transport (100 microM cytochalasin B) and protein synthesis (1 mM cycloheximide) also markedly reduced insulin biosynthesis.	Cytochalasin B	52-66	insulin	Homo sapiens	133-140
7779771-1	1995	Interaction of cytochalasin B and D-glucose with the glucose transporter Glut1.	Cytochalasin B	15-29	solute carrier family 2 member 1	Homo sapiens	73-78
7487915-12	1995	The ability of the truncated GLUt1s to bind the exofacial ligand, 2-N-4-(1-zai-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos- 4-yl-oxy) -2-propylamine (ATB-BMPA), and the endofacial ligand, cytochalasin B, were assessed by photolabelling procedures.	Cytochalasin B	191-205	solute carrier family 2, facilitated glucose transporter member 1	Cricetulus griseus	29-34
8595070-5	1995	In formyl-methionyl-leucyl-phenylalanine-stimulated neutrophils (treated with cytochalasin B), these IC50 values were 30 and 50 mumol/l for PAF and LTB4 synthesis, respectively.	Cytochalasin B	78-92	PCNA clamp associated factor	Homo sapiens	140-143
7559408-9	1995	The effect on PLD activity and ARF membrane content achieved through fMLP stimulation was greatly enhanced by prior treatment of the cells with cytochalasin B.	Cytochalasin B	144-158	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	14-17
7559408-9	1995	The effect on PLD activity and ARF membrane content achieved through fMLP stimulation was greatly enhanced by prior treatment of the cells with cytochalasin B.	Cytochalasin B	144-158	formyl peptide receptor 1	Homo sapiens	69-73
7665597-5	1995	Furthermore, the cytochalasin B binding activity of purified human erythrocyte GLUT1 reconstituted in liposomes was significantly reduced in the presence of cytosol derived from azide-treated Clone 9 cells but not in the presence of cytosol from control cells; this effect was heat-labile and abolished by the presence of the peptide corresponding to the GLUT1 COOH-terminal sequence.	Cytochalasin B	17-31	solute carrier family 2 member 1	Homo sapiens	79-84
7665597-5	1995	Furthermore, the cytochalasin B binding activity of purified human erythrocyte GLUT1 reconstituted in liposomes was significantly reduced in the presence of cytosol derived from azide-treated Clone 9 cells but not in the presence of cytosol from control cells; this effect was heat-labile and abolished by the presence of the peptide corresponding to the GLUT1 COOH-terminal sequence.	Cytochalasin B	17-31	solute carrier family 2 member 1	Rattus norvegicus	355-360
7543529-8	1995	DATK44-induced aggregation of TK1 cells is temperature sensitive and blocked by pretreatment of the cells with metabolic inhibitors, genestein, dibutyl cAMP or cytochalasin B, while colchicine, staurosporin, sphingosine, okadaic acid, and W7 are without effect.	Cytochalasin B	160-174	thymidine kinase 1	Homo sapiens	30-33
7626647-7	1995	In contrast, the cytochalasin B binding capacity of GLUT1 and the Kd(app) for cytochalasin B binding to the transporter are doubled following exofacial tryptic digestion of GLUT1.	Cytochalasin B	17-31	solute carrier family 2 member 1	Homo sapiens	52-57
7626647-7	1995	In contrast, the cytochalasin B binding capacity of GLUT1 and the Kd(app) for cytochalasin B binding to the transporter are doubled following exofacial tryptic digestion of GLUT1.	Cytochalasin B	17-31	solute carrier family 2 member 1	Homo sapiens	173-178
7626647-7	1995	In contrast, the cytochalasin B binding capacity of GLUT1 and the Kd(app) for cytochalasin B binding to the transporter are doubled following exofacial tryptic digestion of GLUT1.	Cytochalasin B	78-92	solute carrier family 2 member 1	Homo sapiens	173-178
7626647-8	1995	Photoaffinity labeling experiments show that increased cytochalasin B binding results from increased ligand binding to the 25 kDa carboxyl-terminal GLUT1 peptide.	Cytochalasin B	55-69	solute carrier family 2 member 1	Homo sapiens	148-153
7626647-12	1995	Studies with reconstituted purified GLUT1 confirm that the action of trypsin on cytochalasin B binding is direct, show that proteolysis increases the apparent affinity of the sugar efflux site for transported sugars, and suggest that the membrane bilayer stabilizes GLUT1 noncovalent structure and catalytic function following GLUT1 proteolysis.	Cytochalasin B	80-94	solute carrier family 2 member 1	Homo sapiens	36-41
7626647-12	1995	Studies with reconstituted purified GLUT1 confirm that the action of trypsin on cytochalasin B binding is direct, show that proteolysis increases the apparent affinity of the sugar efflux site for transported sugars, and suggest that the membrane bilayer stabilizes GLUT1 noncovalent structure and catalytic function following GLUT1 proteolysis.	Cytochalasin B	80-94	solute carrier family 2 member 1	Homo sapiens	266-271
7626647-12	1995	Studies with reconstituted purified GLUT1 confirm that the action of trypsin on cytochalasin B binding is direct, show that proteolysis increases the apparent affinity of the sugar efflux site for transported sugars, and suggest that the membrane bilayer stabilizes GLUT1 noncovalent structure and catalytic function following GLUT1 proteolysis.	Cytochalasin B	80-94	solute carrier family 2 member 1	Homo sapiens	266-271
7624317-4	1995	We demonstrate that collagenase expression stimulated by trypsin or cytochalasin B is regulated entirely through an autocrine cytokine, interleukin 1 alpha (IL-1 alpha).	Cytochalasin B	68-82	interleukin 1 alpha	Homo sapiens	136-155
7624317-4	1995	We demonstrate that collagenase expression stimulated by trypsin or cytochalasin B is regulated entirely through an autocrine cytokine, interleukin 1 alpha (IL-1 alpha).	Cytochalasin B	68-82	interleukin 1 alpha	Homo sapiens	157-167
7730638-4	1995	In addition, TCA3 treatment induced the production of reactive nitrogen intermediates, whereas stimulation with higher concentrations (100 nM) of TCA3 induced the exocytosis of lysozyme and elastase in the presence of cytochalasin B (7 micrograms/ml).	Cytochalasin B	218-232	chemokine (C-C motif) ligand 1	Mus musculus	146-150
7536788-6	1995	Cytochalasin B did, however, inhibit granulocytic HL60 adherence to fibronectin by 50%, demonstrating that actin polymerization is important for optimal beta 1-dependent granulocytic adherence.	Cytochalasin B	0-14	fibronectin 1	Homo sapiens	68-79
7722326-5	1995	Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells.	Cytochalasin B	45-59	ribonuclease A family member 2	Homo sapiens	85-88
7722326-5	1995	Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells.	Cytochalasin B	45-59	myelin basic protein	Homo sapiens	108-111
7722326-5	1995	Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells.	Cytochalasin B	45-59	eosinophil peroxidase	Homo sapiens	116-119
7722326-5	1995	Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells.	Cytochalasin B	45-59	myelin basic protein	Homo sapiens	152-155
7722326-5	1995	Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells.	Cytochalasin B	45-59	eosinophil peroxidase	Homo sapiens	160-163
7536788-6	1995	Cytochalasin B did, however, inhibit granulocytic HL60 adherence to fibronectin by 50%, demonstrating that actin polymerization is important for optimal beta 1-dependent granulocytic adherence.	Cytochalasin B	0-14	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	153-159
7696290-11	1995	The functional GLUT 1 transporter had an apparent Km value of around 0.9 mM, and was sensitive to cytochalasin B, phloretin, phlorizin and pCMBS.	Cytochalasin B	98-112	solute carrier family 2 member 1	Rattus norvegicus	15-21
7878669-14	1995	The enhancing effect of cytochalasin B on PCB-induced O2- production, however, likely involves other mechanisms.	Cytochalasin B	24-38	pyruvate carboxylase	Rattus norvegicus	42-45
7756561-8	1995	The force required to hold a tether at zero velocity (F0) was greater than forces generated by single molecular motors, kinesin and myosin; and F0 decreased with cytochalasin B or D and DMSO in correlation with the changes in the probability of tether formation.	Cytochalasin B	162-176	myosin heavy chain 14	Homo sapiens	132-138
7883711-4	1995	Consistent with this is that S. pombe cells harboring bfr1+ on pDB248" are resistant to actinomycin D, cerulenin, and cytochalasin B, as well as to BFA.	Cytochalasin B	118-132	Bfr1p	Saccharomyces cerevisiae S288C	54-58
7531728-4	1995	If cytochalasin B (5 micrograms/ml) was coincubated with PAF (1 mumol/L) to enhance the secretory response, histamine release was maximal at time 0 and decreased in parallel with the time of the basophils" exposure to Ca2+, like 0.1 microgram/ml anti-IgE-induced histamine secretion but unlike 1 mumol/L formyl-methionyl-leucyl-phenylalanine-induced histamine secretion.	Cytochalasin B	3-17	PCNA clamp associated factor	Homo sapiens	57-60
7849318-8	1995	GM-CSF stimulated glucose uptake in four of the melanoma cell lines expressing the alpha subunit, presumably through facilitative glucose transporters, as uptake was blocked by cytochalasin B but not cytochalasin E.	Cytochalasin B	177-191	colony stimulating factor 2	Homo sapiens	0-6
7864871-4	1995	Insulin-independent and insulin-stimulated 2-deoxyglucose uptake were inhibited by cytochalasin B, indicating that both were transporter-mediated.	Cytochalasin B	83-97	insulin	Homo sapiens	0-7
7864871-4	1995	Insulin-independent and insulin-stimulated 2-deoxyglucose uptake were inhibited by cytochalasin B, indicating that both were transporter-mediated.	Cytochalasin B	83-97	insulin	Homo sapiens	24-31
7812007-8	1995	The ability of IL-8 to stimulate the activity of PLD was additively enhanced, or primed, by cytochalasin B and by tumor necrosis factor alpha.	Cytochalasin B	92-106	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
7741187-6	1995	Morphologic signs of degranulation induced by C5a and PAF were accompanied by the significantly increased release of eosinophil cationic protein and eosinophil peroxidase in the presence of cytochalasin B.	Cytochalasin B	190-204	complement C5a receptor 1	Homo sapiens	46-49
7741187-6	1995	Morphologic signs of degranulation induced by C5a and PAF were accompanied by the significantly increased release of eosinophil cationic protein and eosinophil peroxidase in the presence of cytochalasin B.	Cytochalasin B	190-204	PCNA clamp associated factor	Homo sapiens	54-57
7741187-10	1995	In addition, CL responses upon stimulation with C5a and PAF were abrogated by cytochalasin B, staurosporine, and wortmannin, and were almost completely blocked by pertussis toxin.	Cytochalasin B	78-92	complement C5a receptor 1	Homo sapiens	48-51
7741187-10	1995	In addition, CL responses upon stimulation with C5a and PAF were abrogated by cytochalasin B, staurosporine, and wortmannin, and were almost completely blocked by pertussis toxin.	Cytochalasin B	78-92	PCNA clamp associated factor	Homo sapiens	56-59
7553917-14	1995	The cells constricted to apparent completion, but after about 30 min the furrow regressed, forming a binucleate cell, much as after treatment with cytochalasin B or D. Postcytokinesis spreading of these T beta 4-injected cells was often inhibited.	Cytochalasin B	147-161	thymosin beta 4 X-linked	Homo sapiens	203-211
7812007-8	1995	The ability of IL-8 to stimulate the activity of PLD was additively enhanced, or primed, by cytochalasin B and by tumor necrosis factor alpha.	Cytochalasin B	92-106	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	49-52
7523418-5	1994	Here we show that cells enucleated with cytochalasin B still undergo apoptosis induced either by treatment with menadione, an oxidant quinone compound, or by triggering APO-1/Fas, a cell surface molecule involved in physiological cell death.	Cytochalasin B	40-54	Fas cell surface death receptor	Homo sapiens	169-174
7802684-2	1994	Both effects of okadaic acid were amplified when PLD activation was primed with cytochalasin B.	Cytochalasin B	80-94	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	49-52
7706407-4	1994	The appearance of Cx26 in the centrilobular hepatocytes was inhibited by treatment with cytoskeleton disruptors such as colchicine and cytochalasin B, and intracytoplasmic transport inhibitors such as brefeldin A.	Cytochalasin B	135-149	gap junction protein, beta 2	Rattus norvegicus	18-22
7521839-6	1994	Additional findings supported the conclusion that this pattern of syndecan-1 distribution reflected an association with microfilaments: aggregated syndecan-1 was resistant to extraction by nonionic detergent; incubation of the cells with cytochalasin b, but not colchicine, altered the pattern of aggregated syndecan-1 distribution; antibody-induced clustering of syndecan-1 led to a reorganization of actin filaments.	Cytochalasin B	238-252	syndecan 1	Homo sapiens	66-76
8092986-0	1994	Replacement of both tryptophan residues at 388 and 412 completely abolished cytochalasin B photolabelling of the GLUT1 glucose transporter.	Cytochalasin B	76-90	solute carrier family 2, facilitated glucose transporter member 1	Cricetulus griseus	113-118
8000707-7	1994	TNF alpha-induced responses were completely inhibited by cytochalasin B and staurosporin, and partially blocked by pertussis toxin.	Cytochalasin B	57-71	tumor necrosis factor	Homo sapiens	0-9
8002545-4	1994	In addition, we found that hypoxia increased the density of GLUT in isolated cerebral microvessels as determined by specific cytochalasin B binding.	Cytochalasin B	125-139	glutaminase	Rattus norvegicus	60-64
7516398-8	1994	By scanning electron microscopy, RANTES induced characteristic changes that were completely abrogated in the presence of cytochalasin B.	Cytochalasin B	121-135	C-C motif chemokine ligand 5	Homo sapiens	33-39
8089498-6	1994	In the presence of cytochalasin B, only fMLP and C5a caused the activation of phospholipase D in intact leukocytes and enhanced desensitization of IL-8 and C5a but not fMLP receptors.	Cytochalasin B	19-33	C-X-C motif chemokine ligand 8	Homo sapiens	147-151
8089498-6	1994	In the presence of cytochalasin B, only fMLP and C5a caused the activation of phospholipase D in intact leukocytes and enhanced desensitization of IL-8 and C5a but not fMLP receptors.	Cytochalasin B	19-33	complement C5a receptor 1	Homo sapiens	156-159
7838370-3	1994	Concurrent addition of 1 nM endothelin-3 prevented astrocytic stellation by dibutyryl cAMP and cytochalasin B.	Cytochalasin B	95-109	endothelin 3	Rattus norvegicus	28-40
7838370-5	1994	Endothelin-1 and sarafotoxin S6b prevented the cytochalasin B-induced stellation with similar potencies to endothelin-3.	Cytochalasin B	47-61	endothelin 1	Rattus norvegicus	0-12
7838370-6	1994	Endothelin-3 reversed the stellate morphology of cytochalasin B-treated cells.	Cytochalasin B	49-63	endothelin 3	Rattus norvegicus	0-12
7838370-7	1994	Sixty minutes after addition of endothelin-3, most cytochalasin B-treated astrocytes lost their apparent distinction between cell body and processes.	Cytochalasin B	51-65	endothelin 3	Rattus norvegicus	32-44
7838370-12	1994	Endothelin-3 stimulated reorganization of stress fibers both in the dibutyryl cAMP- and the cytochalasin B-treated astrocytes.	Cytochalasin B	92-106	endothelin 3	Rattus norvegicus	0-12
7980021-5	1994	In the presence of cytochalasin B (5 micrograms/ml), PAF (10(-8) M, 10(-7) M, 10(-6) M) did not induce any significant release of TxB2 from granulocytes.	Cytochalasin B	19-33	PCNA clamp associated factor	Homo sapiens	53-56
7517206-3	1994	Cathepsin G resulted in proteolysis of the vWF binding site on GPIb alpha (defined by monoclonal antibody [MoAb] 6D1), as determined by increased supernatant glycocalicin fragment (a proteolytic product of GPIb alpha); decreased total platelet content of GPIb; and lack of effect of either cytochalasin B (an inhibitor of actin polymerization), prostaglandin I2 (an inhibitor of platelet activation), or prior fixation of the platelets.	Cytochalasin B	290-304	cathepsin G	Homo sapiens	0-11
7517206-3	1994	Cathepsin G resulted in proteolysis of the vWF binding site on GPIb alpha (defined by monoclonal antibody [MoAb] 6D1), as determined by increased supernatant glycocalicin fragment (a proteolytic product of GPIb alpha); decreased total platelet content of GPIb; and lack of effect of either cytochalasin B (an inhibitor of actin polymerization), prostaglandin I2 (an inhibitor of platelet activation), or prior fixation of the platelets.	Cytochalasin B	290-304	von Willebrand factor	Homo sapiens	43-46
7517206-3	1994	Cathepsin G resulted in proteolysis of the vWF binding site on GPIb alpha (defined by monoclonal antibody [MoAb] 6D1), as determined by increased supernatant glycocalicin fragment (a proteolytic product of GPIb alpha); decreased total platelet content of GPIb; and lack of effect of either cytochalasin B (an inhibitor of actin polymerization), prostaglandin I2 (an inhibitor of platelet activation), or prior fixation of the platelets.	Cytochalasin B	290-304	glycoprotein Ib platelet subunit alpha	Homo sapiens	63-73
7517206-5	1994	In contrast to its proteolytic effect on GPIb alpha, the cathepsin G-induced decrease in platelet surface GPIX and the remnant of the GPIb-IX complex (defined by MoAbs FMC25 and AK1) was via a cytoskeletal-mediated redistribution, as determined by lack of change in the total platelet content of GPIX and the GPIb-IX complex; complete inhibition by cytochalasin B, prostaglandin I2, and prior fixation of platelets.	Cytochalasin B	349-363	cathepsin G	Homo sapiens	57-68
8049134-3	1994	The microfilament disrupting agent cytochalasin B (5 x 10(-5) M) induced a reversible inhibition of the spontaneous secretion of corticosteroid and blocked the response of adrenocortical cells to ET-1 (5 x 10(-9) M).	Cytochalasin B	35-49	endothelin 1	Canis lupus familiaris	196-200
8156000-3	1994	C3a and C5a induced remarkable ECP release when Eos were preincubated with cytochalasin B.	Cytochalasin B	75-89	complement C3	Homo sapiens	0-3
7515890-8	1994	Fc gamma RIII/CR3 synergy is abolished by cytochalasin B and herbimicin, suggesting that both the actin cytoskeleton and tyrosine phosphorylation are necessary for activation of the synergistic respiratory burst.	Cytochalasin B	42-56	Fc gamma receptor IIIa	Homo sapiens	0-13
7515890-8	1994	Fc gamma RIII/CR3 synergy is abolished by cytochalasin B and herbimicin, suggesting that both the actin cytoskeleton and tyrosine phosphorylation are necessary for activation of the synergistic respiratory burst.	Cytochalasin B	42-56	teratocarcinoma-derived growth factor 1 pseudogene 3	Homo sapiens	14-17
7913925-9	1994	After reoxygenation (> 90% O2 saturation), CD11b/CD18 expression was restored, and this was abrogated by exposure to cytochalasin B.	Cytochalasin B	120-134	integrin subunit alpha M	Homo sapiens	46-51
7913925-9	1994	After reoxygenation (> 90% O2 saturation), CD11b/CD18 expression was restored, and this was abrogated by exposure to cytochalasin B.	Cytochalasin B	120-134	integrin subunit beta 2	Homo sapiens	52-56
8144874-5	1994	GLUT-1 expression was detectable at 24 h, peaked at 48 h, and disappeared at 96 h. The total number of glucose transporters per cell measured as the total capacity of D-glucose displaceable cytochalasin B binding did not change significantly at any time after PHA stimulation.	Cytochalasin B	190-204	solute carrier family 2 member 1	Homo sapiens	0-6
8157690-4	1994	The ability of the Tyr-293-->Ile mutated GLUT1 to bind the exofacial ligand 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos- 4-yloxy)-2- propylamine (ATB-BMPA) and the endofacial ligand cytochalasin B were assessed by photolabeling procedures.	Cytochalasin B	201-215	solute carrier family 2 member 1	Homo sapiens	44-49
8131837-7	1994	The flow cytometry pattern in IL-6-treated Mm1 was the same as that of cytochalasin B-treated Mm1.	Cytochalasin B	71-85	prefoldin 5	Mus musculus	94-97
8141278-4	1994	Cytochalasin B treatment caused disappearance of microfilaments and blocked the stimulatory action of ACTH and DBcAMP on cortisol secretion.	Cytochalasin B	0-14	proopiomelanocortin	Homo sapiens	102-106
8113023-6	1994	The mechanism of thrombin-induced RPE cell gap formation was studied by preincubation with specific drugs, including a protein kinase inhibitor (staurosporine), protein kinase C inhibitors (H-7 and calphostin C), cyclic adenosine monophosphate (cAMP) inducer (forskolin), and cytoskeleton-disrupting agents (cytochalasin B or colchicine).	Cytochalasin B	308-322	coagulation factor II, thrombin	Bos taurus	17-25
8304489-6	1994	Calmodulin inhibitors or disruption of cytoskeletal elements with cytochalasin B and colchicine also reduced pHi recovery significantly.	Cytochalasin B	66-80	glucose-6-phosphate isomerase	Rattus norvegicus	109-112
7832591-2	1994	It is suggested to be the bacterial equivalent of the mammalian glucose transporter, GLUT1, since these proteins share sequence homology, recognise and transport similar substrates and are both inhibited by cytochalasin B and forskolin.	Cytochalasin B	207-221	solute carrier family 2 member 1	Homo sapiens	85-90
8031242-2	1994	Transfer of the virus-binding MOLT-4#8 cells from 4 degrees C to 37 degrees C resulted in increased detection of the viral gp46 and p19 MA protein on the cells, which was, however, inhibited by 4 degrees C or cytochalasin B treatment.	Cytochalasin B	209-223	serpin family H member 1	Homo sapiens	123-127
8031242-2	1994	Transfer of the virus-binding MOLT-4#8 cells from 4 degrees C to 37 degrees C resulted in increased detection of the viral gp46 and p19 MA protein on the cells, which was, however, inhibited by 4 degrees C or cytochalasin B treatment.	Cytochalasin B	209-223	interleukin 23 subunit alpha	Homo sapiens	132-135
8156000-3	1994	C3a and C5a induced remarkable ECP release when Eos were preincubated with cytochalasin B.	Cytochalasin B	75-89	complement C5a receptor 1	Homo sapiens	8-11
8282794-3	1994	(a) Selective stimulation of azurophil granule secretion by the Na-ionophore Monensin, or nonselective stimulation by FMLP after cytochalasin B pretreatment elicited marked pinocytic activity in parallel with azurophil granule release, whereas FMLP alone, selective for specific granules, elicited little fluid pinocytosis.	Cytochalasin B	129-143	formyl peptide receptor 1	Homo sapiens	118-122
18472929-3	1994	But after a 20 min incubation of alpha(2)-macroglobulin at 37 degrees C with 2 x 10(6) human polymorphonuclear leukocytes activated by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (10(-7) M) and cytochalasin B (10(-8) M), 100% of trypsin activity was recovered, indicating a total inactivation of alpha(2)-macroglobuHn.	Cytochalasin B	196-210	alpha-2-macroglobulin	Homo sapiens	33-55
8246607-2	1993	This MPO release was greatly augmented by Cytochalasin B (Cy B), but after the addition of Cy B the priming effects of GM-CSF became less obvious.	Cytochalasin B	42-56	myeloperoxidase	Homo sapiens	5-8
8246607-2	1993	This MPO release was greatly augmented by Cytochalasin B (Cy B), but after the addition of Cy B the priming effects of GM-CSF became less obvious.	Cytochalasin B	58-62	myeloperoxidase	Homo sapiens	5-8
8324074-0	1993	Induction of interleukin-2 receptor alpha-chain gene expression by cytochalasin B and 12-O-tetradecanoylphorbol-13-acetate in T lymphocytes.	Cytochalasin B	67-81	interleukin 2 receptor subunit alpha	Homo sapiens	13-41
7954851-5	1994	When axoplasm was extruded on these cover slips in the buffer containing cytochalasin B that prevents the formation of endogenous axonal actin filaments, organelles were observed to move at the fast transport rate.	Cytochalasin B	73-87	actin	Oryctolagus cuniculus	137-142
8011428-4	1994	Activation of intact neutrophils with formyl-methionyl-leucyl-phenylalanine (FMLP), in the presence of cytochalasin-B, caused the development of invaginations of the plasma membrane.	Cytochalasin B	103-117	formyl peptide receptor 1	Homo sapiens	77-81
8225024-6	1993	In the presence of the actin polymerization inhibitor, cytochalasin B, superoxide generation was persistent, even when measurements were conducted at 37 degrees C. A possible explanation for these observations is that the fMLP receptor complexes quickly aggregate and are internalized at physiological temperature, but not at room temperature.	Cytochalasin B	55-69	formyl peptide receptor 1	Homo sapiens	222-235
8408238-5	1993	The inhibition of the uptake of (3H)2-deoxyglucose by either 10 microM cytochalasin B or phloretin, added at the time of monocyte activation, was accompanied by significant reduction in ATP/ADP ratio and the inhibition of the production of IL-1 beta by activated monocytes.	Cytochalasin B	71-85	interleukin 1 beta	Homo sapiens	240-249
8104228-8	1993	Despite its apparent CD18 independence, LRI/IAP-initiated respiratory burst requires a solid phase ligand and is sensitive to cytochalasin B.	Cytochalasin B	126-140	CD47 molecule	Homo sapiens	44-47
8357820-7	1993	Significant uptake of 125I-TNF into T-24 cells was observed when these immunoliposomes were used, and this uptake of TNF was inhibited by cytochalasin B or chloroquine.	Cytochalasin B	138-152	tumor necrosis factor	Homo sapiens	27-30
8357820-7	1993	Significant uptake of 125I-TNF into T-24 cells was observed when these immunoliposomes were used, and this uptake of TNF was inhibited by cytochalasin B or chloroquine.	Cytochalasin B	138-152	tumor necrosis factor	Homo sapiens	117-120
8362986-9	1993	Cytochalasin B, preventing actin polymerization, inhibits the mitogenic response to FGF-2 but not the response to colchicine.	Cytochalasin B	0-14	fibroblast growth factor 2	Bos taurus	84-89
8372873-3	1993	To test whether the insulin-like growth factor-I receptors on amnion cells are functional, cytochalasin B-inhibitable 2-deoxyglucose uptake was measured after stimulating the cells with insulin-like growth factor-I.	Cytochalasin B	91-105	insulin like growth factor 1	Homo sapiens	20-48
8372873-3	1993	To test whether the insulin-like growth factor-I receptors on amnion cells are functional, cytochalasin B-inhibitable 2-deoxyglucose uptake was measured after stimulating the cells with insulin-like growth factor-I.	Cytochalasin B	91-105	insulin like growth factor 1	Homo sapiens	186-214
8372873-6	1993	Both primary amnion cells and WISH cells exhibited cytochalasin B-inhibitable tritiated 2-deoxyglucose uptake in response to insulin-like growth factor-I treatment.	Cytochalasin B	51-65	insulin like growth factor 1	Homo sapiens	125-153
8360687-5	1993	nAChR up-regulation is evident after 1-2 days of cytochalasin B exposure, is maximal after 3-6 days of drug treatment, and is dominated by an approximately 10-fold increase (per cell) in an intracellular nAChR pool.	Cytochalasin B	49-63	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	0-5
8315346-3	1993	Full activation of PLD by fMLP required the simultaneous presence of both Ca2+ and cytochalasin B, a condition that caused no further enhancement of PLC.	Cytochalasin B	83-97	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	19-22
8315346-3	1993	Full activation of PLD by fMLP required the simultaneous presence of both Ca2+ and cytochalasin B, a condition that caused no further enhancement of PLC.	Cytochalasin B	83-97	formyl peptide receptor 1	Homo sapiens	26-30
8492082-7	1993	Cytochalasin B decreased calcium uptake in 9-day and 12-day vitamin D-treated embryos to about 60% of their hormone-enhanced level and also decreased PTH-stimulated 45Ca uptake into yolk sac disks by about 50% in embryos of all age groups tested.	Cytochalasin B	0-14	parathyroid hormone	Gallus gallus	150-153
8391786-7	1993	The soluble aggregates, but not the insoluble aggregates, also activated the secretion of myeloperoxidase from neutrophils that had either been pretreated with cytochalasin B or primed with GM-CSF.	Cytochalasin B	160-174	myeloperoxidase	Homo sapiens	90-105
8242794-8	1993	Expression of ornithine decarboxylase mRNA and protein is increased by vinblastine sulfate but decreased by cytochalasin B in TPA treated cells.	Cytochalasin B	108-122	ornithine decarboxylase, structural 1	Mus musculus	14-37
8324074-4	1993	In this study, we examined the effect of cytochalasin B (CB) plus 12-O-tetradecanoylphorbol-13-acetate (TPA) on expression of IL-2 and IL-2R.	Cytochalasin B	41-55	interleukin 2	Homo sapiens	126-130
8324074-4	1993	In this study, we examined the effect of cytochalasin B (CB) plus 12-O-tetradecanoylphorbol-13-acetate (TPA) on expression of IL-2 and IL-2R.	Cytochalasin B	41-55	interleukin 2 receptor subunit alpha	Homo sapiens	135-140
8455041-5	1993	These enhancing effects of CTB were blocked by the presence of cytochalasin B in the culture medium but were not affected by the presence of colchicine or by the depletion of Ca2+ in the medium.	Cytochalasin B	63-77	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	27-30
8457197-5	1993	Cytochalasin B is a non-competitive inhibitor of glucose transport by the well-characterized GLUT1 isoform.	Cytochalasin B	0-14	solute carrier family 2 (facilitated glucose transporter), member 1 L homeolog	Xenopus laevis	93-98
8457197-6	1993	We show here that cytochalasin B is also a non-competitive inhibitor of the transport of deoxyglucose and alternative substrates by GLUT2 and GLUT3 expressed in oocytes.	Cytochalasin B	18-32	solute carrier family 2 member 2 S homeolog	Xenopus laevis	132-137
8457197-6	1993	We show here that cytochalasin B is also a non-competitive inhibitor of the transport of deoxyglucose and alternative substrates by GLUT2 and GLUT3 expressed in oocytes.	Cytochalasin B	18-32	solute carrier family 2 member 3 L homeolog	Xenopus laevis	142-147
8492111-4	1993	Growth of neurites in the presence of cytochalasin B (CB) was not inhibited on substrates of L1 or P84 but was markedly inhibited on N-CAM.	Cytochalasin B	38-52	neural cell adhesion molecule 1	Homo sapiens	133-138
8440692-1	1993	The chemotactic peptide fMLP (N-formyl-methionyl-leucyl-phenylalanine) induced the production of platelet-activating factor (PAF) by human polymorphonuclear leukocytes (PMN) incubated with cytochalasin B (CB).	Cytochalasin B	189-203	formyl peptide receptor 1	Homo sapiens	24-28
8093876-5	1993	Quantitative Western blotting employing purified human erythrocyte glucose transporter as an assay standard showed that the concentration of immunoreactive GLUT1 protein in 70-day-old rabbit brain microvessels (111 +/- 3 pmol/mg protein) was not significantly different from the concentration of D-glucose-displaceable cytochalasin-B-binding sites (102 +/- 25 pmol/mg protein).	Cytochalasin B	319-333	solute carrier family 2 member 1	Homo sapiens	156-161
8423781-4	1993	This THT1-encoded transport system for glucose differs from the human erythrocyte-type glucose transporter by its moderate sensitivity to cytochalasin B and its capacity to transport D-fructose.	Cytochalasin B	138-152	solute carrier family 19 member 2	Homo sapiens	5-9
18475515-5	1993	The data show that HGF at 1-10 ng/ml increased lysosomal enzyme release from both specific and azurophilic granules of cytochalasin-B treated neutrophils.	Cytochalasin B	119-133	hepatocyte growth factor	Homo sapiens	19-22
8455356-11	1993	In contrast, actin microfilament disaggregation with cytochalasin B or D did not change the rate of DNA synthesis in response to EGF but did attenuate the antiproliferative effect of TGF-beta 1 on EGF-induced DNA synthesis cells.	Cytochalasin B	53-67	pro-epidermal growth factor	Oryctolagus cuniculus	197-200
1281207-6	1992	RANTES and MIP-1 alpha induced eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in contrast to other chemotactic agonists such as C5a and formyl-methionyl-leucyl-phenylalanine (FMLP).	Cytochalasin B	70-84	C-C motif chemokine ligand 5	Homo sapiens	0-6
1281207-6	1992	RANTES and MIP-1 alpha induced eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in contrast to other chemotactic agonists such as C5a and formyl-methionyl-leucyl-phenylalanine (FMLP).	Cytochalasin B	70-84	C-C motif chemokine ligand 3	Homo sapiens	11-22
1281207-6	1992	RANTES and MIP-1 alpha induced eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in contrast to other chemotactic agonists such as C5a and formyl-methionyl-leucyl-phenylalanine (FMLP).	Cytochalasin B	70-84	ribonuclease A family member 3	Homo sapiens	31-58
1358626-3	1992	As tested by immunofluorescence, neutrophil CD43 membrane expression was shown to decrease by up to 80% upon cell activation by phorbol myristate acetate (10 ng/ml) or by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP; 10(-6) M) in the presence of cytochalasin B.	Cytochalasin B	253-267	sialophorin	Homo sapiens	44-48
1417839-3	1992	This immunoreactive band in GLUT3 injected oocytes is photolabelled by cytochalasin-B in the presence of L- but not D-glucose indicating that it is a glucose transporter.	Cytochalasin B	71-85	solute carrier family 2 member 3	Homo sapiens	28-33
1331280-5	1992	Pretreatment of the cells with cytochalasin B augmented generation of LTB4 in response to fMLP (339 +/- 79 pg/10(7) cells).	Cytochalasin B	31-45	formyl peptide receptor 1	Homo sapiens	90-94
1420159-3	1992	In a similar fashion, the uptake of 2-deoxyglucose by GLUT1-, GLUT2-, and GLUT3-expressing oocytes was inhibited by a series of unlabeled hexoses and pentoses and by cytochalasin B in a similar hierarchical order.	Cytochalasin B	166-180	solute carrier family 2 member 1	Homo sapiens	54-59
1420159-3	1992	In a similar fashion, the uptake of 2-deoxyglucose by GLUT1-, GLUT2-, and GLUT3-expressing oocytes was inhibited by a series of unlabeled hexoses and pentoses and by cytochalasin B in a similar hierarchical order.	Cytochalasin B	166-180	solute carrier family 2 member 2	Homo sapiens	62-67
1420159-3	1992	In a similar fashion, the uptake of 2-deoxyglucose by GLUT1-, GLUT2-, and GLUT3-expressing oocytes was inhibited by a series of unlabeled hexoses and pentoses and by cytochalasin B in a similar hierarchical order.	Cytochalasin B	166-180	solute carrier family 2 member 3	Homo sapiens	74-79
1397712-7	1992	Cytochalasin-B photolabeled a 53,000-M(r) protein in small intestine membranes that was immunoprecipitated by the GLUT5 antibody; labeling was inhibited by D- but not L-glucose.	Cytochalasin B	0-14	solute carrier family 2 member 5	Homo sapiens	114-119
1397084-5	1992	Three different cytochalasans, cytochalasin B, cytochalasin D, and chaetoglobosin C, all of which bind to cellular actin with different affinities and only one of which affects glucose transport, induced IL-2 receptors in combination with PMA.	Cytochalasin B	31-45	interleukin 2	Homo sapiens	204-208
1322441-5	1992	By contrast, when specific granule secretion was induced in the presence of cytochalasin B, a marked decrease in reactivity of beta fractions with anti-p55 TNF-R antibody was observed.	Cytochalasin B	76-90	TNF receptor superfamily member 1A	Homo sapiens	152-155
1468436-9	1992	After a similar treatment with cytochalasin B, plectin"s association with stress fibers again was completely abolished, although stress fibers were still present.	Cytochalasin B	31-45	plectin	Rattus norvegicus	47-54
1338103-16	1992	The pHi response induced by the hyperosmotic stress was abolished by two calmodulin inhibitors, W-7 and chlorpromazine (50% inhibition, Ki at 28 and 20 microM, respectively), 20 microM cytochalasin B, but not by 10 microM colchicine.	Cytochalasin B	185-199	glucose-6-phosphate isomerase	Rattus norvegicus	4-7
1325374-0	1992	The differential role of Cys-421 and Cys-429 of the Glut1 glucose transporter in transport inhibition by p-chloromercuribenzenesulfonic acid (pCMBS) or cytochalasin B (CB).	Cytochalasin B	152-166	solute carrier family 2 (facilitated glucose transporter), member 1 L homeolog	Xenopus laevis	52-57
1482554-5	1992	In the presence of 10(-5) M cytochalasin B, the microfilament staining of the cells disappeared, while residual filamentous structures were labeled with anti-HSP90 antibodies.	Cytochalasin B	28-42	heat shock protein 90 alpha family class A member 1	Homo sapiens	158-163
1482554-7	1992	Conversely, similar reorganized morphology of filamentous structures stained with both anti-HSP90 and anti-cytokeratins antibodies were observed when Ishikawa cells were treated with 2 x 10(-5) M cytochalasin B and 2 x 10(-5) M colchicine.	Cytochalasin B	196-210	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
1530597-7	1992	The hexose-transport inhibitors phloretin, cytochalasin B and 4,6-O-ethylidene-D-glucose all inhibited the photolabelling by ATB-BMPA of immunoprecipitable GLUT2.	Cytochalasin B	43-57	solute carrier family 2 member 2	Homo sapiens	156-161
1355095-4	1992	Disruption of microfilaments with cytochalasin B (CCB) changed the localization of wild-type ICAM-1 but had no effect on GPI-ICAM-1.	Cytochalasin B	34-48	intercellular adhesion molecule 1	Homo sapiens	93-99
1355095-4	1992	Disruption of microfilaments with cytochalasin B (CCB) changed the localization of wild-type ICAM-1 but had no effect on GPI-ICAM-1.	Cytochalasin B	50-53	intercellular adhesion molecule 1	Homo sapiens	93-99
1355095-6	1992	CCB also induced redistribution of ICAM-1 in these cells.	Cytochalasin B	0-3	intercellular adhesion molecule 1	Homo sapiens	35-41
1323622-2	1992	1-hp (6-25 microM), but not pyocyanin, caused a dose-dependent enhancement of elastase release by FMLP:cytochalasin B (CB)-activated human neutrophils.	Cytochalasin B	103-117	formyl peptide receptor 1	Homo sapiens	98-102
1461633-7	1992	Changes in distribution of actin, myosin and spectrin during oocyte maturation are discussed with reference to the cortical contractility, spatial distribution of yolk platelets and regional sensitivity to cytochalasin B.	Cytochalasin B	206-220	actin like 6A S homeolog	Xenopus laevis	27-32
1323612-3	1992	After short term priming (5 min) by TNF-alpha, suspended cytochalasin B-treated PMN responded to NAP-2 or rIL-8 by substantial augmentation of the degranulation response.	Cytochalasin B	57-71	tumor necrosis factor	Homo sapiens	36-45
1323612-3	1992	After short term priming (5 min) by TNF-alpha, suspended cytochalasin B-treated PMN responded to NAP-2 or rIL-8 by substantial augmentation of the degranulation response.	Cytochalasin B	57-71	pro-platelet basic protein	Homo sapiens	97-102
1331257-1	1992	Cytochalasin B, a drug that alters microfilament structure, was found to modulate interferon-alpha (IFN-alpha)-induced changes in ion fluxes, in motional freedom of spin probes, and lateral diffusion of surface antigens.	Cytochalasin B	0-14	interferon alpha 1	Homo sapiens	100-109
1627802-1	1992	Human polymorphonuclear leukocytes (PMN) activated by n-formyl-methionyl-leucyl-phenylalanine (fMLP), in the presence of cytochalasin B, are able to induce activation of coincubated autologous platelets "via" cathepsin G released from the azurophilic granules.	Cytochalasin B	121-135	formyl peptide receptor 1	Homo sapiens	95-99
1627802-1	1992	Human polymorphonuclear leukocytes (PMN) activated by n-formyl-methionyl-leucyl-phenylalanine (fMLP), in the presence of cytochalasin B, are able to induce activation of coincubated autologous platelets "via" cathepsin G released from the azurophilic granules.	Cytochalasin B	121-135	cathepsin G	Homo sapiens	209-220
1417873-4	1992	Moreover, activity of the stimulatory FN was not affected by inclusion of cytochalasin B, which is known to release FN from cell surface by disorganizing actin cytoarchitecture.	Cytochalasin B	74-88	fibronectin 1	Mus musculus	116-118
1504749-7	1992	In the presence of cytochalasin B, FMLP stimulated elastase release from neutrophils was also inhibited to unstimulated levels by 5 min pretreatment with alpha-cyano-3,4-dihydroxythiocinnamamide.	Cytochalasin B	19-33	formyl peptide receptor 1	Homo sapiens	35-39
1322441-5	1992	By contrast, when specific granule secretion was induced in the presence of cytochalasin B, a marked decrease in reactivity of beta fractions with anti-p55 TNF-R antibody was observed.	Cytochalasin B	76-90	TNF receptor superfamily member 1A	Homo sapiens	156-161
1640174-2	1992	Pretreatment of neutrophils with cytochalasin B abolished the LAI effect of IL-8, suggesting a microfilament-dependent mechanism.	Cytochalasin B	33-47	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
1640174-3	1992	Interleukin-8 induced a rapid increase (less than or equal to 15 s) in the polymerization of actin filaments in human neutrophils that was blocked by pretreatment with cytochalasin B.	Cytochalasin B	168-182	C-X-C motif chemokine ligand 8	Homo sapiens	0-13
1376114-2	1992	TSP receptor expression increases 30-fold after activation with the synthetic chemotactic peptide, N-formylmethionyl-leucylphenylalanine (FMLP) or the Ca2+ ionophore A23187, in combination with cytochalasin B.	Cytochalasin B	194-208	thrombospondin 1	Homo sapiens	0-3
1376114-6	1992	When PMNs were exposed to cytochalasin B and FMLP or to cytochalasin B and ionophore A23187 in the presence of 30-100 microM-DIDS, TSP receptor expression increased coincidently with vitamin B12-binding protein release from specific granules.	Cytochalasin B	26-40	thrombospondin 1	Homo sapiens	131-134
1376114-6	1992	When PMNs were exposed to cytochalasin B and FMLP or to cytochalasin B and ionophore A23187 in the presence of 30-100 microM-DIDS, TSP receptor expression increased coincidently with vitamin B12-binding protein release from specific granules.	Cytochalasin B	56-70	thrombospondin 1	Homo sapiens	131-134
1534653-4	1992	Changes in GLUT4 glucose transporter protein mirrored changes in cytochalasin B binding in plasma membranes.	Cytochalasin B	65-79	solute carrier family 2 member 4	Rattus norvegicus	11-16
1612297-6	1992	Preincubation with 10 microM cytochalasin B for 5 min before FMLP stimulation markedly enhanced both of these changes.	Cytochalasin B	29-43	formyl peptide receptor 1	Homo sapiens	61-65
1315831-10	1992	The microfilament disrupter, cytochalasin b, inhibited IL-8 induced stimulation of PIP kinase.	Cytochalasin B	29-43	C-X-C motif chemokine ligand 8	Homo sapiens	55-59
1315831-10	1992	The microfilament disrupter, cytochalasin b, inhibited IL-8 induced stimulation of PIP kinase.	Cytochalasin B	29-43	prolactin induced protein	Homo sapiens	83-86
1578146-6	1992	IL-8 release was dependent on FMLP-induced de novo protein synthesis because it was inhibited by cycloheximide, was paralleled by enhanced expression of IL-8 mRNA and was potentiated from two- to sixfold after preincubation of PMN with cytochalasin B.	Cytochalasin B	236-250	formyl peptide receptor 1	Homo sapiens	30-34
1560011-8	1992	The ID50 for cytochalasin B inhibition of 2-deoxyglucose uptake was increased from 5 x 10(-7) M for the wild-type Glut1 to 4 x 10(-6) M in the 388 mutants but was unaltered in the 412 mutants.	Cytochalasin B	13-27	solute carrier family 2 (facilitated glucose transporter), member 1 L homeolog	Xenopus laevis	114-119
1578146-6	1992	IL-8 release was dependent on FMLP-induced de novo protein synthesis because it was inhibited by cycloheximide, was paralleled by enhanced expression of IL-8 mRNA and was potentiated from two- to sixfold after preincubation of PMN with cytochalasin B.	Cytochalasin B	236-250	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
1545129-5	1992	The addition of FMLP to [3H]cytidine-prelabeled neutrophils elicited an increase in the accumulation of [3H]CDP-DG that was maximally enhanced in cells that were pretreated with cytochalasin B.	Cytochalasin B	178-192	formyl peptide receptor 1	Homo sapiens	16-20
1311169-7	1992	Cytochalasin B (5 micrograms/ml), an agent which disrupts actin filaments, completely blocked association of [3H]fMLP with cytoskeletal preparations, as previously reported.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	113-117
1712815-9	1991	Treating PMN with cytochalasin B followed by FMLP caused a 30-fold increase in TSP receptor expression.	Cytochalasin B	18-32	thrombospondin 1	Homo sapiens	79-82
1733814-5	1992	Cytochalasin B-inhibitable 2-DG uptake (basal and insulin stimulated) was higher in control than in IDDM subjects (P less than 0.001).	Cytochalasin B	0-14	insulin	Homo sapiens	50-57
1346398-6	1992	Stimulation of neutrophils respiratory burst by both anti-CD18, and anti-LFA-1 or gp150/95 mAbs was totally inhibited by the microfilaments disrupting agent, cytochalasin B, and by a permeable cAMP analogue.	Cytochalasin B	158-172	integrin subunit beta 2	Homo sapiens	73-78
1346398-6	1992	Stimulation of neutrophils respiratory burst by both anti-CD18, and anti-LFA-1 or gp150/95 mAbs was totally inhibited by the microfilaments disrupting agent, cytochalasin B, and by a permeable cAMP analogue.	Cytochalasin B	158-172	integrin subunit beta 4	Homo sapiens	82-87
1732416-7	1992	A role for cytolysin in endocytosis of fragmentin was suggested by the observation that treatment of YAC-1 with cytochalasin B or sodium azide and 2-deoxyglucose blocked DNA fragmentation but not cytolysin activity.	Cytochalasin B	112-126	perforin 1 (pore forming protein)	Mus musculus	11-20
1732416-7	1992	A role for cytolysin in endocytosis of fragmentin was suggested by the observation that treatment of YAC-1 with cytochalasin B or sodium azide and 2-deoxyglucose blocked DNA fragmentation but not cytolysin activity.	Cytochalasin B	112-126	ADP-ribosyltransferase 1	Mus musculus	101-106
1660059-9	1991	Secretion was enhanced by the addition of 5 micrograms/ml cytochalasin B to 10(-6) M fMLP (25.9 +/- 12.7% total EPO content, P = 0.043 vs. control); similar decreases were noted in eosinophil EPO concentration (71.7 +/- 16.1% of control, P = 0.043).	Cytochalasin B	58-72	formyl peptide receptor 1	Homo sapiens	85-89
1660059-9	1991	Secretion was enhanced by the addition of 5 micrograms/ml cytochalasin B to 10(-6) M fMLP (25.9 +/- 12.7% total EPO content, P = 0.043 vs. control); similar decreases were noted in eosinophil EPO concentration (71.7 +/- 16.1% of control, P = 0.043).	Cytochalasin B	58-72	eosinophil peroxidase	Homo sapiens	112-115
1660059-9	1991	Secretion was enhanced by the addition of 5 micrograms/ml cytochalasin B to 10(-6) M fMLP (25.9 +/- 12.7% total EPO content, P = 0.043 vs. control); similar decreases were noted in eosinophil EPO concentration (71.7 +/- 16.1% of control, P = 0.043).	Cytochalasin B	58-72	eosinophil peroxidase	Homo sapiens	192-195
1939644-8	1991	Injection with 1-50 ng of in vitro-transcribed GLUT1 mRNA increased 3H-methylglucose uptake greater than 15-fold in a cytochalasin B-sensitive manner and increased Pf from (3.7 +/- 0.4) x 10(-4) cm/s (SE, n = 16, 10 degrees C) in water-injected oocytes up to (13 +/- 1) x 10(-4) cm/s (n = 18).	Cytochalasin B	118-132	solute carrier family 2 member 1	Homo sapiens	47-52
1717468-2	1991	In this report we examine the role of integrin alpha v beta 3 in mediating cell attachment to vitronectin or a RGD-containing peptide in the presence of cytochalasin B to prevent actin polymerization.	Cytochalasin B	153-167	integrin subunit alpha V	Homo sapiens	38-61
1717468-2	1991	In this report we examine the role of integrin alpha v beta 3 in mediating cell attachment to vitronectin or a RGD-containing peptide in the presence of cytochalasin B to prevent actin polymerization.	Cytochalasin B	153-167	vitronectin	Homo sapiens	94-105
1832992-6	1991	CD9-induced activation requires cytoskeletal rearrangement because it is inhibited by cytochalasin B.	Cytochalasin B	86-100	CD9 molecule	Homo sapiens	0-3
1660854-3	1991	Incubation of the cells with IFN-alpha and subsequent stimulation with FMLP (in the presence of cytochalasin b) reduced the generation of the chemotactic active leukotriene B4 (LTB4).	Cytochalasin B	96-110	interferon alpha 1	Homo sapiens	29-38
1660854-3	1991	Incubation of the cells with IFN-alpha and subsequent stimulation with FMLP (in the presence of cytochalasin b) reduced the generation of the chemotactic active leukotriene B4 (LTB4).	Cytochalasin B	96-110	formyl peptide receptor 1	Homo sapiens	71-75
1832880-11	1991	SIC did not induce significant levels of TNF-alpha secretion by PAM; however, SIC with cytochalasin B-pretreated PAM induced equivalent levels of TNF-alpha secretion as IIC-activated PAM.	Cytochalasin B	87-101	tumor necrosis factor	Homo sapiens	146-155
1832880-12	1991	We conclude that IIC or SIC with cytochalasin B pretreatment, both of which prevent internalization of IgG immune complex-bound Fc receptor (FcR), provide a signal for PAM to generate TNF-alpha through FcR modulation.	Cytochalasin B	33-47	tumor necrosis factor	Homo sapiens	184-193
1716731-0	1991	Differentiation of erythrocyte-(GLUT1), liver-(GLUT2), and adipocyte-type (GLUT4) glucose transporters by binding of the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and isobutylmethylxanthine.	Cytochalasin B	140-154	solute carrier family 2 member 1	Rattus norvegicus	32-37
1716731-0	1991	Differentiation of erythrocyte-(GLUT1), liver-(GLUT2), and adipocyte-type (GLUT4) glucose transporters by binding of the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and isobutylmethylxanthine.	Cytochalasin B	140-154	solute carrier family 2 member 2	Rattus norvegicus	47-52
1716731-0	1991	Differentiation of erythrocyte-(GLUT1), liver-(GLUT2), and adipocyte-type (GLUT4) glucose transporters by binding of the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and isobutylmethylxanthine.	Cytochalasin B	140-154	solute carrier family 2 member 4	Rattus norvegicus	75-80
1716731-6	1991	These data demonstrate striking differences of GLUT1, GLUT2, and GLUT4 with respect to their binding affinity for the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and IBMX.	Cytochalasin B	137-151	solute carrier family 2 member 1	Rattus norvegicus	47-52
1716731-6	1991	These data demonstrate striking differences of GLUT1, GLUT2, and GLUT4 with respect to their binding affinity for the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and IBMX.	Cytochalasin B	137-151	solute carrier family 2 member 2	Rattus norvegicus	54-59
1716731-6	1991	These data demonstrate striking differences of GLUT1, GLUT2, and GLUT4 with respect to their binding affinity for the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and IBMX.	Cytochalasin B	137-151	solute carrier family 2 member 4	Rattus norvegicus	65-70
1874738-2	1991	zLYCK (10 microM) inhibited the fMLP-induced respiratory burst in neutrophils treated with cytochalasin B.	Cytochalasin B	91-105	formyl peptide receptor 1	Homo sapiens	32-36
1864964-4	1991	Pretreatment of cells with various concentrations of propranolol enhanced (less than or equal to 200 microM) or inhibited (greater than 300 microM) PLD-induced production of PA (mass and radiolabel) in a manner that correlated with enhancement or inhibition of O2 consumption in PMN stimulated with 1 microM FMLP in the absence of cytochalasin B.	Cytochalasin B	331-345	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	148-151
1859454-2	1991	Cytochalasin B enhanced fMLP-induced respiratory burst in neutrophils whereas the opposite effect, i.e. an inhibition close to 50%, was elicited in fMLP-stimulated monocytes.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	24-28
1647433-4	1991	PMN adhered to fibrinogen in the presence of rTNF alpha could be further stimulated with cytochalasin B and N-formyl-methionyl-leucyl-phenylalanine (FMLP) to release azurophilic granule markers as measured by increasing MPO activity and A alpha(1-21) production over time.	Cytochalasin B	89-103	fibrinogen beta chain	Homo sapiens	15-25
1647433-4	1991	PMN adhered to fibrinogen in the presence of rTNF alpha could be further stimulated with cytochalasin B and N-formyl-methionyl-leucyl-phenylalanine (FMLP) to release azurophilic granule markers as measured by increasing MPO activity and A alpha(1-21) production over time.	Cytochalasin B	89-103	tumor necrosis factor	Rattus norvegicus	45-55
1675425-3	1991	Cytochalasin B and phloretin, two inhibitors of the mammalian facilitative glucose transporters, can overcome the reduced drug accumulation conferred by expression of the rat GLUT1 protein in Xenopus oocytes but have no significant effect on the accumulation of drug by Xenopus oocytes expressing the mouse Mdr1b P-glycoprotein.	Cytochalasin B	0-14	solute carrier family 2 member 1	Rattus norvegicus	175-180
1675425-3	1991	Cytochalasin B and phloretin, two inhibitors of the mammalian facilitative glucose transporters, can overcome the reduced drug accumulation conferred by expression of the rat GLUT1 protein in Xenopus oocytes but have no significant effect on the accumulation of drug by Xenopus oocytes expressing the mouse Mdr1b P-glycoprotein.	Cytochalasin B	0-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	307-312
1675425-3	1991	Cytochalasin B and phloretin, two inhibitors of the mammalian facilitative glucose transporters, can overcome the reduced drug accumulation conferred by expression of the rat GLUT1 protein in Xenopus oocytes but have no significant effect on the accumulation of drug by Xenopus oocytes expressing the mouse Mdr1b P-glycoprotein.	Cytochalasin B	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	313-327
1659029-8	1991	Phorbol myristate acetate, calcium ionophore, hOZ, FMLP and Con A did stimulate human neutrophils pretreated with cytochalasin B to release elastase.	Cytochalasin B	114-128	formyl peptide receptor 1	Homo sapiens	51-55
1726113-6	1991	Bradykinin stimulated formation of venular FITC-D leakage sites and increases in [FITC-D]S, [FITC-D]S/[FITC-D]p. 10(-6), and FITC-D clearance were not affected by treatment with calmidazolium, cytochalasin B, DDAVP, diphenhydramine, tubulazole C, or verapamil.	Cytochalasin B	193-207	kininogen 1	Homo sapiens	0-10
2054963-1	1991	We studied the effect of aminosugars on the elastase enzyme released from cytochalasin-B treated polymorphonuclear neutrophils (PMN) and stimulated by F-Met-Leu-Phe (FMLP).	Cytochalasin B	74-88	elastase, neutrophil expressed	Homo sapiens	44-52
2054963-1	1991	We studied the effect of aminosugars on the elastase enzyme released from cytochalasin-B treated polymorphonuclear neutrophils (PMN) and stimulated by F-Met-Leu-Phe (FMLP).	Cytochalasin B	74-88	formyl peptide receptor 1	Homo sapiens	166-170
1902435-5	1991	Sodium azide and Cytochalasin B greatly depressed both basal and aluminum-induced stimulation of LECL production, suggesting that, in this system, most of this stimulation was due to myeloperoxidase.	Cytochalasin B	17-31	myeloperoxidase	Homo sapiens	183-198
1663143-7	1991	Cytochalasin B totally inhibited superoxide induced by GM-CSF under conditions that promote the fMet-Leu-Phe-induced response.	Cytochalasin B	0-14	colony stimulating factor 2	Homo sapiens	55-61
1700998-5	1990	Coincubation of PAF with cytochalasin B (5 micrograms/ml) enhanced the release of histamine induced by PAF and activated the release process in most donors (42 of 44).	Cytochalasin B	25-39	PCNA clamp associated factor	Homo sapiens	16-19
1700998-5	1990	Coincubation of PAF with cytochalasin B (5 micrograms/ml) enhanced the release of histamine induced by PAF and activated the release process in most donors (42 of 44).	Cytochalasin B	25-39	PCNA clamp associated factor	Homo sapiens	103-106
2174064-5	1990	EGTA inhibited the cytochalasin B/fMLP-induced increment in [Ca]i and O2- production by 75% and 50%, respectively, and completely ablated the response to cytochalasin B/Con A, suggesting a role for extracellular as well as intracellular calcium in the respiratory burst.	Cytochalasin B	19-33	formyl peptide receptor 1	Homo sapiens	34-38
2174064-5	1990	EGTA inhibited the cytochalasin B/fMLP-induced increment in [Ca]i and O2- production by 75% and 50%, respectively, and completely ablated the response to cytochalasin B/Con A, suggesting a role for extracellular as well as intracellular calcium in the respiratory burst.	Cytochalasin B	154-168	formyl peptide receptor 1	Homo sapiens	34-38
2212672-12	1990	Both forms of IL-8 promoted degranulation of cytochalasin B-treated neutrophils [[ser-IL-8]72 (ED50 greater than 10 nM) was two- to three-fold more potent than [ala-IL-8]77], although in this regard they were less active than FMLP.	Cytochalasin B	45-59	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
2212672-12	1990	Both forms of IL-8 promoted degranulation of cytochalasin B-treated neutrophils [[ser-IL-8]72 (ED50 greater than 10 nM) was two- to three-fold more potent than [ala-IL-8]77], although in this regard they were less active than FMLP.	Cytochalasin B	45-59	formyl peptide receptor 1	Homo sapiens	226-230
1966696-6	1990	Cytochalasin B which blocks formation of actin filaments induced rounding-up of Y-1 cells and inhibited increases of steroid synthesis induced by ACTH.	Cytochalasin B	0-14	pro-opiomelanocortin-alpha	Mus musculus	146-150
1940372-7	1991	Addition of protease inhibitors to the FMLP-stimulated cytochalasin B-treated PMN abrogated the inactivation of TNF cytotoxicity for L cells, whereas scavengers were not protective.	Cytochalasin B	55-69	formyl peptide receptor 1	Homo sapiens	39-43
1940372-7	1991	Addition of protease inhibitors to the FMLP-stimulated cytochalasin B-treated PMN abrogated the inactivation of TNF cytotoxicity for L cells, whereas scavengers were not protective.	Cytochalasin B	55-69	tumor necrosis factor	Homo sapiens	112-115
2029513-6	1991	GLUT1-DTT displays D-glucose-inhibitable cytochalasin B binding and, upon reconstitution into proteoliposomes, catalyzes cytochalasin B inhibitable D-glucose transport.	Cytochalasin B	41-55	solute carrier family 2 member 1	Homo sapiens	0-5
2029513-6	1991	GLUT1-DTT displays D-glucose-inhibitable cytochalasin B binding and, upon reconstitution into proteoliposomes, catalyzes cytochalasin B inhibitable D-glucose transport.	Cytochalasin B	121-135	solute carrier family 2 member 1	Homo sapiens	0-5
1708255-2	1991	Substance P was cleaved by unstimulated neutrophils, but the rate of hydrolysis increased greatly (about 4-fold) when the cells were lysed by freezing and thawing or stimulated to release with fMet-Leu-Phe and cytochalasin B.	Cytochalasin B	210-224	tachykinin precursor 1	Homo sapiens	0-11
1726153-0	1991	Cytochalasin B stimulates insulin-like growth factor-binding protein-1 production by Hep G2 cells.	Cytochalasin B	0-14	insulin like growth factor binding protein 1	Homo sapiens	26-70
1726153-2	1991	Cytochalasin B (100 microM) specifically inhibited 2-deoxyglucose uptake by Hep G2 cells and stimulated IGFBP-1 production 2-fold.	Cytochalasin B	0-14	insulin like growth factor binding protein 1	Homo sapiens	104-111
1905006-6	1991	In agreement with the proposed role of rac1 in exocytosis, these results could explain the inhibitory effect of cytochalasin B on secretory processes.	Cytochalasin B	112-126	Rac family small GTPase 1	Mus musculus	39-43
1652125-6	1991	Both an elevation of ambient osmolality to 600-750 mOsm/kg and disruption of the cytoskeleton by cytochalasin B (0.1 mmol/l) reduce initial FITC-albumin uptake by 50%-60% in a non-additive fashion.	Cytochalasin B	97-111	albumin	Bos taurus	145-152
2015820-6	1991	The disruption of microfilaments by cytochalasin B and subsequent stimulation of PMNL with the formyl-peptide led to the secretion of elastase, myeloperoxidase and lactoferrin, and enhanced the release of gelatinase.	Cytochalasin B	36-50	myeloperoxidase	Homo sapiens	144-159
1706397-9	1991	Interestingly, pretreatment of basophils with drugs that either inhibited or enhanced histamine release (isobutylmethylxanthine and cyclosporin A vs cytochalasin B, respectively) significantly decreased the magnitude of anti-IgE-induced CD11b up-regulation; down-regulation of Leu 8 expression was also partially inhibited by treatment with isobutylmethylaxanthine.	Cytochalasin B	149-163	integrin subunit alpha M	Homo sapiens	237-242
1706397-9	1991	Interestingly, pretreatment of basophils with drugs that either inhibited or enhanced histamine release (isobutylmethylxanthine and cyclosporin A vs cytochalasin B, respectively) significantly decreased the magnitude of anti-IgE-induced CD11b up-regulation; down-regulation of Leu 8 expression was also partially inhibited by treatment with isobutylmethylaxanthine.	Cytochalasin B	149-163	selectin L	Homo sapiens	277-282
1652381-2	1991	These stimuli, as well as aggregated IgG (A-IgG), could also cause the release of beta-glucuronidase (beta-g) and myeloperoxidase (MPO) from PMN, on the other hand, elastase (NE) release was not noticed when PMN was treated with r-C5ai and FMLP, which generally stimulated PMN in a cytochalasin B-dependent manner.	Cytochalasin B	282-296	glucuronidase beta	Homo sapiens	82-100
1652381-2	1991	These stimuli, as well as aggregated IgG (A-IgG), could also cause the release of beta-glucuronidase (beta-g) and myeloperoxidase (MPO) from PMN, on the other hand, elastase (NE) release was not noticed when PMN was treated with r-C5ai and FMLP, which generally stimulated PMN in a cytochalasin B-dependent manner.	Cytochalasin B	282-296	glucuronidase beta	Homo sapiens	82-88
1847714-6	1991	A likely explanation for the potentiating effects of cytochalasin B and tetracaine is provided by our observation that both of these substances reduced the acid-resistant binding of fMet-Leu-Phe (interpreted as a decrease in the internalization of fMet-Leu-Phe-receptor-complexes), resulting in an enhanced formation of second messengers (diacylglycerol).	Cytochalasin B	53-67	formyl peptide receptor 1	Homo sapiens	248-269
2053708-1	1991	The role of actin bundles on the heart looping of chick embryos was examined by using cytochalasin B, which binds to the barbed end of actin filaments and inhibits association of the subunits.	Cytochalasin B	86-100	actin, beta	Gallus gallus	12-17
2053708-1	1991	The role of actin bundles on the heart looping of chick embryos was examined by using cytochalasin B, which binds to the barbed end of actin filaments and inhibits association of the subunits.	Cytochalasin B	86-100	actin, beta	Gallus gallus	135-140
1699986-3	1990	In addition to temperature dependency and inhibition by ethylenediaminetetraacetic acid reported previously, PAF-induced histamine release was enhanced by cytochalasin B and indomethacin and inhibited by dexamethasone.	Cytochalasin B	155-169	PCNA clamp associated factor	Homo sapiens	109-112
2212672-12	1990	Both forms of IL-8 promoted degranulation of cytochalasin B-treated neutrophils [[ser-IL-8]72 (ED50 greater than 10 nM) was two- to three-fold more potent than [ala-IL-8]77], although in this regard they were less active than FMLP.	Cytochalasin B	45-59	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
2212672-12	1990	Both forms of IL-8 promoted degranulation of cytochalasin B-treated neutrophils [[ser-IL-8]72 (ED50 greater than 10 nM) was two- to three-fold more potent than [ala-IL-8]77], although in this regard they were less active than FMLP.	Cytochalasin B	45-59	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
2211679-2	1990	The hypothesis that the GLUT-1 glucose transporter isoform is expressed selectively in brain at the capillary endothelium, i.e. the blood-brain barrier (BBB), was tested by using quantitative Western blotting, cytochalasin B binding, and in situ hybridization in bovine brain cortex.	Cytochalasin B	210-224	solute carrier family 2 member 1	Homo sapiens	24-30
2121685-1	1990	Supernatant obtained from granulocytes stimulated in the presence of cytochalasin B by the chemotactic peptide N-formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl- lysine displayed an inhibitory effect on the plasmin-dependent conversion of tumor urokinase-type plasminogen activator proenzyme (pro-uPA) to the active form of uPA.	Cytochalasin B	69-83	plasminogen activator, urokinase	Homo sapiens	304-307
2121685-1	1990	Supernatant obtained from granulocytes stimulated in the presence of cytochalasin B by the chemotactic peptide N-formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl- lysine displayed an inhibitory effect on the plasmin-dependent conversion of tumor urokinase-type plasminogen activator proenzyme (pro-uPA) to the active form of uPA.	Cytochalasin B	69-83	plasminogen activator, urokinase	Homo sapiens	331-334
1697466-3	1990	GM-CSF-induced O2- release was inhibited by cyclic AMP agonists and cytochalasin B.	Cytochalasin B	68-82	colony stimulating factor 2	Homo sapiens	0-6
2207116-10	1990	The action of ALP is consistent with a mechanism in which ALP interacts with a transmembrane portion of the sugar transport molecule resulting in a competitive displacement of D-glucose or cytochalasin B from the cytosolic facing side of the transport molecule.	Cytochalasin B	189-203	ATHS	Homo sapiens	14-17
2207116-10	1990	The action of ALP is consistent with a mechanism in which ALP interacts with a transmembrane portion of the sugar transport molecule resulting in a competitive displacement of D-glucose or cytochalasin B from the cytosolic facing side of the transport molecule.	Cytochalasin B	189-203	ATHS	Homo sapiens	58-61
2223628-1	1990	Fibrinogen coupled to colloidal gold (Fgn/Au) has been used to follow GPIIb-IIIa receptors on surface-activated platelets and to evaluate the effects of the anti-actin agent, cytochalasin B (CB), on the movement of receptor-ligand complexes.	Cytochalasin B	175-189	fibrinogen beta chain	Homo sapiens	0-10
2209808-8	1990	When recovered after treatment with cytochalasin B, in presence of ADR (or DAU) (5 x 10(-5), 10(-4) mM), cells showed a microfilament pattern rearranged differently as compared to that of cells recovered in anthracycline-free medium.	Cytochalasin B	36-50	aldo-keto reductase family 1 member B	Homo sapiens	67-70
1695907-5	1990	These cells exhibited increased uPA mRNA and protein after disruption of microtubules by colchicine or nocodazole treatment or after disruption of microfilaments by cytochalasin B treatment.	Cytochalasin B	165-179	plasminogen activator, urokinase	Sus scrofa	32-35
1695907-9	1990	Inhibition of protein synthesis by cycloheximide prior to the exposure of LLC-PK1 cells to colchicine, nocodazole, or cytochalasin B, largely prevented the induction of uPA mRNA.	Cytochalasin B	118-132	plasminogen activator, urokinase	Sus scrofa	169-172
2161892-3	1990	Incubation of cells with cytochalasin B was required for MPO secretion, and it enhanced lactoferrin secretion.	Cytochalasin B	25-39	myeloperoxidase	Homo sapiens	57-60
2182761-10	1990	Also, in cytochalasin B-pretreated PMNL, NAP-3 elicited release of myeloperoxidase and beta-glucuronidase.	Cytochalasin B	9-23	C-X-C motif chemokine ligand 1	Homo sapiens	41-46
2159345-7	1990	Binding of fMLP to the cells was decreased by IgG, resembling the effect of cytochalasin B.	Cytochalasin B	76-90	formyl peptide receptor 1	Homo sapiens	11-15
2159710-1	1990	Medium hyposmolarity induced in human polymorphonuclear leukocytes treated with cytochalasin B a rapid exocytosis of the lysosomal enzyme, myeloperoxidase (MPO), which was linearly proportional to the degree of hyposmolarity between a 5 and 30% decrease (r = 0.92, p less than 0.001).	Cytochalasin B	80-94	myeloperoxidase	Homo sapiens	139-154
2159710-1	1990	Medium hyposmolarity induced in human polymorphonuclear leukocytes treated with cytochalasin B a rapid exocytosis of the lysosomal enzyme, myeloperoxidase (MPO), which was linearly proportional to the degree of hyposmolarity between a 5 and 30% decrease (r = 0.92, p less than 0.001).	Cytochalasin B	80-94	myeloperoxidase	Homo sapiens	156-159
2182761-10	1990	Also, in cytochalasin B-pretreated PMNL, NAP-3 elicited release of myeloperoxidase and beta-glucuronidase.	Cytochalasin B	9-23	glucuronidase beta	Homo sapiens	87-105
34336974-4	2021	We report for the first time the inhibitory activity of juglone on the degranulation of neutrophils induced by cytochalasin B and formyl-methionyl-leucyl-phenylalanine as monitored by the MPO release (>90% inhibition for 25 and 50 muM).	Cytochalasin B	111-125	myeloperoxidase	Equus caballus	188-191
2155218-6	1990	In the presence of cytochalasin B, PAF (200 nM) induces degranulation only in differentiated cells and this response also is blocked by PAF receptor antagonists.	Cytochalasin B	19-33	PCNA clamp associated factor	Homo sapiens	35-38
2155218-6	1990	In the presence of cytochalasin B, PAF (200 nM) induces degranulation only in differentiated cells and this response also is blocked by PAF receptor antagonists.	Cytochalasin B	19-33	PCNA clamp associated factor	Homo sapiens	136-139
2155963-8	1990	However, MDNCF/IL-8 was capable of releasing azurophilic enzymes from cytochalasin B-treated PMN into the extracellular space.	Cytochalasin B	70-84	C-X-C motif chemokine ligand 8	Homo sapiens	9-14
2155963-8	1990	However, MDNCF/IL-8 was capable of releasing azurophilic enzymes from cytochalasin B-treated PMN into the extracellular space.	Cytochalasin B	70-84	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
1689652-2	1990	Cytochalasin B (100 microM), but not cytochalasin E, inhibited 2-deoxyglucose uptake by fetal liver explants and increased production of IGFBP-1 2-fold.	Cytochalasin B	0-14	insulin like growth factor binding protein 1	Homo sapiens	137-144
1689652-6	1990	Insulin (300 nM) had no effect on hexose uptake by human fetal liver explants but inhibited IGFBP-1 production, both basally and when stimulated by cytochalasin B (100 microM) or cholera toxin (1 microgram/ml).	Cytochalasin B	148-162	insulin	Homo sapiens	0-7
2155276-7	1990	Cytochalasin B, which enhances degranulation and fMLP-stimulated superoxide production, was found to inhibit beta-glucan particle-stimulated superoxide production.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	49-53
2155277-4	1990	Formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated O2- release by cytochalasin B-treated PMNL was not inhibited significantly by either PMXB or H-7.	Cytochalasin B	71-85	formyl peptide receptor 1	Homo sapiens	39-43
34379448-3	2021	Whereas the destabilization of actin filaments by Latrunculin B, Cytochalasin B or Jasplakinolide decreases BER factor accumulation at laser-induced damage, inhibition of tubulin polymerization by Nocodazole increases it.	Cytochalasin B	65-79	actin	Saccharomyces cerevisiae S288C	31-36
2170521-8	1990	Additionally, 1.5 microM MBP in combination with FMLP or platelet-activating factor stimulated a synergistic increase in O2- release from cytochalasin B-treated neutrophils.	Cytochalasin B	138-152	myelin basic protein	Homo sapiens	25-28
2170521-8	1990	Additionally, 1.5 microM MBP in combination with FMLP or platelet-activating factor stimulated a synergistic increase in O2- release from cytochalasin B-treated neutrophils.	Cytochalasin B	138-152	formyl peptide receptor 1	Homo sapiens	49-53
2407478-6	1990	In rat skeletal muscle, acute treatment with insulin in vivo increases glucose-transport activity and the number of specific cytochalasin B-binding sites at the plasma membrane.	Cytochalasin B	125-139	insulin	Homo sapiens	45-52
2307846-14	1990	We conclude that, in cytochalasin B-treated neutrophils stimulated with C5a, PLD-catalyzed hydrolysis of PC determines the levels of both PA and DG with potentially important ramifications for neutrophil-mediated defense functions.	Cytochalasin B	21-35	complement C5a receptor 1	Homo sapiens	72-75
1966366-2	1990	PMNL during 60 min incubation with DNA (10 micrograms/ml) and with DNA and cytochalasin B (4.8 micrograms/ml) released 14.4 +/- 3.4 and 25.5 +/- 4.8% (n = 7) of the total MPO cell activity, respectively.	Cytochalasin B	75-89	myeloperoxidase	Homo sapiens	171-174
2176783-9	1990	Cytochalasin B having a weak influence on FMLP- and Con A-mediated H2O2 production enhanced strongly their stimulatory effect on MPO release.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	42-46
2176783-9	1990	Cytochalasin B having a weak influence on FMLP- and Con A-mediated H2O2 production enhanced strongly their stimulatory effect on MPO release.	Cytochalasin B	0-14	myeloperoxidase	Homo sapiens	129-132
2329729-4	1990	Hypersecretion of HC1 induced by a parasympathetic stimulant, bethanechol, was inhibited by blood loss or infusion of cytochalasin B, an actin depolymerizing agent.	Cytochalasin B	118-132	Hypercalciuria QTL 1	Rattus norvegicus	18-21
8577661-4	1995	Densitometric analysis of blots showed that GLUT1 accounts for approximately 90 and 65 per cent of the D-glucose-sensitive cytochalasin B binding sites present in brush-border and basal membranes, respectively.	Cytochalasin B	123-137	solute carrier family 2 member 1	Homo sapiens	44-49
35562357-4	2022	Here, we report the cryo-EM structures of human GLUT4 bound to a small molecule inhibitor cytochalasin B (CCB) at resolutions of 3.3 A in both detergent micelles and lipid nanodiscs.	Cytochalasin B	90-104	solute carrier family 2 member 4	Homo sapiens	48-53
35562357-4	2022	Here, we report the cryo-EM structures of human GLUT4 bound to a small molecule inhibitor cytochalasin B (CCB) at resolutions of 3.3 A in both detergent micelles and lipid nanodiscs.	Cytochalasin B	106-109	solute carrier family 2 member 4	Homo sapiens	48-53
35562357-5	2022	CCB-bound GLUT4 exhibits an inward-open conformation.	Cytochalasin B	0-3	solute carrier family 2 member 4	Homo sapiens	10-15
35455997-4	2022	CTGF and CYR61 gene expression were down-regulated in all PDAC 3D compared to 2D cultures, without any significant effect following actin cytoskeleton inhibition by Cytochalasin B (CyB) treatment.	Cytochalasin B	165-179	cellular communication network factor 2	Homo sapiens	0-4
35477545-5	2022	Interestingly, cytochalasin B, an inhibitor of action polymerization, blocked LPC-induced CD63 surface expression.	Cytochalasin B	15-29	CD63 molecule	Homo sapiens	90-94
35455997-4	2022	CTGF and CYR61 gene expression were down-regulated in all PDAC 3D compared to 2D cultures, without any significant effect following actin cytoskeleton inhibition by Cytochalasin B (CyB) treatment.	Cytochalasin B	181-184	cellular communication network factor 2	Homo sapiens	0-4
35455997-4	2022	CTGF and CYR61 gene expression were down-regulated in all PDAC 3D compared to 2D cultures, without any significant effect following actin cytoskeleton inhibition by Cytochalasin B (CyB) treatment.	Cytochalasin B	181-184	cellular communication network factor 1	Homo sapiens	9-14
2681270-4	1989	Stimulation of cytochalasin B-treated neutrophils with FMLP induced release of C-ANCA antigen.	Cytochalasin B	15-29	formyl peptide receptor 1	Homo sapiens	55-59
35145427-14	2021	Cytochalasin B and Nocodazole, inhibitors of actin and tubulin filament formation respectively, strongly inhibited the recovery of green fluorescence at the plasma membrane suggestive for inhibition of KIR2.1 forward trafficking (taug,s 13 +- 2 vs. 131 +- 31* and 160 +- 40* min, for control, Cytochalasin B and Nocodazole, respectively (*p < 0.05 vs. control)).	Cytochalasin B	0-14	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	202-208
35145427-14	2021	Cytochalasin B and Nocodazole, inhibitors of actin and tubulin filament formation respectively, strongly inhibited the recovery of green fluorescence at the plasma membrane suggestive for inhibition of KIR2.1 forward trafficking (taug,s 13 +- 2 vs. 131 +- 31* and 160 +- 40* min, for control, Cytochalasin B and Nocodazole, respectively (*p < 0.05 vs. control)).	Cytochalasin B	293-307	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	202-208
35145427-16	2021	Cytochalasin B treatment (20 muM, 24 h) inhibited I KIR2.1.	Cytochalasin B	0-14	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	52-58
2681270-4	1989	Stimulation of cytochalasin B-treated neutrophils with FMLP induced release of C-ANCA antigen.	Cytochalasin B	15-29	proteinase 3	Homo sapiens	79-93
2479763-9	1989	In contrast, cytochalasin B disrupts F-actin, microtubules, and CNPase in the lacy networks, indicating that cross-linking between these three proteins is disrupted.	Cytochalasin B	13-27	2',3'-cyclic nucleotide 3' phosphodiesterase	Mus musculus	64-70
2479763-10	1989	Both colchicine and cytochalasin B cause fusion of myelin basic protein (MBP) domains in membrane sheets.	Cytochalasin B	20-34	myelin basic protein	Mus musculus	51-71
2479763-10	1989	Both colchicine and cytochalasin B cause fusion of myelin basic protein (MBP) domains in membrane sheets.	Cytochalasin B	20-34	myelin basic protein	Mus musculus	73-76
2675839-3	1989	Furthermore, native LUCT enhanced the release of myeloperoxidase and beta-glucuronidase from PMN in the presence of cytochalasin B and FMLP, but LU10 did not.	Cytochalasin B	116-130	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
2675839-3	1989	Furthermore, native LUCT enhanced the release of myeloperoxidase and beta-glucuronidase from PMN in the presence of cytochalasin B and FMLP, but LU10 did not.	Cytochalasin B	116-130	myeloperoxidase	Homo sapiens	49-64
2675839-3	1989	Furthermore, native LUCT enhanced the release of myeloperoxidase and beta-glucuronidase from PMN in the presence of cytochalasin B and FMLP, but LU10 did not.	Cytochalasin B	116-130	glucuronidase beta	Homo sapiens	69-87
2529137-1	1989	Proteolytic enzymes released from granulocytes upon stimulation with the chemotactic N-formyl peptide FNLPNTL (in the presence of cytochalasin B) prevented activation of tumor cell single-chain urokinase-type plasminogen activator (pro-uPA) by plasmin.	Cytochalasin B	130-144	plasminogen activator, urokinase	Homo sapiens	194-230
2529137-1	1989	Proteolytic enzymes released from granulocytes upon stimulation with the chemotactic N-formyl peptide FNLPNTL (in the presence of cytochalasin B) prevented activation of tumor cell single-chain urokinase-type plasminogen activator (pro-uPA) by plasmin.	Cytochalasin B	130-144	plasminogen activator, urokinase	Homo sapiens	236-239
2529137-1	1989	Proteolytic enzymes released from granulocytes upon stimulation with the chemotactic N-formyl peptide FNLPNTL (in the presence of cytochalasin B) prevented activation of tumor cell single-chain urokinase-type plasminogen activator (pro-uPA) by plasmin.	Cytochalasin B	130-144	plasminogen	Homo sapiens	209-216
2899077-6	1988	When 125I-fibronectin was incubated with isolated matrices or with cell layers pretreated with cytochalasin B, it did not bind and could not be cross-linked by Factor XIIIa into the matrix.	Cytochalasin B	95-109	fibronectin 1	Homo sapiens	10-21
2753896-10	1989	However, in neutrophils "primed" with cytochalasin B or phorbol ester, formyl-methionyl-leucyl-phenylalanine caused a significant increase in EAG.	Cytochalasin B	38-52	potassium voltage-gated channel subfamily H member 1	Homo sapiens	142-145
2753896-11	1989	Neutrophils pretreated with cytochalasin B and then stimulated by fMLP showed a rapid (15-60 s) increase (more than 3-fold) in total diglycerides which was sustained beyond 5 min.	Cytochalasin B	28-42	formyl peptide receptor 1	Homo sapiens	66-70
2670752-4	1989	TNF alpha-induced lactoferrin release was enhanced by cytochalasin B pretreatment of the granulocytes, while GCP/IL-8-promoted degranulation was not.	Cytochalasin B	54-68	tumor necrosis factor	Homo sapiens	0-9
2539979-7	1989	Addition of either colchicine or cytochalasin-B during PTH treatment completely abolished the PTH-induced reduction of EGF binding.	Cytochalasin B	33-47	parathyroid hormone	Mus musculus	55-58
2539979-7	1989	Addition of either colchicine or cytochalasin-B during PTH treatment completely abolished the PTH-induced reduction of EGF binding.	Cytochalasin B	33-47	parathyroid hormone	Mus musculus	94-97
2539979-7	1989	Addition of either colchicine or cytochalasin-B during PTH treatment completely abolished the PTH-induced reduction of EGF binding.	Cytochalasin B	33-47	epidermal growth factor	Mus musculus	119-122
2538461-8	1989	Synthesis of PAF in response to C-PAF was not dependent on cytochalasin B pretreatment but was dramatically potentiated by 5-hydroxyeicosatetraenoic acid, which alone was without effect.	Cytochalasin B	59-73	PCNA clamp associated factor	Homo sapiens	13-16
2927434-1	1989	Following activation with the synthetic chemotactic tripeptide FMLP, potentiated by cytochalasin B (CB), blood neutrophils from cigarette smokers generated greater amounts of both extracellular and intracellular reactive oxidants than cells from non-smoking control subjects.	Cytochalasin B	84-98	formyl peptide receptor 1	Homo sapiens	63-67
2736331-8	1989	Corneas cultured in the presence of cytochalasin B also showed FN deposition at the cell-DM interface.	Cytochalasin B	36-50	fibronectin 1	Rattus norvegicus	63-65
2807624-6	1989	In contrast, 5-10 microM cytochalasin B (CB) inhibited ER formation, agglutination, Tac expression and DNA synthesis, but augmented IL-2 production by three- to ten-fold.	Cytochalasin B	25-39	interleukin 2	Homo sapiens	132-136
2495932-7	1989	Furthermore, in cells cultured for 48 h in the presence of cytochalasin-B followed by incubation for 24 h in the absence of the drug, the synthesis of hsp90 and several other proteins characteristic of mature granulosa cells decreased, while that of the actin cytoskeleton increased.	Cytochalasin B	59-73	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	151-156
2522778-2	1989	NAP-2 induced the release of elastase from cytochalasin B-treated human neutrophils.	Cytochalasin B	43-57	pro-platelet basic protein	Homo sapiens	0-5
2612362-10	1989	DRG neurones cultured in cytochalasin B display differences in immunofluorescence staining which further emphasize that these adhesion molecules interact differentially with the actin filament system of migrating growth cones.	Cytochalasin B	25-39	actin, beta	Gallus gallus	178-183
3266692-1	1988	Endocytosis of the epidermal growth factor (EGF) was investigated in three cell lines--A431, 3T6 and Swiss 3T3--after their incubation with cytochalasin B (CB).	Cytochalasin B	140-154	epidermal growth factor	Mus musculus	19-42
3266692-1	1988	Endocytosis of the epidermal growth factor (EGF) was investigated in three cell lines--A431, 3T6 and Swiss 3T3--after their incubation with cytochalasin B (CB).	Cytochalasin B	140-154	epidermal growth factor	Mus musculus	44-47
2459200-2	1988	The neuropeptide substance P (SP), which has been suggested to mediate neurogenic inflammation, induces in human neutrophils the activation of the respiratory burst measured as O2 consumption and H2O2 production, and a cytochalasin B-dependent secretion of specific and azurophilic granules.	Cytochalasin B	219-233	tachykinin precursor 1	Homo sapiens	17-28
2459200-2	1988	The neuropeptide substance P (SP), which has been suggested to mediate neurogenic inflammation, induces in human neutrophils the activation of the respiratory burst measured as O2 consumption and H2O2 production, and a cytochalasin B-dependent secretion of specific and azurophilic granules.	Cytochalasin B	219-233	tachykinin precursor 1	Homo sapiens	30-32
2459200-7	1988	Cytochalasin B significantly depresses the activation of the respiration by SP, whereas it moderately enhances the activation of phosphoinositide turnover and potentiates the increase of intracellular Ca2+ concentration.	Cytochalasin B	0-14	tachykinin precursor 1	Homo sapiens	76-78
2459200-7	1988	Cytochalasin B significantly depresses the activation of the respiration by SP, whereas it moderately enhances the activation of phosphoinositide turnover and potentiates the increase of intracellular Ca2+ concentration.	Cytochalasin B	0-14	carbonic anhydrase 2	Homo sapiens	201-204
3165095-10	1988	A sensitizing effect was noted with amiloride or cytochalasin B, characterized by greater relative increases of [3H]TdR incorporation and TdR kinase activity in response to TNF.	Cytochalasin B	49-63	tumor necrosis factor	Homo sapiens	173-176
2839589-4	1988	In contrast, in formyl-methionyl-leucine-phenylalanine (FMLP)-activated cells the increase in superoxide production was only accompanied by an increase in particulate fraction-associated protein kinase C activity if the cells were pretreated with cytochalasin B.	Cytochalasin B	247-261	formyl peptide receptor 1	Homo sapiens	56-60
2839589-7	1988	This contrasts to FMLP-activated neutrophils, in which a membrane-bound form is only observed after pretreatment with cytochalasin B.	Cytochalasin B	118-132	formyl peptide receptor 1	Homo sapiens	18-22
3421921-4	1988	The C5a-induced increase in F-actin content can be prevented by prior exposure of the cells to cytochalasin B and pertussis toxin.	Cytochalasin B	95-109	complement C5a receptor 1	Homo sapiens	4-7
3260682-5	1988	This re-expression did not occur if the cells were cultured at 4 degrees C, or after treatment with actinomycin D or cytochalasin B, indicating that protein synthesis and intact microfilament function were essential for re-expression of CD4 binding.	Cytochalasin B	117-131	CD4 molecule	Homo sapiens	237-240
3413723-1	1988	The sulfhydryl group oxidizing agent azodicarboxylic acid-bis-dimethylamide (diamide) which causes disulfide-linked polymer formation of certain cytoskeletal proteins, the actin-polymerization inhibitor, cytochalasin B, and 2-mercaptopropionylglycine (2-MPG), a cell-permeable SH-reagent, completely abolish adhesion-induced platelet spreading and mural platelet aggregate formation on collagen-coated surfaces.	Cytochalasin B	204-218	N-methylpurine DNA glycosylase	Homo sapiens	254-257
3283239-5	1988	LYNAP stimulated neutrophil chemotaxis (ED50 of 3 +/- 3 ng/ml), chemokinesis (ED50 of 2 +/- 2 ng/ml), and caused degranulation of cytochalasin B pretreated human neutrophils (ED50 of 20 ng/ml).	Cytochalasin B	130-144	C-X-C motif chemokine ligand 8	Homo sapiens	0-5
3165095-11	1988	In the presence of cytochalasin B, TNF treatment resulted in no change or slight decreases in the percentage of S-phase cells.	Cytochalasin B	19-33	tumor necrosis factor	Homo sapiens	35-38
3277616-9	1988	The activation energy over the higher temperature range was significantly lower in membranes from basal than from insulin-stimulated cells [27.7 +/- 5.0 kJ/mol (6.6 +/- 1.2 kcal/mol) and 45.3 +/- 2.1 kJ/mol (10.8 +/- 0.5 kcal/mol) respectively], giving rise to a larger relative response to insulin when transport was assayed at 37 degrees C as compared with 22 degrees C. The stimulation of transport activity at 22 degrees C was fully accounted for by an increase in the concentration of transporters measured by cytochalasin B binding, if a 5% contamination of plasma membranes with low-density microsomes was assumed.	Cytochalasin B	515-529	insulin	Homo sapiens	114-121
2835037-6	1988	In the presence of cytochalasin B, retinal inhibited the effect of FMLP in HN, whereas retinoic acid inhibited NO activation by FMLP in both cell types.	Cytochalasin B	19-33	formyl peptide receptor 1	Homo sapiens	67-71
3383248-3	1988	Cytochalasin B caused the PMN in low concentrations of FMLP or in plasma to become spherical, but no degranulation of the cells occurred.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	55-59
3120787-6	1988	However, high concentrations of cytochalasin B inhibited the uptake of either phalloidin, cholate or bovine lactoperoxidase.	Cytochalasin B	32-46	lactoperoxidase	Bos taurus	108-123
3286522-8	1988	Pretreatment of cells with cytochalasin B enhanced their response to fMLP, and this response was further increased if the cells had also been pretreated with the cytokines.	Cytochalasin B	27-41	formyl peptide receptor 1	Homo sapiens	69-73
2825844-7	1988	The increase in particulate protein kinase activity induced by PAF required the presence of cytochalasin B, was detectable within 5 seconds of exposure to PAF, and was not reversed by washing the cells free of extracellular PAF after initial exposure.	Cytochalasin B	92-106	PCNA clamp associated factor	Homo sapiens	63-66
2850161-4	1988	In the presence of cytochalasin B, the inhibitory effect of eglin-c on O-2 release following stimulation with FMLP became more pronounced.	Cytochalasin B	19-33	immunoglobulin kappa variable 1D-39	Homo sapiens	71-74
3053359-0	1988	Role of actin polymerization in monocyte phagocytosis of yeast cells effect of cytochalasin B.	Cytochalasin B	79-93	actin	Saccharomyces cerevisiae S288C	8-13
3257187-5	1988	hCG-occupied LH receptors on untreated cells exhibited a mobile fraction of 10.3%, and these mobile complexes had a diffusion coefficient of 3.3 X 10(-11) cm2 sec-1.hCG-occupied LH receptors on cytochalasin B-treated cells had a diffusion coefficient of 9.0 X 10(-11) cm2 sec-1, with 26% fluorescence recovery.	Cytochalasin B	194-208	secretory blood group 1, pseudogene	Homo sapiens	159-164
3257187-5	1988	hCG-occupied LH receptors on untreated cells exhibited a mobile fraction of 10.3%, and these mobile complexes had a diffusion coefficient of 3.3 X 10(-11) cm2 sec-1.hCG-occupied LH receptors on cytochalasin B-treated cells had a diffusion coefficient of 9.0 X 10(-11) cm2 sec-1, with 26% fluorescence recovery.	Cytochalasin B	194-208	secretory blood group 1, pseudogene	Homo sapiens	272-277
3286522-11	1988	The rHuIL-1 alpha increased the release of lysozyme, beta-glucuronidase and myeloperoxidase initiated by cytochalasin B/fMLP, while rHuTNF alpha only increased lysozyme release.	Cytochalasin B	105-119	myeloperoxidase	Homo sapiens	76-91
2450844-1	1988	Platelet-activating factor (PAF) was found to induce histamine release from human basophils in mixed leukocytes in the presence of cytochalasin B.	Cytochalasin B	131-145	PCNA clamp associated factor	Homo sapiens	0-26
2825795-4	1987	In addition, baicalein dose-dependently inhibited beta-glucuronidase and lysozyme releases induced by A23187, leukotriene B4 plus cytochalasin B and platelet-activating factor plus cytochalasin B.	Cytochalasin B	130-144	glucuronidase beta	Homo sapiens	50-68
2450844-1	1988	Platelet-activating factor (PAF) was found to induce histamine release from human basophils in mixed leukocytes in the presence of cytochalasin B.	Cytochalasin B	131-145	PCNA clamp associated factor	Homo sapiens	28-31
2825795-4	1987	In addition, baicalein dose-dependently inhibited beta-glucuronidase and lysozyme releases induced by A23187, leukotriene B4 plus cytochalasin B and platelet-activating factor plus cytochalasin B.	Cytochalasin B	181-195	glucuronidase beta	Homo sapiens	50-68
3570357-7	1987	Examination of lysosomal enzyme release showed that sCM enhanced the release of lysozyme and beta-glucuronidase induced by either FMLP/cytochalasin B or zymosan.	Cytochalasin B	135-149	lysozyme	Homo sapiens	80-88
2824608-4	1987	Purified MONAP stimulate human neutrophil chemotaxis at an estimated molarity of 5 x 10(-11) M. Half-maximal enzyme release of cytochalasin B pretreated neutrophils occurred at 2 to 3 x 10(-10) M, whereas superoxide anion production elicited by various concentrations of MONAP was found to be low.	Cytochalasin B	127-141	C-X-C motif chemokine ligand 8	Homo sapiens	9-14
2824608-4	1987	Purified MONAP stimulate human neutrophil chemotaxis at an estimated molarity of 5 x 10(-11) M. Half-maximal enzyme release of cytochalasin B pretreated neutrophils occurred at 2 to 3 x 10(-10) M, whereas superoxide anion production elicited by various concentrations of MONAP was found to be low.	Cytochalasin B	127-141	C-X-C motif chemokine ligand 8	Homo sapiens	271-276
3297147-8	1987	Based on reported values of cytochalasin B binding sites the turnover rate per site in RBC appears to be as high as in maximally insulin-stimulated fat cells.	Cytochalasin B	28-42	insulin	Homo sapiens	129-136
2953024-4	1987	The ligand-induced accumulation of Triton-insoluble complexes in IFN-sensitive cells was inhibited by cytochalasin B.	Cytochalasin B	102-116	interferon alpha 1	Homo sapiens	65-68
2830072-6	1987	Cytochalasin B-treated beige PMN showed a decreased ability to degranulate myeloperoxidase in response to OZ or PMA.	Cytochalasin B	0-14	myeloperoxidase	Mus musculus	75-90
2820878-8	1987	Cytochalasin B pretreatment greatly enhanced FMLP-induced O2- release, degranulation, aggregation, and depolarization of membrane potential in neutrophils and karyogranuloplasts, but not in cytoplasts.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	45-49
2820878-9	1987	The ability of cytochalasin B to potentiate FMLP-triggered cell function probably depends on granules or cell organelles which are depleted in cytoplasts.	Cytochalasin B	15-29	formyl peptide receptor 1	Homo sapiens	44-48
3113748-0	1987	Cytochalasin B enhances T cell mitogenesis by promoting expression of an interleukin 2 receptor.	Cytochalasin B	0-14	interleukin 2	Homo sapiens	73-86
3113748-1	1987	Low concentrations of cytochalasin B enhanced the T cell mitogenesis induced by concanavalin A (Con A) and interleukin 2 (IL-2).	Cytochalasin B	22-36	interleukin 2	Homo sapiens	107-120
3113748-1	1987	Low concentrations of cytochalasin B enhanced the T cell mitogenesis induced by concanavalin A (Con A) and interleukin 2 (IL-2).	Cytochalasin B	22-36	interleukin 2	Homo sapiens	122-126
3113748-4	1987	Use of the monoclonal antibody that directs the IL-2 receptor showed that cytochalasin B increased the expression of the IL-2 receptor induced by Con A.	Cytochalasin B	74-88	interleukin 2 receptor subunit beta	Homo sapiens	48-61
3113748-4	1987	Use of the monoclonal antibody that directs the IL-2 receptor showed that cytochalasin B increased the expression of the IL-2 receptor induced by Con A.	Cytochalasin B	74-88	interleukin 2 receptor subunit beta	Homo sapiens	121-134
3113748-5	1987	We concluded that cytochalasin b acts on an early phase of T cell mitogenesis and augments the expression of IL-2 receptor which enables certain nonresponsive T cells to respond to IL-2.	Cytochalasin B	18-32	interleukin 2 receptor subunit beta	Homo sapiens	109-122
3113748-5	1987	We concluded that cytochalasin b acts on an early phase of T cell mitogenesis and augments the expression of IL-2 receptor which enables certain nonresponsive T cells to respond to IL-2.	Cytochalasin B	18-32	interleukin 2	Homo sapiens	109-113
3106349-9	1987	Treatment of membranes labeled with either cytochalasin B or forskolin with endo-beta-galactosidase resulted in identical shifts of the 43 to 75-kDa peaks to 42 kDa.	Cytochalasin B	43-57	galactosidase beta 1	Homo sapiens	81-99
3029224-9	1987	However, unlike these direct PKC activators, PAF and LTB4 induced only moderate decreases in cytosolic PKC; acted only on PMN pretreated with cytochalasin B; did not mobilize PKC in disrupted PMN or activate PKC in a cell-free system; and with respect to PAF, induced responses that partially reversed within 30 min.	Cytochalasin B	142-156	PCNA clamp associated factor	Homo sapiens	45-48
3029224-12	1987	Four observations indicated that the cytochalasin B-dependent degranulating actions of PAF and LTB4 involved PKC.	Cytochalasin B	37-51	PCNA clamp associated factor	Homo sapiens	87-90
3102556-3	1987	Using the cytochalasin B binding assay to measure glucose transporters in subcellular membrane subfractions, we found that insulin induced translocation of intracellular glucose transporters to the cell surface.	Cytochalasin B	10-24	insulin	Homo sapiens	123-130
3570357-7	1987	Examination of lysosomal enzyme release showed that sCM enhanced the release of lysozyme and beta-glucuronidase induced by either FMLP/cytochalasin B or zymosan.	Cytochalasin B	135-149	glucuronidase beta	Homo sapiens	93-111
3546049-1	1986	Insulin"s effect on glucose transport activity and the subcellular distribution of glucose transporters have been examined in isolated human abdominal adipose cells, by measuring 3-O-methylglucose transport and specific D-glucose-inhibitable cytochalasin B binding to plasma membranes and low-density microsomes, respectively.	Cytochalasin B	242-256	insulin	Homo sapiens	0-7
3430856-14	1987	Further culture in cytochalasin B-free medium after exposure to this agent permitted a recovery of cell migration and formation of the fiber-like actin fluorescence.	Cytochalasin B	19-33	actin	Oryctolagus cuniculus	146-151
3430856-15	1987	It was suggested that polymerization of actin filaments is activated in the migrating cells during wound-healing, and that cytochalasin B reversibly blocks this polymerization, thereby suppressing cell migration.	Cytochalasin B	123-137	actin	Oryctolagus cuniculus	40-45
3782096-6	1986	Cytochalasin B enhances several fMLP-stimulated neutrophil responses, including aggregation, superoxide production, and degranulation.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	32-36
3782096-7	1986	Pretreatment of neutrophils with cytochalasin B markedly increased the rate and extent of the diacylglycerol response to fMLP stimulation.	Cytochalasin B	33-47	formyl peptide receptor 1	Homo sapiens	121-125
3026327-1	1986	The role of myeloperoxidase in the regulation of the respiratory burst of human neutrophils activated by the chemotactic peptide (N-formyl-L-methionyl-L-leucyl-L-phenylalanine) plus cytochalasin B was determined by using anti-(human myeloperoxidase) antibody.	Cytochalasin B	182-196	myeloperoxidase	Homo sapiens	12-27
3021817-3	1986	In addition, rH GM-CSF enhanced N-formylmethionylleucylphenylalanine(FMLP)-stimulated degranulation of Cytochalasin B pretreated neutrophils and FMLP-stimulated superoxide production.	Cytochalasin B	103-117	colony stimulating factor 2	Homo sapiens	16-22
3021817-3	1986	In addition, rH GM-CSF enhanced N-formylmethionylleucylphenylalanine(FMLP)-stimulated degranulation of Cytochalasin B pretreated neutrophils and FMLP-stimulated superoxide production.	Cytochalasin B	103-117	formyl peptide receptor 1	Homo sapiens	69-73
3018003-1	1986	The subcellular distribution of the Ah receptor from the mouse hepatoma line, Hepa-1, was investigated following cytochalasin B treatment and cell enucleation.	Cytochalasin B	113-127	aryl-hydrocarbon receptor	Mus musculus	36-47
3018003-4	1986	We therefore undertook an investigation to determine the fate of the Ah receptor in the presence of cytochalasin B.	Cytochalasin B	100-114	aryl-hydrocarbon receptor	Mus musculus	69-80
3089579-6	1986	The number of high affinity cytochalasin B binding sites was 175,000 receptors/cell (about 0.6 pmol/mg protein) and Kd = 1 X 10(-7) M. Insulin increased glucose utilization and lactate production by about 70% and caused a 56% increase in transport without alterations in the Kd of the site.	Cytochalasin B	28-42	insulin	Homo sapiens	135-142
3488736-4	1986	Both the inhibition by cytochalasin B and also the relative degree of competition by high concentrations of a series of glucose analogues suggest that the basal and CSF-1 stimulated 2-deoxyglucose uptake occur via a carrier facilitated D-glucose transport system.	Cytochalasin B	23-37	colony stimulating factor 1 (macrophage)	Mus musculus	165-170
3017475-8	1986	The percentage of depolarizing PMNs in response to FMLP was significantly correlated with the percentage of NBT-positive cells from both purified PMNs and from whole blood (r = .849, P less than .0005, r = .857, P less than .05, respectively), and with the amount of superoxide produced, expressed as a percentage of that amount produced by cytochalasin B (cyto-B)-pretreated cells (r = .565, P less than .01).	Cytochalasin B	341-355	formyl peptide receptor 1	Homo sapiens	51-55
3016031-3	1986	Purified myeloperoxidase, and neutrophils stimulated with fMet-Leu-Phe and cytochalasin B, strongly inhibited this hydroxyl radical production in a concentration-dependent manner.	Cytochalasin B	75-89	myeloperoxidase	Homo sapiens	9-24
2938015-6	1986	Conversely, disruption of the actin cytoskeleton by treatment with cytochalasin B leads to release of fibronectin from the cell surface.	Cytochalasin B	67-81	fibronectin 1	Homo sapiens	102-113
3100542-1	1986	Rabbit neutrophils, exposed either to partially purified human C5a or to formylmethionyl-leucyl-phenylalanine in the presence of 5 micrograms ml-1 cytochalasin B underwent a rapid, compound exocytosis.	Cytochalasin B	147-161	complement C5a receptor 1	Homo sapiens	63-66
3491698-3	1986	The presence of cytochalasin B enhanced LPS-induced IL-1 secretion without altering IL-1 synthesis.	Cytochalasin B	16-30	interleukin 1 alpha	Homo sapiens	52-56
3006834-4	1986	The addition of 12-hydroperoxyeicosatetraenoic acid (12-HPETE), a labile AA metabolite via the platelet lipoxygenase pathway, could activate the 5-lipoxygenase pathway in neutrophils incubated with FMLP, cytochalasin B and AA, but its stable end product, 12-hydroxyeicosatetraenoic acid, could not.	Cytochalasin B	204-218	arachidonate 5-lipoxygenase	Homo sapiens	145-159
3510887-1	1986	Inhibition by cytochalasin B and D. We have demonstrated previously a rapid increase in ATP turnover soon after adding epidermal growth factor (EGF) and insulin to quiescent cultures of Swiss 3T3 cells.	Cytochalasin B	14-28	epidermal growth factor	Mus musculus	119-142
3011441-1	1986	The secretory response of cytochalasin B-treated human polymorphonuclear neutrophils to the peptide chemoattractant f-Met-Leu-Phe (FMLP), the calcium ionophore A23187 and other secretagogues was measured by assaying neutrophil supernatants for the granular enzymes beta-glucuronidase and lysozyme.	Cytochalasin B	26-40	formyl peptide receptor 1	Homo sapiens	131-135
3005456-1	1986	Platelet factor (PF4) prepared from human outdated platelets by heparinagarose affinity chromatography was confirmed to be chemotactic for human neutrophils and in a concentration-dependent fashion caused significant release of lysosomal enzymes (myeloperoxidase, lysozyme, beta-glucuronidase) from human neutrophils treated with cytochalasin B.	Cytochalasin B	330-344	platelet factor 4	Homo sapiens	17-20
3485080-5	1986	The involvement of cytoskeleton components in the EGF effects on intercellular adhesion was shown by its susceptibility to cytochalasin B, known to disorganize actin-containing microfilaments.	Cytochalasin B	123-137	epidermal growth factor	Homo sapiens	50-53
3510887-1	1986	Inhibition by cytochalasin B and D. We have demonstrated previously a rapid increase in ATP turnover soon after adding epidermal growth factor (EGF) and insulin to quiescent cultures of Swiss 3T3 cells.	Cytochalasin B	14-28	epidermal growth factor	Mus musculus	144-147
3510123-8	1986	The T3-stimulated sugar uptake was completely blocked by 5 X 10(-6) M cytochalasin B, suggesting that T3 acts, like insulin, by the translocation of glucose transporters to the plasma membrane.	Cytochalasin B	70-84	insulin	Gallus gallus	116-123
3942740-2	1986	In isolated parietal cells pretreatment with colchicine or cytochalasin B abolished the amino [14C]pyrine accumulation and the rise in cytosolic Ca2+ concentration evoked by gastrin.	Cytochalasin B	59-73	gastrin	Homo sapiens	174-181
3012935-6	1986	Cytochalasin B enhanced the response both to LTB4 and fMLP, and LTB4 responses became biphasic with an early peak preceding the major response.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	54-58
3944767-10	1986	Another agent that provokes edema, cytochalasin B, also increased lung wet-to-dry weight ratios and blunted Ang II-, hypoxia-, and KCI-induced pressor responses.	Cytochalasin B	35-49	angiotensinogen	Rattus norvegicus	108-114
3001181-4	1986	The requirement for cytochalasin B in order for FMLP, but not the calcium ionophore, to stimulate leukotriene generation is compatible with the ability of cytochalasin B to augment in other cells certain stimulus-specific transmembrane responses that are not dependent on the integrity of the cytoskeleton.	Cytochalasin B	20-34	formyl peptide receptor 1	Homo sapiens	48-52
2420732-2	1986	Myeloperoxidase (MPO) and lysozyme secretion was markedly attenuated if neutrophils were not exposed to cytochalasin B (CB) prior to contact with IL-1.	Cytochalasin B	104-118	myeloperoxidase	Homo sapiens	0-15
3001181-7	1986	The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion.	Cytochalasin B	85-99	formyl peptide receptor 1	Homo sapiens	103-107
3001181-5	1986	Resolution by reverse phase high performance liquid chromatography of the products released from monocytes pretreated with cytochalasin B and stimulated with FMLP or calcium ionophore yielded a single peak of immunoreactive LTB4 eluting at the same retention time as the synthetic standard; immunoreactive C-6 sulfidopeptide leukotrienes eluted at the retention times of leukotriene C4 (LTC4) and leukotriene D4 (LTD4).	Cytochalasin B	123-137	formyl peptide receptor 1	Homo sapiens	158-162
3001181-7	1986	The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion.	Cytochalasin B	85-99	formyl peptide receptor 1	Homo sapiens	253-266
3001181-7	1986	The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion.	Cytochalasin B	85-99	formyl peptide receptor 1	Homo sapiens	253-257
3000940-9	1985	Since PARG acted both as a cytolytic agent and as a inducer of O2- generation, we postulate that lytic agents might also act as "primers" of the nascent membrane oxidase which could, however, be further potentiated and activated by soluble agents acting in "multiple hits," PARG could be totally replaced either by LL or by digitonin in the generation of O2- provided that both PHA and cytochalasin B were present in the reaction mixtures.	Cytochalasin B	386-400	poly(ADP-ribose) glycohydrolase	Homo sapiens	6-10
2879379-2	1986	ACTH increases the basal steroidogenic activity of cultured adrenocortical tumor cells, whereas moderate-high doses of cytochalasin B (CB) inhibit both basal and ACTH-induced steroidogenesis.	Cytochalasin B	119-133	proopiomelanocortin	Homo sapiens	162-166
4076535-5	1985	In addition, cytochalasin B (5 X 10(-5) M) totally inhibited the stimulatory effect of angiotensin II, prostaglandin E1 and VIP.	Cytochalasin B	13-27	vasoactive intestinal peptide	Canis lupus familiaris	117-127
3877483-9	1985	Kallikrein-like activity in the BAL from the patients with ARDS was significantly correlated with the number of neutrophils in the BAL, the neutrophil elastase concentration, and the ability of the BAL to release elastase from cytochalasin-B-treated neutrophils.	Cytochalasin B	227-241	kallikrein related peptidase 4	Homo sapiens	0-10
4063390-3	1985	Colchicine, vincristine and cytochalasin B all caused dose- and time-dependent inhibition of iron absorption, and the effects of cytochalasin B were reversible within 1 h. It is not known which cellular component is the vehicle for the transcellular movement of iron from the intestinal lumen onto plasma transferrin; however, this study showed that the uptake of iron by ferritin in an iron-absorbing loop of intestine paralleled the actual absorption of iron into the carcass.	Cytochalasin B	28-42	transferrin	Rattus norvegicus	305-316
4084546-4	1985	The rate of depolymerization of F-actin by destrin is much faster than that of spontaneous depolymerization induced by dilution and is not markedly decreased by the addition of end-blocking reagents such as cytochalasin B.	Cytochalasin B	207-221	destrin, actin depolymerizing factor	Homo sapiens	43-50
3931463-4	1985	With the use of cytochalasin B, a potent competitive inhibitor of glucose transport, glucose-sensitive cytochalasin B binding was studied in basal and insulin-stimulated adipocytes from control and sulfonylurea-treated tissue.	Cytochalasin B	103-117	insulin	Homo sapiens	151-158
2995525-7	1985	Oxidation of NAD(P)H also occurred when cytochalasin B-treated PMN were stimulated with 25 nM C5a or 100 nM formyl-methionyl-leucyl-phenylalanine (f-MLP), but occurred more rapidly, peaking at 1 to 3 min.	Cytochalasin B	40-54	complement C5a receptor 1	Homo sapiens	94-97
2995525-7	1985	Oxidation of NAD(P)H also occurred when cytochalasin B-treated PMN were stimulated with 25 nM C5a or 100 nM formyl-methionyl-leucyl-phenylalanine (f-MLP), but occurred more rapidly, peaking at 1 to 3 min.	Cytochalasin B	40-54	cysteine and glycine rich protein 3	Homo sapiens	149-152
2995525-10	1985	Comparative studies showed that the cytochalasin-B treatment was essential for measurement of NAD(P)H oxidation, in response to C5a and F-MLP.	Cytochalasin B	36-50	complement C5a receptor 1	Homo sapiens	128-131
2995525-10	1985	Comparative studies showed that the cytochalasin-B treatment was essential for measurement of NAD(P)H oxidation, in response to C5a and F-MLP.	Cytochalasin B	36-50	cysteine and glycine rich protein 3	Homo sapiens	138-141
2992505-1	1985	Human monocyte-derived Interleukin-1 (IL-1) stimulated a concentration-dependent extracellular release of azurophil (myeloperoxidase) and specific (vitamin B12-binding protein) granule constituents from cytochalasin B-treated human neutrophils.	Cytochalasin B	203-217	interleukin 1 alpha	Homo sapiens	23-36
2992505-1	1985	Human monocyte-derived Interleukin-1 (IL-1) stimulated a concentration-dependent extracellular release of azurophil (myeloperoxidase) and specific (vitamin B12-binding protein) granule constituents from cytochalasin B-treated human neutrophils.	Cytochalasin B	203-217	interleukin 1 alpha	Homo sapiens	38-42
2988756-2	1985	The reduction was inhibited by phospholipase A2 inhibitors, such as dibromoacetophenone, the lipoxygenase inhibitor nordihydroguaiaretic acid, an NADH-dehydrogenase inhibitor, the microfilament inhibitor cytochalasin B, oxygen radical scavengers such as superoxide dismutase, antioxidants such as butyl hydroxyanisole and non-specific inhibitors such as retinoic acid.	Cytochalasin B	204-218	phospholipase A2, group IB, pancreas	Mus musculus	31-47
2989375-5	1985	Release of beta-glucuronidase from azurophilic (lysosomal) granules provoked by various chemotaxins in the presence of cytochalasin B was not affected by anthralin over a wide range of concentrations.	Cytochalasin B	119-133	glucuronidase beta	Homo sapiens	11-29
4037794-1	1985	Human neutrophilic polymorphonuclear leukocytes (PMN) stimulated with N"-formyl-methionyl-leucyl-phenylalanine (FMLP) in the presence of cytochalasin B but in the absence of human serum albumin (HSA) synthesized only small amounts of platelet-activating factor (PAF) that attained maximum levels within 60-120 s after stimulation; in addition, no release of PAF occurred.	Cytochalasin B	137-151	formyl peptide receptor 1	Homo sapiens	112-116
3894559-5	1985	The addition of 14.3 mumol cytochalasin B/1 to the incubation medium significantly increased the amount of LH released in the first hour of incubation when compared with the amount of LH released by LHRH alone, but completely abolished the priming effect of LHRH.	Cytochalasin B	27-41	gonadotropin releasing hormone 1	Mus musculus	199-203
3894559-5	1985	The addition of 14.3 mumol cytochalasin B/1 to the incubation medium significantly increased the amount of LH released in the first hour of incubation when compared with the amount of LH released by LHRH alone, but completely abolished the priming effect of LHRH.	Cytochalasin B	27-41	gonadotropin releasing hormone 1	Mus musculus	258-262
3894559-6	1985	Cytochalasin B also prevented the LHRH-induced increase in the length and the change in orientation of the microfilaments.	Cytochalasin B	0-14	gonadotropin releasing hormone 1	Mus musculus	34-38
2989173-6	1985	Pretreatment of the PMNLs with cytochalasin B strongly potentiated (up to six-fold) the stimulatory effect of f-Met-Leu-Phe on 5-lipoxygenase product synthesis, whereas cytochalasin B alone or with arachidonic acid had no significant effect.	Cytochalasin B	31-45	arachidonate 5-lipoxygenase	Homo sapiens	127-141
6519775-2	1984	The soluble stimuli formlymethionyl-leucyl-phenylalanine and the low-molecular-weight complement fragment C5a both promote the dose-dependent release of NCBP from cytochalasin B-treated neutrophils in vitro.	Cytochalasin B	163-177	nuclear cap binding protein subunit 1	Homo sapiens	153-157
2984301-3	1985	Nicotine, however, inhibited both extracellular release of lysosomal enzymes from PMN and O-2 production of PMN, both of which were induced by fMet-Leu-Phe and cytochalasin B.	Cytochalasin B	160-174	immunoglobulin kappa variable 1D-39	Homo sapiens	90-93
3845309-7	1985	The intensive release of both beta-glucuronidase (beta-G) and ELP by the PMNLs of aged subjects after in vitro treatment with calcium ionophore A23187, Cytochalasin B or low density lipoprotein (LDL) suggests that they could play an important role in some age-related disorders.	Cytochalasin B	152-166	nuclear receptor subfamily 5 group A member 1	Homo sapiens	62-65
3974886-10	1985	When cytochalasin B (10 microM) was present during the homogenization of the hearts the soluble fraction of dopamine beta-hydroxylase was reduced to the same extent as in the presence of Gd3+.	Cytochalasin B	5-19	dopamine beta-hydroxylase	Oryctolagus cuniculus	108-133
6595215-5	1984	Phagocytosis through Fc mu-receptor is decreased by Cytochalasin B and by Vinblastine treatment, whereas ADCC is enhanced by Cytochalasin B.	Cytochalasin B	52-66	Fc mu receptor	Homo sapiens	21-35
6491756-8	1984	Degranulation, as measured by the release of beta-glucuronidase into the extracellular medium after stimulation of PMN by opsonized zymosan in the presence of cytochalasin B, was unaffected by GSH-Px deficiency.	Cytochalasin B	159-173	glucuronidase, beta	Rattus norvegicus	45-63
6541527-7	1984	Cytochalasin B, which impedes actin filament interactions, inhibited AII-stimulated phagocytosis.	Cytochalasin B	0-14	arginase type II	Mus musculus	69-72
6470036-3	1984	Stimulation of PMN by greater than 1 nM FMLP resulted in a dose-dependent and reversible increase in F-actin in 70-95% of PMN by 30 s. The induced increase in F-actin was blocked by 30 microM cytochalasin B or by a t-BOC peptide that competitively inhibits FMLP binding.	Cytochalasin B	192-206	formyl peptide receptor 1	Homo sapiens	40-44
6488324-3	1984	Induction of ornithine decarboxylase by parathyroid hormone, which is a good marker of differentiated chondrocytes, was markedly potentiated in the spherical cells which had been pretreated with cytochalasin B, whereas pretreatment with colchicine inhibited the induction of the enzyme.	Cytochalasin B	195-209	parathyroid hormone	Oryctolagus cuniculus	40-59
6430298-7	1984	The microfilament poison cytochalasin B increased the release of arylsulphatase and beta-galactosidase, but not lactate dehydrogenase, in the perfused non-loaded livers, but failed to augment the release of any of the enzymes or 125I-PVP in the loaded livers.	Cytochalasin B	25-39	galactosidase, beta 1	Rattus norvegicus	84-102
6329209-3	1984	O-2 generation is markedly reduced if cells are not preincubated with cytochalasin B prior to contact with ZAS .	Cytochalasin B	70-84	immunoglobulin kappa variable 1D-39	Homo sapiens	0-3
6202424-0	1984	A variant form of beta-actin in a mutant of KB cells resistant to cytochalasin B.	Cytochalasin B	66-80	POTE ankyrin domain family member F	Homo sapiens	18-28
6202424-6	1984	These results suggest that the primary site of action of cytochalasin B on cellular motility processes is beta-actin.	Cytochalasin B	57-71	POTE ankyrin domain family member F	Homo sapiens	106-116
6145157-5	1984	The enhancement of the prostaglandin E1-induced cAMP response caused by treatment of the lymphocytes with either cytochalasin B or 3-deazaadenosine in the presence or absence of L-homocysteine was not antagonized by taxol.	Cytochalasin B	113-127	cathelicidin antimicrobial peptide	Homo sapiens	48-52
6324816-4	1984	A time-dependent desensitization for O-2 production was demonstrated in neutrophilis which were stimulated with AGEPC prior to contact with cytochalasin B.	Cytochalasin B	140-154	immunoglobulin kappa variable 1D-39	Homo sapiens	37-40
6592607-4	1984	Inhibitors of calmodulin and actin filaments, trifluoperazine and cytochalasin B, respectively, inhibited the Ca2+-induced contractions.	Cytochalasin B	66-80	carbonic anhydrase 2	Rattus norvegicus	110-113
6383069-9	1984	Basal and insulin-stimulated uptake showed equal sensitivity to cytochalasin B.	Cytochalasin B	64-78	insulin	Homo sapiens	10-17
6430792-5	1984	PMA activation in the presence of cytochalasin B augments the release of lysozyme and initiates the release of beta glucuronidase through recruitment of the azurophilic granule but has no incremental effect on the release of vitamin B12-binding protein and histaminase observed with PMA alone.	Cytochalasin B	34-48	lysozyme	Homo sapiens	73-81
6430792-5	1984	PMA activation in the presence of cytochalasin B augments the release of lysozyme and initiates the release of beta glucuronidase through recruitment of the azurophilic granule but has no incremental effect on the release of vitamin B12-binding protein and histaminase observed with PMA alone.	Cytochalasin B	34-48	glucuronidase beta	Homo sapiens	111-129
6430792-5	1984	PMA activation in the presence of cytochalasin B augments the release of lysozyme and initiates the release of beta glucuronidase through recruitment of the azurophilic granule but has no incremental effect on the release of vitamin B12-binding protein and histaminase observed with PMA alone.	Cytochalasin B	34-48	amine oxidase copper containing 1	Homo sapiens	257-268
6430234-1	1984	Extracellular Ca2+ regulated the synthesis and release of platelet-activating factor (PAF) from human polymorphonuclear leukocytes (PMN) stimulated with N"-formyl-methionyl-leucyl-phenylalanine (FMLP) in the presence of cytochalasin B.	Cytochalasin B	220-234	PCNA clamp associated factor	Homo sapiens	58-84
6430234-1	1984	Extracellular Ca2+ regulated the synthesis and release of platelet-activating factor (PAF) from human polymorphonuclear leukocytes (PMN) stimulated with N"-formyl-methionyl-leucyl-phenylalanine (FMLP) in the presence of cytochalasin B.	Cytochalasin B	220-234	PCNA clamp associated factor	Homo sapiens	86-89
6470036-3	1984	Stimulation of PMN by greater than 1 nM FMLP resulted in a dose-dependent and reversible increase in F-actin in 70-95% of PMN by 30 s. The induced increase in F-actin was blocked by 30 microM cytochalasin B or by a t-BOC peptide that competitively inhibits FMLP binding.	Cytochalasin B	192-206	formyl peptide receptor 1	Homo sapiens	257-261
6690613-6	1984	In addition, the release of IgA was blocked by inhibitors of actin filaments (cytochalasin B) and microtubules (colchicine).	Cytochalasin B	78-92	CD79a molecule	Homo sapiens	28-31
6698968-4	1984	Insulin stimulation of 2-deoxyglucose uptake is detectable within 3 min, becomes maximal within 15 min, and is mediated by a rapid increase of plasma membrane transport units, as determined by D-glucose-inhibitable cytochalasin B binding, resulting in a 2-fold increase in the Vmax for 2-deoxyglucose transport with no change in Km.	Cytochalasin B	215-229	insulin	Homo sapiens	0-7
6229490-6	1984	When lymphocytes were preincubated with both cytochalasin B and colchicine, the clustering of FcR was not affected.	Cytochalasin B	45-59	Fc gamma receptor Ia	Homo sapiens	94-97
6199791-7	1984	Likewise, treatment with cytochalasin B (10 micrograms/ml, 1 hr) produced a star-like arrangement of the keratin and vimentin filaments and, in most cases, these codistributed with patches of actin.	Cytochalasin B	25-39	vimentin	Homo sapiens	117-125
6317543-6	1984	Both cytochalasin B, cytochalasin D and hydrocortisone reduced the release of ECP.	Cytochalasin B	5-19	ribonuclease A family member 3	Homo sapiens	78-81
6556194-5	1983	Kallikrein, 0.1-1.0 U/ml, (0.045-0.45 microM), was incubated with neutrophils that were preincubated with cytochalasin B (5 micrograms/ml).	Cytochalasin B	106-120	kallikrein related peptidase 4	Homo sapiens	0-10
6624881-2	1983	The secretion of phospholipase A2, like that of the known granule enzymes, requires cytochalasin B and is enhanced by extracellular Ca2+, and the time course of the release is rapid, being completed in less than a minute.	Cytochalasin B	84-98	phospholipase A2	Oryctolagus cuniculus	17-33
6643465-12	1983	Cytochalasin B decreases cytoskeletal actin and myosin and causes a shift in the amount of actin and myosin from the cytoskeleton to the cytoplasm both under fMet-Leu-Phe-stimulated and control conditions.	Cytochalasin B	0-14	actin	Oryctolagus cuniculus	38-43
6643465-12	1983	Cytochalasin B decreases cytoskeletal actin and myosin and causes a shift in the amount of actin and myosin from the cytoskeleton to the cytoplasm both under fMet-Leu-Phe-stimulated and control conditions.	Cytochalasin B	0-14	actin	Oryctolagus cuniculus	91-96
6643465-13	1983	In the presence of 1.6 mM extracellular Ca2+ and cytochalasin B (5 micrograms/ml) the amount of actin associated with the cytoskeleton under control and stimulated conditions is reduced to 13 +/- 2.2 and 10.2 +/- 3.5% of total cell actin, and that of myosin is reduced to 50.2 +/- 14 and 2.3 +/- 0.8% of the total cell myosin.	Cytochalasin B	49-63	actin	Oryctolagus cuniculus	96-101
6643465-13	1983	In the presence of 1.6 mM extracellular Ca2+ and cytochalasin B (5 micrograms/ml) the amount of actin associated with the cytoskeleton under control and stimulated conditions is reduced to 13 +/- 2.2 and 10.2 +/- 3.5% of total cell actin, and that of myosin is reduced to 50.2 +/- 14 and 2.3 +/- 0.8% of the total cell myosin.	Cytochalasin B	49-63	actin	Oryctolagus cuniculus	232-237
6643465-14	1983	The effect of cytochalasin B on actin does not depend on the time of its addition relative to that of fMet-Leu-Phe and is more pronounced in the presence of Ca2+.	Cytochalasin B	14-28	actin	Oryctolagus cuniculus	32-37
6687337-5	1983	Finally, it is shown that the nonspecific cytotoxicity generated by exposing PAM to immune complexes in suspension in conjunction with cytochalasin B, so that the immune complex-bound Fc receptor (FcR) cannot be internalized, also was susceptible to catalase.	Cytochalasin B	135-149	catalase	Homo sapiens	250-258
6860565-4	1983	The liberation of (lysosomal) beta-glucuronidase was also determined in cytochalasin B-treated cells confronted with increased concentrations of the chemotaxins.	Cytochalasin B	72-86	glucuronidase beta	Homo sapiens	30-48
6684122-4	1983	Cholera toxin-GM1, like surface-Ig capping, is an energy-dependent process and is inhibited by sodium azide, low temperatures, or cytochalasin B, but is unaffected by demecolcine.	Cytochalasin B	130-144	coenzyme Q10A	Mus musculus	14-17
6307056-3	1983	We have extended previous functional studies with cytochalasin B and have demonstrated that dihydrocytochalasin B, a more specific inhibitor of actin filament elongation, similarly diminishes the hydrosmotic response to vasopressin.	Cytochalasin B	50-64	arginine vasopressin	Homo sapiens	220-231
6346894-5	1983	The stimulations caused by both insulin and high K+ were markedly inhibited by cytochalasin B.	Cytochalasin B	79-93	insulin	Homo sapiens	32-39
6191552-1	1983	N-Formylmethionyl-leucyl-phenylalanine (FMLP) is a synthetic chemotactic peptide which induced beta-glucuronidase and lysozyme release from human neutrophils treated with cytochalasin B.	Cytochalasin B	171-185	formyl peptide receptor 1	Homo sapiens	40-44
6308042-7	1983	Prolonged O-2 release also follows fMLP stimulation in suspensions of PMN pretreated with cytochalasin B, in which case aggregation becomes irreversible during the 20-min burst.	Cytochalasin B	90-104	immunoglobulin kappa variable 1D-39	Homo sapiens	10-13
6308042-7	1983	Prolonged O-2 release also follows fMLP stimulation in suspensions of PMN pretreated with cytochalasin B, in which case aggregation becomes irreversible during the 20-min burst.	Cytochalasin B	90-104	formyl peptide receptor 1	Homo sapiens	35-39
6191552-1	1983	N-Formylmethionyl-leucyl-phenylalanine (FMLP) is a synthetic chemotactic peptide which induced beta-glucuronidase and lysozyme release from human neutrophils treated with cytochalasin B.	Cytochalasin B	171-185	glucuronidase beta	Homo sapiens	95-113
6815087-5	1982	On the other hand, treatment of the L929 cells with the cytoskeleton agents colchicine or cytochalasin B or with N-ethylmaleimide inhibited neither the phospholipase A activity nor the loss of membrane integrity.	Cytochalasin B	90-104	phospholipase A and acyltransferase 1	Mus musculus	152-167
6305669-6	1983	Cytochalasin B (20 microM), without effect on basal PRL binding, prevents the down-regulation of PRL receptors, whereas colchicine (10 microM) results in a decline of PRL receptor levels both in the absence and in the presence of oPRL.	Cytochalasin B	0-14	prolactin	Rattus norvegicus	97-100
6305669-6	1983	Cytochalasin B (20 microM), without effect on basal PRL binding, prevents the down-regulation of PRL receptors, whereas colchicine (10 microM) results in a decline of PRL receptor levels both in the absence and in the presence of oPRL.	Cytochalasin B	0-14	prolactin	Rattus norvegicus	97-100
6401935-7	1983	Colchicine and cytochalasin B also inhibited the ADH-induced capacitance increase.	Cytochalasin B	15-29	arginine vasopressin	Homo sapiens	49-52
6197243-4	1983	The introduction of cytochalasin B and colchicine into HSC partially destroyed the CFN, and, as a result, the morphology of the HSC mitochondria changed to become similar to those of NHK.	Cytochalasin B	20-34	fucosyltransferase 1 (H blood group)	Homo sapiens	55-58
6197243-4	1983	The introduction of cytochalasin B and colchicine into HSC partially destroyed the CFN, and, as a result, the morphology of the HSC mitochondria changed to become similar to those of NHK.	Cytochalasin B	20-34	fucosyltransferase 1 (H blood group)	Homo sapiens	128-131
6819863-2	1982	Calmodulin antagonists, such as trifluoperazine, dibucaine and quinacrine, inhibited the secretion of N-acetyl-beta-d-glucosaminidase from cytochalasin B-treated macrophages when the macrophages were stimulated by the chemotactic peptide, formylmethionyl-leucyl-phenylalanine (f Met-Leu-Phe) or the Ca(2+) ionophore A23187.	Cytochalasin B	139-153	calmodulin-3	Cavia porcellus	0-10
6298110-9	1982	D2O enhanced the extracellular release of MPO, but not lactate dehydrogenase, by neutrophils only in the simultaneous presence of cytochalasin B and latex particles.	Cytochalasin B	130-144	myeloperoxidase	Homo sapiens	42-45
6961445-2	1982	Similar concentrations of cytochalasin B inhibit the formation and metabolism of arachidonic acid in horse platelets stimulated by low concentrations of thrombin (0.1-0.5 unit/ml).	Cytochalasin B	26-40	coagulation factor II, thrombin	Homo sapiens	153-161
7055639-8	1982	When cytochalasin-B-treated granulocytes were incubated with dexamethasone or hydrocortisone prior to the addition of FMLP, the subsequent release of lactoferrin was substantially blocked, whereas the release of the primary granule products, lysozyme and beta-glucuronidase, was attenuated but not completely blocked.	Cytochalasin B	5-19	formyl peptide receptor 1	Homo sapiens	118-122
6810708-2	1982	In the presence of a transmural osmotic gradient, addition of ADH resulted in a measured osmotic permeability coefficient (Pf) of 190 +/- 12 micrometers/s; preincubation with cytochalasin B (2 x 10(-5) M) reduced this value to 138 +/- 6.	Cytochalasin B	175-189	arginine vasopressin	Homo sapiens	62-65
6810708-3	1982	However, ADH-induced diffusional permeability to tritiated water (PD) was enhanced by 17% with cytochalasin B.	Cytochalasin B	95-109	arginine vasopressin	Homo sapiens	9-12
7093528-4	1982	Morphological observations suggested that the enhancement of O2- and H2O2 release was caused by excessive release of the oxygen metabolites into the extracellular medium from incompletely formed phagocytic vacuoles as was observed with cytochalasin-B-treated cells.	Cytochalasin B	236-250	immunoglobulin kappa variable 1D-39	Homo sapiens	61-73
6818089-7	1982	Moreover, addition of cytochalasin B suppressed the productions of MAF and IFN but not that of D-factor by Con A-stimulated spleen cells.	Cytochalasin B	22-36	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	67-70
6283001-3	1982	Aggregation of 1 x 10(7) cytochalasin B-treated PMNs in response to 2 x 10(-7)M FMLP, as assessed by light scattering, was inhibited in a dose-dependent fashion by both drugs.	Cytochalasin B	25-39	formyl peptide receptor 1	Homo sapiens	80-84
6283001-8	1982	Correspondingly, the drugs suppressed lysosomal enzyme release induced by FMLP of PMNs rendered secretory with cytochalasin B.	Cytochalasin B	111-125	formyl peptide receptor 1	Homo sapiens	74-78
6802816-8	1982	AAGPC also caused a dose-dependent degranulation of cytochalasin B-treated rabbit polymorphonuclear leukocytes as shown by the release of beta-glucuronidase and lysozyme.	Cytochalasin B	52-66	lysozyme C-like	Oryctolagus cuniculus	161-169
7126637-6	1982	Similarly, neutrophils exposed to N-formylmethionylleucylphenylalanine and then restimulated by N-formylmethionylleucylphenylalanine in the presence of cytochalasin B secreted the azurophil granule enzyme beta-glucuronidase; release of the enzyme was also inversely related to the initial concentration of N-formylmethionylleucylphenylalanine.	Cytochalasin B	152-166	glucuronidase beta	Homo sapiens	205-223
6954518-2	1982	In our model cytochalasin B binds to the glucose carrier through hydrogen bonds at N2 (donates), O7 (accepts), and O23 (accepts) analogous to O6, O3, and O1, respectively, on beta-D-glucose.	Cytochalasin B	13-27	immunoglobulin kappa variable 1D-35 (pseudogene)	Homo sapiens	142-156
6809339-0	1982	Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine, and cytochalasin B.	Cytochalasin B	116-130	interleukin 1 alpha	Homo sapiens	14-27
7055639-3	1982	Dexamethasone was added to suspensions of cytochalasin B-treated granulocytes; it markedly impaired the aggregation response of the granulocytes of FMLP.	Cytochalasin B	42-56	formyl peptide receptor 1	Homo sapiens	148-152
7055639-4	1982	When cytochalasin-B was not used, granulocyte aggregation in response to FMLP or PMA was inhibited by dexamethasone.	Cytochalasin B	5-19	formyl peptide receptor 1	Homo sapiens	73-77
7055639-8	1982	When cytochalasin-B-treated granulocytes were incubated with dexamethasone or hydrocortisone prior to the addition of FMLP, the subsequent release of lactoferrin was substantially blocked, whereas the release of the primary granule products, lysozyme and beta-glucuronidase, was attenuated but not completely blocked.	Cytochalasin B	5-19	glucuronidase beta	Homo sapiens	255-273
6176912-5	1982	The retraction of cell bodies produced by treatment with cytochalasin B was associated with the disappearance of actin filament bundles.	Cytochalasin B	57-71	actin	Oryctolagus cuniculus	113-118
7040255-6	1982	The higher content of actin in spleen cells demonstrated by the absorption experiments was reflected in their more rapid expression of actin during smear formation, and the relative resistance of this to cytochalasin B treatment, compared to thymus and bursa preparations.	Cytochalasin B	204-218	actin, beta	Gallus gallus	22-27
6776037-7	1980	Pre-incubation of phagocytosing leucocytes with cytochalasin B or colchicine produced a diminution of PAF release, whereas beta-glucuronidase liberation was increased.	Cytochalasin B	48-62	PCNA clamp associated factor	Homo sapiens	102-105
6800960-4	1982	Arachidonic acid antagonists, nordihydroguaiaretic acid and quercetin caused dose-dependent inhibition of release induced by C3a plus cytochalasin B, however, lysozyme release induced by C3a in the absence of cytochalasin B was minimally affected.	Cytochalasin B	209-223	complement C3	Homo sapiens	125-128
6980842-2	1982	Simultaneous addition of C3a and cytochalasin B enhances the release of lysosomal enzymes and renders the cell morphology similar to that seen when either C5a or n-formyl peptides are added to PMNs in the presence of cytochalasin B.	Cytochalasin B	217-231	complement C3	Homo sapiens	25-28
6459679-0	1981	Cytochalasin B-induced ATPase activity of actin: dependence on monomer concentration.	Cytochalasin B	0-14	dynein axonemal heavy chain 8	Homo sapiens	23-29
6459679-1	1981	We simultaneously measured polymerization and ATPase activity of actin induced by cytochalasin B.	Cytochalasin B	82-96	dynein axonemal heavy chain 8	Homo sapiens	46-52
7276578-8	1981	Reduction of cytochrome c by cytochalasin B-treated PMN was the same in normal, absorbed, or absorbed plus heat-inactivated serum.	Cytochalasin B	29-43	cytochrome c, somatic	Homo sapiens	13-25
6272020-0	1981	Effects of colchicine and cytochalasin B on vasopressin- and cyclic adenosine monophosphate-induced changes in toad urinary bladder.	Cytochalasin B	26-40	arginine vasopressin	Homo sapiens	44-55
6267133-7	1981	When cytochalasin B was added subsequently and PMN challenged with AGEPC or C5a, stimulus-specific desensitization to AGEPC but not C5a-induced lysosomal enzyme release occurred.	Cytochalasin B	5-19	complement C5a receptor 1	Homo sapiens	76-79
7275176-7	1981	Cytochalasin B reduced zymosan and digitonin stimulated chemiluminescence but increased FMLP stimulated chemiluminescence.	Cytochalasin B	0-14	formyl peptide receptor 1	Homo sapiens	88-92
7262837-6	1981	Although GH (5 microgram/ml) stimulated sugar transport in the presence of cytochalasin B, the response to GH was significantly attenuated.	Cytochalasin B	75-89	gonadotropin releasing hormone receptor	Rattus norvegicus	9-11
6283720-3	1981	Cytochalasin B (CB) inhibited SRF of PTL of both species to a higher degree as compared to Th.	Cytochalasin B	0-14	pancreatic lipase	Sus scrofa	37-40
6894389-3	1981	Binding of [3H]actin was partially inhibited by cytochalasin B.	Cytochalasin B	48-62	actin epsilon 1	Bos taurus	15-20
7203529-6	1981	Similarly, the ingestion of EA-IgM was also inhibited when peritoneal exudate cells (PEC) were pre-treated with colchicine or vinblastine or cytochalasin B.	Cytochalasin B	141-155	immunoglobulin heavy chain 6	Rattus norvegicus	28-34
7461731-1	1981	Angiotensin II (At II) in the concentration range of 10(-5) to 5 x 10(-7) M inhibited active and passive erythrocyte-antibody (EA) rosette formation on monolayers of rat peritoneal macrophages (PM) but stimulated it in the range of 10(-7) -10(08) M. Cytochalasin B (CB) and vinblastin (Vb) inhibited the dose-dependent biphasic effect of At II on the Fc receptor (FcR) expression of macrophages.	Cytochalasin B	250-264	angiotensinogen	Rattus norvegicus	0-14
7461731-1	1981	Angiotensin II (At II) in the concentration range of 10(-5) to 5 x 10(-7) M inhibited active and passive erythrocyte-antibody (EA) rosette formation on monolayers of rat peritoneal macrophages (PM) but stimulated it in the range of 10(-7) -10(08) M. Cytochalasin B (CB) and vinblastin (Vb) inhibited the dose-dependent biphasic effect of At II on the Fc receptor (FcR) expression of macrophages.	Cytochalasin B	250-264	angiotensinogen	Rattus norvegicus	16-21
6790652-3	1981	The 64-cell-stage embryos which had been permanently cleavage-arrested with cytochalasin B developed AChE in all the eight presumptive muscle cells, but the same stage embryos which had been prevented from undergoing further divisions by simultaneous treatment with aphidicolin and cytochalasin did not produce AChE at all.	Cytochalasin B	76-90	acetylcholinesterase (Cartwright blood group)	Homo sapiens	101-105
6790652-5	1981	The early gastrulae which had been arrested with cytochalasin B produced AChE in all the sixteen presumptive muscle cells, while the same stage embryos arrested with aphidicolin and cytochalasin in as many as twelve cells.	Cytochalasin B	49-63	acetylcholinesterase (Cartwright blood group)	Homo sapiens	73-77
7204483-5	1981	The distinction between fibronectin- or glycosidase- and lectin- or galactose oxidase (an enzyme with lectin-type characteristics)-coated surfaces was further supported by the finding that cytochalasin B and EDTA inhibited cell attachment to fibronectin- and glycosidase-coated surfaces but not lectin-coated surfaces.	Cytochalasin B	189-203	fibronectin 1	Homo sapiens	24-35
7204483-5	1981	The distinction between fibronectin- or glycosidase- and lectin- or galactose oxidase (an enzyme with lectin-type characteristics)-coated surfaces was further supported by the finding that cytochalasin B and EDTA inhibited cell attachment to fibronectin- and glycosidase-coated surfaces but not lectin-coated surfaces.	Cytochalasin B	189-203	fibronectin 1	Homo sapiens	242-253
7024999-6	1981	Neuraminidase removal of the sialic acid component of the glomerular glycocalyx and exposure to either cytochalasin B (25 microgram/ml) or cytochalasin D (2 microgram/ml), prevent the in vitro formation of podocyte microprojections.	Cytochalasin B	103-117	neuraminidase 1	Homo sapiens	0-13
7198795-12	1981	Disruption of the cytoskeletal framework of the mucosal cells by Cytochalasin B or colchicine depresses mucin production.	Cytochalasin B	65-79	solute carrier family 13 member 2	Rattus norvegicus	104-109
6172448-3	1982	Cytochalasin B-treated human neutrophils stimulated with N-formyl-L-methionyl-L-leucyl-L-phenylalanine released beta-glucuronidase, lysozyme, and angiotensin II-generating protease in a dose-dependent fashion, consistent with localization of this protease to the neutrophil granule.	Cytochalasin B	0-14	angiotensinogen	Homo sapiens	112-160
7030757-0	1981	Cytochalasin B-induced alterations of insulin binding and microfilament organization in cultured fibroblasts.	Cytochalasin B	0-14	insulin	Homo sapiens	38-45
7327176-1	1981	Cytochalasin B (CB), a potent inhibitor of cytokinesis in mammalian cells, has been shown to cause the rapid inhibition of ornithine decarboxylase and S-adenosyl methionine decarboxylase activities followed by a gradual but marked decline in intracellular levels of both putrescine and spermidine.	Cytochalasin B	0-14	ornithine decarboxylase 1	Homo sapiens	123-146
6274792-1	1981	The interaction of cytochalasin B-treated human neutrophils with the synthetic tripeptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP) results in a time- and concentration-dependent generation of superoxide anion (O2-) by an extracellular release of granule-associated beta-glucuronidase and lysozyme from these cells.	Cytochalasin B	19-33	formyl peptide receptor 1	Homo sapiens	132-136
7028538-6	1981	Cytochalasin B, an agent which disrupts receptor aggregates, lowered average affinity at 24 degrees C. Phospholipase C treatment slowed the dissociation rate in "infinite dilution" at 24 degrees C but the accelerating effect of 100 ng/ml insulin (negative cooperativity) was greatly enhanced.	Cytochalasin B	0-14	insulin	Homo sapiens	238-245
6776037-7	1980	Pre-incubation of phagocytosing leucocytes with cytochalasin B or colchicine produced a diminution of PAF release, whereas beta-glucuronidase liberation was increased.	Cytochalasin B	48-62	glucuronidase beta	Homo sapiens	123-141
6247227-0	1980	Effects of lysosomotropic agents, cytochalasin B and colchicine on the "down-regulation" of prolactin receptors in mammary gland explants.	Cytochalasin B	34-48	prolactin	Oryctolagus cuniculus	92-101
6995792-6	1980	Under these conditions, cytochalasin B increased polymerized tubulin content in a manner that parallels its enhancing effect on insulin release.	Cytochalasin B	24-38	insulin	Homo sapiens	128-135
7191828-3	1980	Sensitivity to cytochalasin B treatment of SRBC rosette formation was dependent on the class of antibody and decreased in the following order: IgM &gt; IgG1 &gt; IgG2a.	Cytochalasin B	15-29	gamma-2a immunoglobulin heavy chain	Rattus norvegicus	162-167
6991024-2	1980	The C-induced aggregation of PMNs treated with cytochalasin-B (CB) is markedly enhanced and irreversible, and the magnitude of the response is proportional to the log (concentration of activated plasma), allowing use of this technique to detect C5a and hence C-activation.	Cytochalasin B	47-61	complement C5a receptor 1	Homo sapiens	245-248
6892735-2	1980	Platelet-mediated clot retraction in dilute platelet-rich plasma (PRP) is inhibited progressively at cytochalasin B concentrations of 0.01 mg/ml, 0.05 mg/ml and 0.1 mg/ml.	Cytochalasin B	101-115	complement component 4 binding protein alpha	Homo sapiens	44-64
6248861-2	1980	Lysosomal enzyme release from cytochalasin B-treated human neutrophils stimulated by immune complexes (bovine serum albumin and IgG anti-bovine serum albumin) was inhibited by DIDS, SITS, and pyridoxal phosphate at concentrations that inhibited sulfate fluxes.	Cytochalasin B	30-44	albumin	Homo sapiens	110-123
6248861-2	1980	Lysosomal enzyme release from cytochalasin B-treated human neutrophils stimulated by immune complexes (bovine serum albumin and IgG anti-bovine serum albumin) was inhibited by DIDS, SITS, and pyridoxal phosphate at concentrations that inhibited sulfate fluxes.	Cytochalasin B	30-44	albumin	Homo sapiens	144-157
6892735-2	1980	Platelet-mediated clot retraction in dilute platelet-rich plasma (PRP) is inhibited progressively at cytochalasin B concentrations of 0.01 mg/ml, 0.05 mg/ml and 0.1 mg/ml.	Cytochalasin B	101-115	complement component 4 binding protein alpha	Homo sapiens	66-69
6153550-0	1980	Redistribution of endorphin and enkephalin immunoreactivity in the rat brain and pituitary after in vivo treatment with colchicine or cytochalasin B.	Cytochalasin B	134-148	proenkephalin	Rattus norvegicus	32-42
7404479-0	1980	Relationship of ADP-induced fibrinogen binding to platelet shape change and aggregation elucidated by use of colchicine and cytochalasin B.	Cytochalasin B	124-138	fibrinogen beta chain	Homo sapiens	28-38
6102386-5	1980	The rise in ODCase activity stimulated by isoproterenol, dibutyryl cyclic AMP, or serum was also blocked by the microtubule disrupting agents, vinblastine and colchicine, and by the microfilament disrupting agent, cytochalasin B.	Cytochalasin B	214-228	ornithine decarboxylase, structural 1	Mus musculus	12-18
118820-4	1979	Cytochalasin B inhibited only partly the lactogenic action of prolactin while it has no effect on the down-regulation of the receptor.	Cytochalasin B	0-14	prolactin	Oryctolagus cuniculus	62-71
95572-4	1979	Treatment of the cells with cytochalasin B, a drug disrupting microfilament structure, inhibited the effects induced by H-2d antiserum.	Cytochalasin B	28-42	histocompatibility 2, D region	Mus musculus	120-124
490626-3	1979	Moreover exposure to cytochalasin B, 2.1 X 10(-5) M, either before or after initiation of the hormonal effect also delays the return of water permeability to normal following removal of ADH.	Cytochalasin B	21-35	arginine vasopressin	Homo sapiens	186-189
87244-5	1979	Cytochalasin B blocked transport of protein waves I (72--192 mn/day) and III (13--20 mm/day) and decreased hypothalamic levels of TH to 60.1% of control after bilateral injections.	Cytochalasin B	0-14	tyrosine hydroxylase	Rattus norvegicus	130-132
438322-11	1979	The correlation between the effects of cytochalasin B on insulin receptor distribution and glucose transport leads to the speculation that the glycoprotein molecules containing the insulin receptor are functionally linked with the glucose transport system.	Cytochalasin B	39-53	insulin receptor	Rattus norvegicus	57-73
438322-11	1979	The correlation between the effects of cytochalasin B on insulin receptor distribution and glucose transport leads to the speculation that the glycoprotein molecules containing the insulin receptor are functionally linked with the glucose transport system.	Cytochalasin B	39-53	insulin receptor	Rattus norvegicus	181-197
219119-7	1979	Pretreatment of the PMNs with cytochalasin B enhanced the release of O-2 by PMNs exposed to FMLP.	Cytochalasin B	30-44	immunoglobulin kappa variable 1D-39	Homo sapiens	69-72
219119-7	1979	Pretreatment of the PMNs with cytochalasin B enhanced the release of O-2 by PMNs exposed to FMLP.	Cytochalasin B	30-44	formyl peptide receptor 1	Homo sapiens	92-96
229657-2	1979	Cytochalasin B (CB; 1--1 muM) induced similar morphological changes.	Cytochalasin B	0-14	latexin	Homo sapiens	25-28
572336-3	1979	Similarly, cytochalasin B, an agent that interferes with microfilament function, doubled both basal hCG secretion, and secretion of hCG stimulated by 1 mM dibutyryl cyclic AMP plus 1 mM theophylline (dbT).	Cytochalasin B	11-25	hypertrichosis 2 (generalised, congenital)	Homo sapiens	100-103
572336-3	1979	Similarly, cytochalasin B, an agent that interferes with microfilament function, doubled both basal hCG secretion, and secretion of hCG stimulated by 1 mM dibutyryl cyclic AMP plus 1 mM theophylline (dbT).	Cytochalasin B	11-25	hypertrichosis 2 (generalised, congenital)	Homo sapiens	132-135
571277-1	1979	Induction of ornithine decarboxylase elicited in response to nerve-growth factor in target organs is greatly decreased by preincubation of these tissues with cytoskeletal poisons such as vinblastine, diamide, cytochalasin B and colchicine.	Cytochalasin B	209-223	ornithine decarboxylase 1	Homo sapiens	13-36
571277-1	1979	Induction of ornithine decarboxylase elicited in response to nerve-growth factor in target organs is greatly decreased by preincubation of these tissues with cytoskeletal poisons such as vinblastine, diamide, cytochalasin B and colchicine.	Cytochalasin B	209-223	nerve growth factor	Homo sapiens	61-80
107810-4	1979	The results indicate that during initiation the aggregation and water flow responses to vasopressin are each colchicine- and cytochalasin B-sensitive and that these sensitivities can be wholly additive.	Cytochalasin B	125-139	arginine vasopressin	Homo sapiens	88-99
107810-5	1979	However, after full vasopressin stimulation is established, the same responses demonstrate sensitivity only to cytochalasin B, not to colchicine.	Cytochalasin B	111-125	arginine vasopressin	Homo sapiens	20-31
759526-1	1979	CFI of whole human serum was measured by a new assay that utilizes chemotactic factor-induced release of a lysosomal enzyme (N-acetyl glucosaminidase) from cytochalasin B-exposed neutrophils as an index of chemotactic activity.	Cytochalasin B	156-170	complement factor I	Homo sapiens	0-3
717537-6	1978	Cytochalasin B (CB) had no apparent effect on the cross-linking of randomly associated actin TM-TP filaments induced by either protein alone but prevented development of bundles of parallel filaments when ABP and alphaA were added sequentially.	Cytochalasin B	0-14	sex hormone binding globulin	Homo sapiens	205-208
211165-5	1978	Interaction of neutrophils with C5a was shown to result in a concentration-dependent rapid desensitization that could not be overcome by later addition of cytochalasin B or of cytochalasin B and C5a.	Cytochalasin B	155-169	complement C5a receptor 1	Homo sapiens	32-35
211165-5	1978	Interaction of neutrophils with C5a was shown to result in a concentration-dependent rapid desensitization that could not be overcome by later addition of cytochalasin B or of cytochalasin B and C5a.	Cytochalasin B	176-190	complement C5a receptor 1	Homo sapiens	32-35
211165-7	1978	Cytochalasin B effects on neutrophils appear to mimic those of surface binding of soluble stimuli such as C5a and immune complexes.	Cytochalasin B	0-14	complement C5a receptor 1	Homo sapiens	106-109
279010-6	1978	Both C5a-mediated leukocyte chemotaxis and C5a-induced lysosomal enzyme release from cytochalasin B-treated cells closely paralleled uptake of the ligand, clearly indicating that it is a receptor-C5a interaction that leads to stimulation of these cellular responses.	Cytochalasin B	85-99	complement C5a receptor 1	Homo sapiens	43-46
279010-6	1978	Both C5a-mediated leukocyte chemotaxis and C5a-induced lysosomal enzyme release from cytochalasin B-treated cells closely paralleled uptake of the ligand, clearly indicating that it is a receptor-C5a interaction that leads to stimulation of these cellular responses.	Cytochalasin B	85-99	complement C5a receptor 1	Homo sapiens	43-46
659965-5	1978	Release of TFa is inhibited by vinblastine and cytochalasin B.	Cytochalasin B	47-61	coagulation factor III, tissue factor	Homo sapiens	11-14
563793-0	1978	Cytochalasin B releases a major surface-associated glycoprotein, fibronectin, from cultured fibroblasts.	Cytochalasin B	0-14	fibronectin 1	Homo sapiens	65-76
656374-5	1978	An even faster degradation of F-actin by subtilisin is observed in the presence of Mg2+ plus cytochalasin B.	Cytochalasin B	93-107	actin	Oryctolagus cuniculus	32-37
723265-2	1978	Both control and insulin-stimulated D-glucose transport activities were inhibited by cytochalasin B and thiol reagents.	Cytochalasin B	85-99	insulin	Homo sapiens	17-24
199619-7	1977	Under the influence of inhibited phagosome formation by cytochalasin B, the cells released an increased amount of superoxide and peroxide into the extracellular medium relative to oxygen consumption, and all detectable peroxide release could be inhibited by the addition of ferricytochrome c. Decreased H(2)O(2) production in the presence of this compound could not be ascribed to diminished bacterial binding, decreased oxidase activity, or increased H(2)O(2) catabolism and was reversed by the simultaneous addition of SOD.	Cytochalasin B	56-70	superoxide dismutase 1	Homo sapiens	521-524
723265-6	1978	Cytochalasin B binding activity was also retained by extracted membrane vesicles and D-glucose uptake into extracted vesicles derived from untreated or insulin-treated fat cells was inhibited by cytochalasin B.	Cytochalasin B	0-14	insulin	Homo sapiens	152-159
723265-6	1978	Cytochalasin B binding activity was also retained by extracted membrane vesicles and D-glucose uptake into extracted vesicles derived from untreated or insulin-treated fat cells was inhibited by cytochalasin B.	Cytochalasin B	195-209	insulin	Homo sapiens	152-159
103244-1	1978	Cytochalasin B depresses the hydroosmotic response of the toad urinary bladder to vasopressin without affecting basal (bulk flow) permeability, diffusional permeability, or the hormone induced increase in short circuit current.	Cytochalasin B	0-14	arginine vasopressin	Homo sapiens	82-93
563407-0	1977	Reversible inhibition of the hydrocortisone induction of glycerol phosphate dehydrogenase by cytochalasin B in rat glial C6 cells.	Cytochalasin B	93-107	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	57-89
563407-1	1977	The hydrocortisone (HC) induction of glycerol phosphate dehydrogenase (GPDH; EC 1.1.1.8) in rat glial C6 cells was inhibited reversibly and in a dose-dependent manner by cytochalasin B (CB).	Cytochalasin B	170-184	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	37-69
563407-1	1977	The hydrocortisone (HC) induction of glycerol phosphate dehydrogenase (GPDH; EC 1.1.1.8) in rat glial C6 cells was inhibited reversibly and in a dose-dependent manner by cytochalasin B (CB).	Cytochalasin B	170-184	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	71-75
411883-3	1977	Embryos in which cell division was blocked with cytochalasin B at early cleavage stages up to the 64-cell stage, eventually differentiated strong alkaline phosphatase activity in certain cells at each cleavage-arrested stage.	Cytochalasin B	48-62	alkaline phosphatase	Ciona intestinalis	146-166
410816-9	1977	Magnesium-ethylene glycol bis[beta-aminoethyl ether]N,N"-tetraacetic acid (Mg [2.5 mM]-EGTA [5.0 mM]) blocked the C5a-evoked potential changes, whereas colchine (10(- 6)M) and cytochalasin B (3.0 mug/ml did not.	Cytochalasin B	176-190	complement C5a receptor 1	Homo sapiens	114-117
65434-7	1977	Cytochalasin B, which gives a variable enhancement of IgE-mediated release, had a marked enhancing effect on the serum-induced reaction in all subjects tested.	Cytochalasin B	0-14	immunoglobulin heavy constant epsilon	Homo sapiens	54-57
836339-3	1977	These glucocorticoids also inhibited zymosan-induced release of beta-glucuronidase from neutrophils that had been pretreated with cytochalasin B in order to completely prevent the onset of phagocytosis.	Cytochalasin B	130-144	glucuronidase beta	Homo sapiens	64-82
977662-10	1976	Sulfhydryl reagents (ethacrynic acid and NEM) and cytochalasin B clearly inhibited the AIB transport into glia cells whereas the effect on glioma cells was minimal.	Cytochalasin B	50-64	ANIB1	Homo sapiens	87-90
981704-1	1976	Cytochalasin B inhibits the production of prostaglandins by serum-, thrombin-, and bradykinin-stimulated MC5-5 cells.	Cytochalasin B	0-14	coagulation factor II	Mus musculus	68-76
135766-3	1976	Low concentrations (greater than or equal to 10(-7) M) of cytochalasin B reversibly inhibit the temperature-dependent gelation of actin by an actin-binding protein.	Cytochalasin B	58-72	actin	Oryctolagus cuniculus	130-135
135766-3	1976	Low concentrations (greater than or equal to 10(-7) M) of cytochalasin B reversibly inhibit the temperature-dependent gelation of actin by an actin-binding protein.	Cytochalasin B	58-72	actin	Oryctolagus cuniculus	142-147
135766-4	1976	The cytochalasin B concentrations which maximally inhibit actin gel formation are 10-fold lower than the concentrations which maximally impair phagocytosis by intact macrophages.	Cytochalasin B	4-18	actin	Oryctolagus cuniculus	58-63
135766-5	1976	Cytochalasin B also prevents the polymerization of monomeric actin in sucrose extracts of macrophages in the absence but not the presence of 0.1 M CKl.	Cytochalasin B	0-14	actin	Oryctolagus cuniculus	61-66
135766-6	1976	10(-6) M cytochalasin B dissolves macrophage extract gels and gels comprised of purified actin and actin-binding protein by dissociating actin-binding protein from actin filaments.	Cytochalasin B	9-23	actin	Oryctolagus cuniculus	89-94
135766-6	1976	10(-6) M cytochalasin B dissolves macrophage extract gels and gels comprised of purified actin and actin-binding protein by dissociating actin-binding protein from actin filaments.	Cytochalasin B	9-23	actin	Oryctolagus cuniculus	99-104
135766-6	1976	10(-6) M cytochalasin B dissolves macrophage extract gels and gels comprised of purified actin and actin-binding protein by dissociating actin-binding protein from actin filaments.	Cytochalasin B	9-23	actin	Oryctolagus cuniculus	99-104
135766-6	1976	10(-6) M cytochalasin B dissolves macrophage extract gels and gels comprised of purified actin and actin-binding protein by dissociating actin-binding protein from actin filaments.	Cytochalasin B	9-23	actin	Oryctolagus cuniculus	99-104
181401-3	1976	Pretreatment of the cells with cytochalasin B decreased these activities but increased release of lysosomal beta-glucuronidase, suggesting that degranulation and the burst of oxygen metabolism that characterizes phagocytes are independently regulated functions.	Cytochalasin B	31-45	glucuronidase beta	Homo sapiens	108-126
196628-1	1977	The ability of cytochalasin B to inhibit the steroidogenic response of mouse adrenal tumor cells (Y-1) to adrenocorticotropin (ACTH) was examined with two aims: to consider the specificity of the inhibitor and to determine at what point(s) in the steroidogenic pathway it acts.	Cytochalasin B	15-29	pro-opiomelanocortin-alpha	Mus musculus	127-131
402420-3	1977	Zymosan-induced histaminase release from eosinophils but not from neutrophils was abolished or markedly reduced in the presence of cytochalasin B, suggesting a difference in the mechanisms of histaminase release from the two granulocyte cell types.	Cytochalasin B	131-145	amine oxidase copper containing 1	Homo sapiens	192-203
1034635-4	1976	The present experiments showed that the percent inhibition of insulin-activated transport rates by submaximal levels of cytochalasin B was decreased compared to its effects on basal transport.	Cytochalasin B	120-134	insulin	Homo sapiens	62-69
1034635-6	1976	When insulin or the oxidant vitamin K5 was added to cells 5 minutes before the N-ethylmaleimide, the elevated transport activity was also resistant to the sulfhydryl reagent, but cytochalasin B retained its potent inhibitory effect on transport.	Cytochalasin B	179-193	insulin	Homo sapiens	5-12
1034635-7	1976	The data demonstrate that unique properties characterize basal versus insulin-activated transport activity with respect to the sensitivity of cytochalasin B action to sulfhydryl blockade in isolated fat cells.	Cytochalasin B	142-156	insulin	Homo sapiens	70-77
185075-0	1976	MSH stimulates adenylate cyclase and tyrosinase in cultivated melanoma cells in the presence of cytochalasin B.	Cytochalasin B	96-110	msh homeobox 2	Homo sapiens	0-3
24194453-2	1976	Release ofBeta-glucuronidase and lysozyme from cytochalasin B-treated cells exposed to serum-treated zymosan, heat-aggregated human IgG, and the complement component C5a was significantly reduced by pretreatment with hydrocortisone sodium succinate and methylprednisolone sodium succinate (5x10(-4) M).	Cytochalasin B	47-61	complement C5a receptor 1	Homo sapiens	166-169
1257610-2	1976	Vincristine, vinblastine, and cytochalasin B were found to cause 50% inhibition of serotonin binding to SBP at 1.5 X 10(-6)M, 7.5 X 10(-6)M and 50 X 10(-6)M, respectively.	Cytochalasin B	30-44	selenium binding protein 1	Homo sapiens	104-107
1247530-10	1976	Acquisition of specific Hex A isozyme activity by cells (determined by DEAE-cellulose chromatography) was not due to surface adsorption since cytochalasin B, which prevents phagocytosis but not surface adherence; blocked uptake.	Cytochalasin B	142-156	hexosaminidase subunit alpha	Homo sapiens	24-29
171281-4	1975	Cytochalasin B-treated cells exposed to (a) serum-treated zymosan, a C3b receptor stimulus; (b) heat aggregated human IgG, an Fc receptor stimulus; and (c) the complement component, C5a, generated enhanced amounts of O-.2 in a time and concentration-dependent fashion.	Cytochalasin B	0-14	complement C5a receptor 1	Homo sapiens	182-185
1100722-2	1975	The data indicate that cytochalasin B inhibits MIF production if added at the initiation of culture but not if added 2 hr after antigen.	Cytochalasin B	23-37	macrophage migration inhibitory factor	Cavia porcellus	47-50
1158973-2	1975	PMA enhanced release of the azurophil granule enzyme, beta-glucuronidase, as well as lysozyme, from cytochalasin B-treated PMN"s exposed to either zymosan particles or C5a.	Cytochalasin B	100-114	glucuronidase beta	Homo sapiens	54-72
1158973-2	1975	PMA enhanced release of the azurophil granule enzyme, beta-glucuronidase, as well as lysozyme, from cytochalasin B-treated PMN"s exposed to either zymosan particles or C5a.	Cytochalasin B	100-114	lysozyme	Homo sapiens	85-93
1158973-2	1975	PMA enhanced release of the azurophil granule enzyme, beta-glucuronidase, as well as lysozyme, from cytochalasin B-treated PMN"s exposed to either zymosan particles or C5a.	Cytochalasin B	100-114	complement C5a receptor 1	Homo sapiens	168-171
1151072-1	1975	The complement component, C5a provokes the selective release of granule-associated enzymes from the intact, viable cytochalasin B-treated human polymorphonuclear leukocytes (PMN) in the absence of phagocytosis or cellular adherence to surfaces.	Cytochalasin B	115-129	complement C5a receptor 1	Homo sapiens	26-29
1151072-3	1975	Cytochalasin B-treated PMN exposed to C5a in calcium and magnesium-free media consistently secreted significant amounts of the granule-associated enzymes, beta-glucuronidase and lysozyme.	Cytochalasin B	0-14	complement C5a receptor 1	Homo sapiens	38-41
1151072-3	1975	Cytochalasin B-treated PMN exposed to C5a in calcium and magnesium-free media consistently secreted significant amounts of the granule-associated enzymes, beta-glucuronidase and lysozyme.	Cytochalasin B	0-14	glucuronidase beta	Homo sapiens	155-173
1080476-1	1975	The effects of cytochalasin B, colchicine and vinblastine on the rosette formation of human T lymphocytes with neuraminidase-treated human erythrocytes (nHRBC) and with sheep red blood cells (SRBC) have been studied.	Cytochalasin B	15-29	neuraminidase 1	Homo sapiens	111-124
1157828-1	1975	The interactions of calcium, vitamin A, vinblastine, and cytochalasin B in PTH secretion.	Cytochalasin B	57-71	parathyroid hormone	Homo sapiens	75-78
164214-10	1975	Disruption of microfilament function by cytochalasin B (10 muM) accelerates the rate of secretion induced by either thrombin or ionophore.	Cytochalasin B	40-54	latexin	Homo sapiens	59-62
164214-10	1975	Disruption of microfilament function by cytochalasin B (10 muM) accelerates the rate of secretion induced by either thrombin or ionophore.	Cytochalasin B	40-54	coagulation factor II, thrombin	Homo sapiens	116-124
48382-11	1975	Whereas cells exposed to MSU crystals released 30% of their content of lysosomal beta-glucuronidase activity and 28% of their cytoplasmic lactate dehydrogenase (LDH) activity within 3 hours, preincubation with cytochalasin B reduced the release of LDH activity within that period to 6% but reduced the release of beta-glucuronidase activity only to 20%.	Cytochalasin B	210-224	glucuronidase beta	Homo sapiens	313-331
1113510-0	1975	Subcellular mechanisms of parathyroid hormone secretion: ultrastructural changes in response to calcium, vitamin A, vinblastine, and cytochalasin B.	Cytochalasin B	133-147	parathyroid hormone	Bos taurus	26-45
167759-0	1975	The influence of cytochalasin B on the response of adrenal tumor cells to ACTH and cyclic AMP.	Cytochalasin B	17-31	proopiomelanocortin	Homo sapiens	74-78
4373479-0	1974	Effects of cytochalasin B on the response of toad urinary bladder to vasopressin.	Cytochalasin B	11-25	arginine vasopressin	Homo sapiens	69-80
765121-4	1976	Cytochalasin B also caused a partial inhibition of 45calcium uptake and proinsulin synthesis evoked by glucose in low concentration (5.6 mM), these findings being compatible with a modest impairment of the process of glucose recognition by the beta-cell.	Cytochalasin B	0-14	insulin	Homo sapiens	72-82